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Abstract 
Inflammation is increasingly thought to play an important role in the pathogenesis of a wide variety of 
acute and chronic diseases including ageing in general. To date, pharmacotherapy of inflammatory 
conditions is based on the use of non-steroidal anti-inflammatory drugs (NSAIDs). However, NSAIDs 
can cause serious gastrointestinal toxicity such as gastric bleeding and the formation of stomach 
ulcers. Even more ominously, some NSAIDs, particularly COX-2 inhibitors, have been linked to 
increased blood pressure, greatly increased risk of congestive heart failure, occurrence of thrombosis 
and myocardial infarction. Together, these findings provide the motivation for the development of 
anti-inflammatory treatments with fewer adverse effects.  
 
Reactive oxygen species (ROS) are produced mainly during oxidative phosphorylation and by 
activated phagocytic cells during oxidative burst. The excessive production of ROS can damage 
lipids, protein, membrane and nucleic acids. They also serve as important intracellular signalling 
molecules that are involved in the production of pro-inflammatory mediators such as cytokines and 
Nitric oxide. 
In chapter 2, hydrogen peroxide showed that it is not only intracellular signalling molecule, but 
travels through the extracellular space and activate adjacent cells. This hypothesis is supported by 
adding  catalase (that converts hydrogen peroxide to water and oxygen in the extracellular space) and  
therefore the pro-inflammatory signal does  not reach the next cell, leading to an overall reduction of 
the readouts, NO and TNF-α. This concept can revolutionize drug development because hydrogen 
peroxide scavengers do not necessarily have to penetrate the cell membrane to exert their action - and 
even extreme hydrophilic molecules would be beneficial in diseases with chronic pro-inflammatory 
conditions.  
 
Antioxidants can protect against the damage induced by free radicals acting at various levels. 
Dietary and other components of plants form major sources of antioxidants.  As ROS are signalling 
molecules, antioxidants which scavenge ROS, would therefore inhibit inflammation. 
In chapter 3,  115 food samples were prepared by a generic food-compatible processing method 
involving heating and tested for their anti-inflammatory activity in murine N11 microglia and RAW 
264.7 macrophages, using nitric oxide (NO) and tumour necrosis factor-α (TNF-α) as pro-
inflammatory readouts. Ten food samples including lime zest, English breakfast tea, honey-brown 
mushroom, button mushroom, oyster mushroom, cinnamon and cloves inhibited NO production in 
N11 microglia, with IC50 values below 0.5 mg/ml. The most active samples were onion, oregano and 
red sweet potato, exhibiting IC50 values below 0.1 mg/ml. When these ten food preparations were 
retested in RAW 264.7 macrophages, they all inhibited NO production similar to the results obtained 
in N11 microglia. In addition, English breakfast tea leaves, oyster mushroom, onion, cinnamon and 
button mushroom preparations suppressed TNF-α production, exhibiting IC50 values below 0.5 mg/ml 
in RAW 264.7 macrophages. 
 
xix 
 
Considering the stability of activity during processing stages (patented processing methods of the 
CSIRO plant and food library), anti-inflammatory activity in both the cell lines and suppression of 
both NO and TNF-α without cytotoxicity, cinnamon was been selected as most interesting extract 
for further chemical analysis – chapter 4 and 5. 
In chapter 4-5, we examined the anti-inflammatory activities of C. zeylanicum and C. cassia extracts 
and their chemical constituents using RAW 264.7 macrophages. When extracts were tested in LPS and 
IFN-γ activated RAW 264.7 macrophages, most of the anti-inflammatory activity, measured by down-
regulation of nitric oxide and TNF-α production, was observed in the organic extracts. The most 
abundant compounds in these extracts were E-cinnamaldehyde and o-methoxycinnamaldehyde. 
When these and other constituents were tested for their anti-inflammatory activity in RAW 264.7 and 
J774A.1 macrophages, the most potent compounds were E-cinnamaldehyde and o-
methoxycinnamaldehyde, and they accounted for most of the inflammatory activity in either 
cinnamon species.  
 
Among the 115 samples, mushrooms were also showed significant anti-inflammatory activity and 
that leads to chapter 6. Edible mushrooms are attracting more and more attention as functional 
foods since they are rich in bioactive compounds, but their anti-inflammatory properties and the 
effect of food processing steps on this activity has not been systematically investigated. 
In chapter 6,  White Button and Honey Brown (both Agaricus bisporus), Shiitake (Lentinus edodes), 
Enoki (Flammulina velutipes) and Oyster mushroom (Pleurotus ostreatus) preparations were tested 
for their anti-inflammatory activity in lipopolysaccharide (LPS) and interferon-γ (IFN-γ) activated 
murine RAW 264.7 macrophages. Potent anti-inflammatory activity (IC50 < 0.1 mg/ml), measured as 
inhibition of NO production, could be detected in all raw mushroom preparations, but only raw Oyster 
(IC50 = 0.035 mg/ml) and Shiitake mushrooms (IC50 = 0.047 mg/ml) showed potent inhibition of TNF-
α production as well. 
 
Not only known traditional foods and plants but unknown Australian bush foods and plants might 
also have those properties. In our quest for the search of novel potent anti-inflammatory 
compounds involved the screening of 72 Australian tropical rainforest plant extracts from Northern 
Queensland. This chapter highlights the bioassay guided isolation and characterization of new anti-
inflammatory compounds from one of the most active plant, Cryptocarya mackinoniana 
The aim of this study (Chapter 7) was the identification of novel anti-inflammatory compounds 
present in Cryptocarya mackioniana young leaves. From this study we were able to identify a new 
compound, 12 and a known metabolite cryptocaryone from the DCM extract. The anti-inflammatory 
activities of both compounds were evaluated against RAW264.7 macrophages and compounds 12 and 
cryptocaryone showed significant inhibition of nitric oxide with IC50 6.36 ± 0.85 µg/mL and 1.26 ± 
0.18 µg/mL respectively. In addition cryptocaryone showed significant inhibition of TNF-α with IC50 
3.58 ± 0.64 µg/mL. Isolation and identification of the remaining compounds is a work in progress.  
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1.1 Chronic inflammatory diseases in the elderly  
The increase in both the absolute number as well as relative proportion of the elderly 
is one of the most important developments facing human society in the next decades 
(Ethgen and Reginster 2004). Chronic inflammation is a contributing factor for many 
age-related diseases including neurodegenerative diseases, degenerative 
musculoskeletal diseases, cardiovascular diseases, diabetes, cancer, asthma, 
rheumatoid arthritis, and inflammatory bowel disease. Increasing evidence suggests 
that systemic low-grade inflammation is a contributing factor in these age-related 
diseases (McGeer and McGeer 1995, Wyss-Coray 2006, Hansson 2005).  
 
1.2 What is Inflammation?  
Inflammation is recognized as a biological process in response to tissue injury. The 
defining clinical features of inflammation are known in Latin as rubor (redness), 
calor (warmth), tumor (swelling) and dolor (pain). Hallmarks of inflammation were 
first described by Aurelius Cornelius, a Roman physician and medical writer who 
lived from about 30 B.C. to 45 A.D (Huang et al. 2011, Yoon and Baek 2005). At the 
site of injury, an increase in blood vessel wall permeability followed by the 
movement of serum proteins and leukocytes (neutrophils, eosinophils and 
macrophages) from the blood to the extra-vascular tissue is observed. The 
inflammatory response is a complex self-limiting process precisely regulated to 
prevent extensive damage to the host (Acute Inflammation). When the self-limiting 
nature of this protective mechanism is inappropriately regulated, it results in chronic 
inflammation which is associated with a number of chronic inflammatory diseases, 
including asthma, rheumatoid arthritis, inflammatory bowel disease, atherosclerosis, 
Alzheimer’s disease, and cancer (Fig.1.1) (Liao et al. 2012, Chang et al. 2011).  
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Fig.1.1 Schematic representation of the different inflammation processes (Pallares 
2012) 
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1.3 Alzheimer’s disease and the role of inflammation  
Alzheimer's disease (AD) is the most common cause of severe mental deterioration 
(dementia) in the elderly(Katzman 1976). AD was known to occur occasionally in 
families but was not necessarily thought to be related to the more frequent 
occurrence of cognition impairment in late life. The latter condition was known as 
senile dementia (Geldmacher and Whitehouse 1997). When results of careful 
pathology studies emerged in the 1970s and 1980s showing that the pathology of the 
brains of patients with early-onset (before the age of 65 years) and late-onset AD was 
the same, research into the pathologic process as well as the clinical manifestations 
accelerated.  
The incidence and prevalence of AD rises with increasing age, especially for those 
over the age of 65 years. The prevalence of AD is range from 3 percent of the 
population between the ages of 65 and 75 years and the highest reported estimate of 
47 percent of people over the age of 85 years. In general, all studies report a 
progressive increase in the prevalence of dementia as a function of age between 65 
and 85 years; more conservative estimates at the higher end are in the range of 30 to 
35 percent, which is still a significant number. Whatever the current estimates, all 
researchers agree that the number of AD cases will probably triple over the next 30 
to 40 years (Geldmacher and Whitehouse 1997).  
Currently there is no cure for AD, and drug treatments are only partially effective at 
suppressing the symptoms in a subset of patients (Geldmacher and Whitehouse 
1997). Alzheimer’s disease is associated with progressive death of neurons in the 
central nervous system (CNS). Specific pathology includes senile plaques, amyloid 
deposits, and abnormal cytoskeletal structures (neurofibrillary tangles) (Fig 1.2).  
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1.3.1 Senile plaque formation in AD  
Amyloid-beta (A-beta) plays a dominant role in AD. This is a small peptide, roughly 
3–4 kDa in size (40–42 amino acids). Amyloid-beta is cut by enzymes from a 
segment of a large (695 amino acids) trans-membrane protein called amyloid 
precursor protein (APP). The mean level of soluble A-beta is much higher in 
Alzheimer’s disease than in normal individuals, and correlates with severity of the 
disease. In familial AD, production of amyloid-beta protein is elevated up to six-fold 
over normal levels (Selkoe 1996 ).  
In AD, soluble β-amyloid undergoes a conformational change that renders it 
relatively insoluble and causes it to deposit in the parenchyma (Wisniewski, Ghiso 
and Frangione 1997). According to the widely held ‘amyloid cascade hypothesis’ the 
β-amyloid peptide is the major constituent of senile plaques, which also contain a 
large variety of proteins, metals and other agents (Halliday et al. 2000). The β-
amyloid peptide is present in a soluble, non-toxic form in all human brains, mainly as 
a 40 amino acid sequence (Aβ1–40), but longer (Aβ1–42) and shorter forms (Aβ1–
28) have also been found (Wisniewski et al. 1997). Amyloid peptide initially 
deposits into amorphous diffuse plaques that are associated with few, if any, 
dystrophic neurites. Over a period of many years, these deposits become compacted 
into mature senile plaques and the β-amyloid becomes fibrillar and displays a β-sheet 
conformation (Wisniewski et al. 1997, Halliday et al. 2000) (Fig.1.2).  
 
1.3.2 Neurofibrillary tangles (NFT) formation in AD  
In the mid-1980s, a number of laboratories discovered that the main protein 
composing neurofibrillary tangles (NFTs) was the microtubule-associated protein, 
tau. NFTs are aggregates of filamentous tau polymers that comprise a portion of the 
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fibrillar pathologies in Alzheimer’s disease (AD), the other elements being the 
neuropil threads and the dystrophic neurites that invade a subset of amyloid plaques 
(neuritic plaques). These structures occur in the regions of the brain responsible for 
the various cognitive domains that are compromised during the course of AD, the 
density of tau inclusions correlating well with regional and global aspects of 
cognitive decline (Akiyama et al. 2000) The functional consequences of tau 
alterations, of which the prime example is phosphorylation, remained obscure until 
the realization that, in order to form filaments, tau had to undergo a massive 
conformational change to begin the aggregation/polymerization process. The extent 
of this change was not appreciated until the discontinuous epitope of the Alz50 
monoclonal antibody was discovered.  
This antibody only binds efficiently to tau when its amino terminus comes into 
contact with the microtubule-binding repeats (MTBR). In order to aggregate into 
filaments, the tau molecule must undergo a shift from an essentially unfolded random 
coil configuration to this more compact “Alz50” state (Morsch 1999 ).  
 
Fig.1.2 β-amyloid plaques and neurofibrillary tangles (NFT) formation in AD brain 
(http://www.brightfocus.org/alzheimers/infographic/amyloid-plaques-and-
neurofibrillary-tangles 2000) 
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1.3.3. Role of microglia and macrophages in the brain 
Microglia represents around 10% of the cells in the nervous system. Although there 
are many theories concerning the origin of microglia, the general consensus today is 
its hematopoietic origin, derived from myeloid precursor cells, which enter the 
developing CNS during embryogenesis. Many questions remain about the 
recruitment and the life of the resident microglial in adult and aging brain (Chan 
2007).  
Microglia has activation states similar to that of macrophages and exhibit functional 
plasticity during activation states. The resting state, or ‘ramified’ state, is relatively 
inactive or ‘quiescent’ but seems to perform surveillance functions (Giulian and 
Baker 1986 ). In addition to the resting state, there are two functionally distinct 
activation states, M1 and M2. The former is classically activated, for instance in 
response to IFN-γ or lipopolysaccharide (LPS), and produces neuronal injury by 
secreting the pro-inflammatory cytokines such as TNF-α, IL-1β, and reactive oxygen 
species/reactive nitrogen species (ROS/NOS) (Fig.1.3). In contrast, the amoeboid M2 
state acts as an anti-inflammatory by blocking the release of proinflammatory 
cytokines, ingesting debris, promoting tissue repair and releasing neurotrophic 
factors. By using in vitro culture techniques, researchers can find ways to simulate 
many homeostatic or pathological conditions by manipulating these states.  
This process plays a fundamental part in the reorganization of neural circuitry and 
repair mechanisms that arise following injury. As part of a beneficial role microglial 
phagocytosis is a highly regulated process, with activated microglia expressing a 
wide, and redundant, variety of distinct receptors for the removal of pathogenic 
organisms, e.g., Toll-like receptors (TLRs) (Neumann, Kotter and Franklin 2009 ), or 
of apoptotic cell debris, e.g., CD36 and integrins. The microglial phagocytic 
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response is thus a central part of the brain’s defense mechanisms, and is a powerful 
contributor to the systems in place that ensure healthy neural function.  
Apart from resident microglia, in the brain there are monocyte-derived macrophages. 
Perivascular macrophages have a phagocytic role and are also implicated in the 
presentation of antigens to T cells that have been activated in the periphery, thereby 
facilitating the recognition of CNS antigens.  
 
Fig 1.3 Chronic production of inflammatory mediators by microglial cells 
(Peterson and Flood 2012) 
 
The macrophage and microglia phenotype has been defined as M1 (classically 
activated via TLRs or interferon γ) and M2 (alternatively activated by interleukin 4 
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or interleukin 13), although it is assumed that a mixed population of both phenotypes 
exists (Cameron and Landreth 2010). Because most techniques are unable to 
differentiate between both populations of microglia and macrophages in the brain, 
they are collectively referred as microglia. However, both microglia and infiltrated 
monocytes are not functionally redundant and have different properties, so they are 
both necessary to display functions such as brain repair.  
Presently there are many models of microglia and microglia-like cell lines used to 
examine neuroinflammatory phenomena. These include primary microglia cultures, 
and immortalized microglia cell cultures, which are either retrovirus transformed or 
non-retrovirus transformed. These culture models share similarities but are also 
separated by crucial differences that must be weighed when choosing an appropriate 
model for neurodegenerative research.  
 
1.3.4. The sequence of inflammatory events in the pathological process of 
Alzheimer’s disease 
The role of inflammatory molecules in the pathological process of Alzheimer’s 
disease is not fully understood, but the present findings suggest that these molecules 
may be involved in a number of key steps in the cascade, as follows:  
 
It has been shown that IL-1 (possibly together with IL-6) can regulate APP synthesis. 
The promoter of the gene encoding APP contains both heat-shock and interleukin-
responsive elements, and IL-1 expression is rapidly induced flowing brain injury and 
other pathogenic insults. This may trigger enhanced APP synthesis and β-amyloid 
protein (β/A4) deposition and set up a vicious cycle whereby amyloid deposits 
stimulate further cytokine production by microglia, leading to even higher expression 
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of APP (Vandenabeele and Fiers 1991).   
1. Recent studies suggest that β/A4-associated proteins are involved in 
regulating aggregation of the β/A4 peptide. Some β/A4-associated proteins 
(such as apolipoprotein E and clusterin) are not only found closely associated 
with the β/A4 peptide in amyloid plaques, but can also bind to the normal 
soluble β/A4 peptide found in CSF and other biological fluids”‘. Recently, it 
was reported that fibril formation from synthetic β/A4 peptide is inhibited in 
the presence of CSF. This may be due to the presence in CSF of β/A4-
associated molecules that bind to and maintain the solubility of the peptide. 
Other β/A4-associated molecules (such as α1-antichymotrypsin and 
apolipoprotein E) can accelerate β/A4 fibrillogenesis. Thus, there seems to be 
a balance between those β/A4-associated proteins that prevent fibril 
formation, and those that stimulate it (Eikelenboom et al. 1994).  
 
2. Activated microglial cells produce and release potential toxic products, 
including cytokines, proteases and free radicals, which could damage 
neuronal cells by ‘bystander lysis’. For this reason, activated microglial cells 
might be the link between β/A4 amyloid deposition and neuronal 
degeneration (Eikelenboom et al. 1994) 
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Fig.1.4 Pathogenic events of inflammation (Rahmadi 2012) 
 
1.4 Main intracellular signaling pathways in inflammation 
Pathogen-associated molecular patterns (PAMPs) such as microbial nucleic acids, 
lipoproteins, and carbohydrates, damage-associated molecular patterns (DAMPs) 
released from injured cells and cytokines such as interleukin 1 (IL-1) and tumor 
necrosis factor-alpha (TNF-α) are the main inflammatory stimuli, which act through 
the toll-like receptors (TLRs), the IL-1 receptor (TIR) family and the tumor necrosis 
factor (TNF) receptor family, respectively (Kaminska 2005) . 
Depending on the primary stimulus, the NF-κB, the JAK/STAT and/or the MAPK 
pathways may become activated triggering an inflammatory state through the 
expression of proinflammatory and anti-inflammatory genes, which promotes the 
neutralization of the damage and leads to the resolution of inflammation.  
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Fig.1.5 Principal signaling pathways in inflammation (Tedgui and Mallat 2006). 
 
1.4.1 MAPK pathway 
Three major groups of distinctly regulated MAPK cascades have been identified in 
mammals that lead to altered gene expression: the extracellular signal-regulated 
kinase 1 and 2 (ERK 1/2), and the two SAPKs families, c-JUN N-terminal kinase 
(JNK) and p38 MAPK. ERK1/2 is activated by MAPK kinase (MKK) and MKK2, 
JNK is activated by MKK4 and MKK7, and p38 MAP kinase is activated by MKK3, 
MKK4, and MKK6. Negative feedback mechanisms including MAPK phosphatases 
(MKPs) exist to ensure that MAPK enzymes are not constitutively activated. Upon 
activation of the MAPKs, transcription factors present in the cytoplasm or nucleus 
are phosphorylated and activated leading to the expression of target genes and 
producing various biological responses such as the inflammatory response 
(Kaminska 2005). Importantly, p38 MAPK is relevant in the activation of 
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inflammation. In this way, this MAP kinase positively regulates expression of many 
genes involved in inflammation, such as those coding for TNF-α, IL-1β, IL-6, IL-8, 
cyclooxygenase- 2, and collagenase-1, -3 and this regulation can occur at both 
transcriptional and posttranscriptional levels. p38 MAPK activation is also involved 
in the increase of iNOS expression, and the final production of NO in activated 
macrophages (Fig 1.4 and 1.5) (Kaminska 2005).  
 
1.4.2 NF-κB pathway 
On the other hand, the NF-κB pathway is one of the main signaling pathways 
activated in response to the proinflammatory cytokines TNF-α, IL-1, and IL-18 as 
well as following the activation of the TLRs that bind to their respective PAMPs 
(Muller J. M. 1993). Activation of the NF-κB pathway plays a central role in 
inflammation through the regulation of genes encoding proinflammatory cytokines, 
adhesion molecules, chemokines, growth factors, and inducible enzymes such as 
cyclooxygenase-2 (COX2) and iNOS (Moriuchi, Moriuchi and Fauci 1997). NF-κB 
is a dimeric transcription factor formed by the hetero- or homodimerization of 
proteins of the REL family including p50 and p65. In its inactive form, NF-κB is 
bound to the inhibitor of κB (Iκ-B) in the cytoplasm. Proinflammatory cytokines and 
pathogens act through distinct signaling pathways that converge on the activation of 
an Iκ-B kinase (IKK) complex containing the two kinases IKK1/IKKα and 
IKK2/IKKβ and the regulatory protein NEMO (NF-κB essential modifier, also 
named IKK-γ)(Muller J. M. 1993, Moriuchi et al. 1997, Zingarelli 2005). IKK 
activation initiates Iκ-B phosphorylation at specific NH2-terminal serine residues, 
which leads to the ubiquitination and subsequent degradation of Iκ-B by the 26S 
proteasome. The degradation of IK-B releases NF-κB dimers from the cytoplasmic 
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NF-κB/Iκ-B complex allowing NF-κB to translocate to the nucleus. Once in the 
nucleus, NF-κB binds to κB enhancer elements on specific genes to promote the 
transcription of NF-κB target genes including Iκ-B, the expression of which ensures 
that NF-κB is only transiently activated. This negative-feedback regulation produces 
the characteristic oscillations observed in NF-κB nuclear translocation (Fig.1.5 and 
1.6) (Tedgui and Mallat 2006, Zingarelli 2005). 
In addition, after NF-κB activation by external inflammatory signals such as bacterial 
endotoxin, it positively regulates the gene expression of several cytokines such as 
TNF-α and β, IL-1β, IL-2, IL-6, IL-8, MCP-1, G-CSF, GM-CSF and IFN-β, which in 
turn can produce a positive feedback and amplify the original inflammatory 
signal.(Blackwell and Christman 1997). 
 
 
Fig.1.6 NF-κB activation, in which once the protein is free as a result of tissue injury, it can 
enter the cell nucleus and activate the DNA to enhance the inflammatory response further by 
the production of additional cytokines, chemokines, and adhesion molecules (Maroon, Bost 
and Maroon 2010). 
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1.4.3 JAK/STAT pathway 
Moreover, IFN-γ, one of the most potent endogenous macrophage-activating factors, 
signals through the JAK/STAT signaling pathway (Hu et al. 2007). The activation of 
JAKs after cytokine stimulation results in the phosphorylation of STATs, which then 
dimerize and translocate to the nucleus to activate gene transcription (Shuai and Liu 
2003). There are seven mammalian STATs: STAT1, STAT2, STAT3, STAT4, 
STAT5A, STAT5B and STAT6 and each one regulates inflammation differently 
having distinct proinflammatory and anti-inflammatory effects depending on the 
particular STAT. For instance, STAT1 plays a major role in mediating immune 
responses and the proinflammatory activity of IFN-γ (Fig.1.5)  (Hu 2002).  
Thus, the study of cross-talk between the proinflammatory pathways and various 
cytokines or other factors that induce these states can help to provide an explanation 
of the effects of bioactive compounds. 
 
1.4.4. Nitric oxide (NO) and inflammation  
Nitric oxide (NO) is a reactive radical molecule produced from the guanidino 
nitrogen of L-arginine, which is oxidized by NO synthase (NOS) (Nathan and Hibbs 
1991). There are three types of nitric oxide synthases (NOS).  Neuronal NOS 
(nNOS) and endothelial NOS (eNOS) activities are dependent on calcium (Ca2+), 
while inducible NOS (iNOS) is Ca2+-independent . L-arginine is oxidized to N-
hydroxy-L–arginine (L-NOHA) and further converted to L–citrulline and nitric oxide 
by NOS (Fig.1.7). NO is essential for host innate immune responses to pathogens 
such as bacteria, viruses, fungi, and parasites. In addition, NO plays an important 
role in the regulation of other physiological functions including neurotransmission, 
vasodilatation, and neurotoxicity. However, excessive NO production can result in 
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the development of inflammatory diseases such as rheumatoid arthritis and 
autoimmune disorders (O'Shea, Ma and Lipsky 2002). 
  
 
 
Fig.1.7 Formation of nitric oxide 
(http://www.pharmacorama.com/en/Sections/NoNitric_2.php) 
 
Macrophage activation by lipopolysaccharides (LPS), which are derived from gram-
negative bacteria cell walls, results in the release of several inflammatory mediators 
including NO (Yoon et al. 2009). Upon induction by certain inflammatory stimuli, 
e.g., bacterial lipopolysaccharide (LPS), the NF-κB signal pathway activates and 
regulate the expression of a wide variety of genes involved in inflammatory 
responses, e.g., the cytokines TNF-α and IL-1β, and the enzymes inducible nitric 
oxide synthase (iNOS) and cyclooxygenase-2. The enzyme iNOS catalyzes the 
conversion of amino acid L-arginine to NO, which is cytotoxic and cytostatic. Thus, 
inhibition of NO production is a major target for anti-inflammatory agent 
development and compounds able to reduce NO production by iNOS may be thus are 
attractive as anti-inflammatory agents and, for this reason; the effects of natural plant 
compounds on iNOS activity have been intensively studied (Kopincová, Púzserová 
and Bernátová 2011). 
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Fig.1.8 Activation of iNOS transcription by inflammatory stimulation (Guix 2005). 
 
 1.4.5. Cytokine system and Inflammation  
Cytokines are produced and secreted by a variety of cell types including 
macrophages and monocytes. They play a major role in the induction and regulation 
of cellular interactions (e.g., inflammation, haematopoiesis, and immune and allergic 
reactions). Cytokines represent a group of multifunctional substances that are 
involved in many steps of the inflammatory response. Until now, more than 100 
members of the cytokine family and their specific receptors have been identified 
(Haddad 2002, Hopkins 2003). Generally, cytokines can be classified as pro- or anti-
inflammatory, depending on the way they influence inflammation. In a more 
simplified view, pro-inflammatory cytokines (e. g., IL-1β, TNF-α, IL-6 and IL-18) 
seem to be involved in the initiation and amplification of the inflammatory process, 
whereas the anti-inflammatory cytokines (e. g., IL-10, TGF-β and IRA) negatively 
modulate these events (Steven and Vera 2000).  
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Cytokines are produced by both resident and migrating cells, such as mast cells, 
macrophages and neutrophils and, after release; they can act either locally or 
systemically. Due to their redundant and pleiotropic actions, cytokines form a 
network in which one cytokine can induce its own production or even the secondary 
generation of other cytokines. In addition, it has been widely shown that most 
cytokine actions involve the activation of transcription factors (e. g., NF-κB and AP-
1) and protein kinases (e. g., MAPK and PKC) that, in turn, regulate the expression 
of many target genes indispensable to the maintenance of the inflammatory state 
(Haddad 2002). For instance, cytokines may be responsible for the induction of 
several enzymes (e. g., iNOS and COX-2), receptors (PAF receptor, IL-2 receptor) 
and adhesion molecules (E-selectin, α- and β-integrins, ICAM-1, VCAM-1) (Haddad 
2002). It has been observed that several compounds are able to decrease the 
expression of different pro-inflammatory cytokines/chemokines such as TNF-α, IL-
1β, IL-6, IL-8, MCP-1 in LPS-activated mouse primary macrophages (Comalada et 
al. 2006b). 
 
1.5 Herbal medicine and Inflammation 
To date, pharmacotherapy of inflammatory conditions is based on the use of non-
steroidal anti-inflammatory drugs (NSAIDs). Considering the prevalence of 
degenerative and inflammatory conditions, it is not surprising that NSAIDs are 
among the most commonly used drugs. However, the prolonged use of NSAIDs 
comes at a price. NSAIDs can cause serious gastrointestinal toxicity. Even more 
ominously, some NSAIDs have been linked to increased blood pressure, greatly 
increased risk of congestive heart failure, stroke and myocardial infarction 
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(Rainsford 1999). Together, these findings provide the motivation for the 
development of anti-inflammatory treatments with fewer adverse effects.  
 
Since ancient times, in various cultures worldwide, inflammatory disorders and 
related diseases have been treated with plants or plant-derived formulations 
(Krishnaswamy 2008, Marc et al. 2008). Plants have long been an important source 
for the discovery of new drugs. Herbal medicines derived secondary metabolites 
such as salicylic acid from the bark of the willow tree (Salix alba) have been used for 
the treatment of inflammatory diseases in the past. In fact, the development of 
acetylsalicylic acid, commonly known as aspirin, as an anti-inflammatory drug at the 
German drug and dye firm Bayer at the end of the 19th century was motivated by the 
desire to find a less-irritating replacement for the traditional salicylate-based 
medicines. Many other medicinal plants are known to have anti-inflammatory 
activity but neither the underlying mechanisms nor their potential for the 
development of new drugs have been fully explored (Ji, Li and Zhang 2009).  
The anti-inflammatory activity of several plant extracts and isolated compounds has 
already been scientifically demonstrated. Turmeric (Curcuma longa), which has 
traditionally been used for treatment of rheumatic disorders in Indian traditional 
medicine, exerts both anti-inflammatory and anti-atherosclerotic effects 
(Krishnaswamy 2008). Ginger extract (Zingiber zerumbet) and its main active 
compound, 3-O-methyl kaempferol, inhibited the production of nitric oxide (NO) 
and prostaglandin E2 (PGE2), as well as iNOS expression in a cell culture model. In 
an in vivo model, carrageenan-induced mouse paw oedema was significantly 
attenuated (Chien et al. 2008). Furthermore, ginger is effective in ameliorating 
arthritic knee pain (Tapsell et al. 2006). Treatment of LPS-stimulated macrophages 
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with extracts from strawberry (Fragaria ananassa), loquat (Eriobotrya japonica), 
mulberry (Morus alba) and bitter melon juice (Momordica charantia) decreased the 
secretion of IL-6 and IL-1β pro-inflammatory cytokines and up-regulated the 
secretion of the anti-inflammatory cytokine IL-10 in a prophylactic cell culture 
model (Lin and Tang 2008).  
Various plant polyphenols have also been shown to exhibit anti-inflammatory 
activity: quercetin inhibits iNOS, COX-2 and C-reactive protein (CRP), and down-
regulates NF-κB and TNF-α secretion(Comalada et al. 2006a); kaempferol inhibits 
iNOS, COX-2, CRP and NF-κB (Hämäläinen et al. 2007); naringenin down-regulates 
the secretion of pro-inflammatory cytokines IL-1β, IL-6, IL-8 and TNF-α and 
inhibits iNOS expression and NF-κB activation(Hämäläinen et al. 2007); and luteolin 
inhibits TNF-α, IL-6 and IL-1β secretion (Comalada et al. 2006a, Mueller, Hobiger 
and Jungbauer 2010) (Fig.1.8). 
 
Fig.1.9 Mechanisms of the biological effects of dietary polyphenols (Han, Shen 
and Lou 2007). 
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Many of today's synthetic drugs originated from the plant kingdom, and only about 
two centuries ago the major pharmacopoeias were dominated by herbal drugs. Herbal 
medicine went into rapid decline when basic and clinical pharmacology established 
themselves as leading branches of medicine. Nevertheless, herbal medicine is still of 
interest in many diseases, in particular, psychiatric and neurological disorders. There 
are some reasons for this issue: 1) patients are dissatisfied with conventional 
treatment, 2) patients want to have control over their healthcare decision, and 3) 
patients see that herbal medicine is congruent with their philosophical values and 
beliefs. There are several studies and documents that indicate a unique role of herbal 
medicines in the treatment of AD (Akhondzadeh 2006).  
 
Preliminary clinical evidence indicates that some herbal medicines (Lemon balm 
(Melissa officinalis) (Perry et al. 1998), sage (Salvia officinalis) (Akhondzadeh et al. 
2003) can ameliorate learning and memory in patients suffering from mild-to-
moderate AD. Potential beneficial actions exerted by the active ingredients of these 
herbs are not limited to the inhibition of AChE and include the modification of Aβ 
processing, protection against apoptosis and oxidative stress, and anti-inflammatory 
effects. Should the efficacy of herbal medicines (particularly G. biloba) receive 
further clinical confirmation (Birks and Grimley Evans 2007, Tan et al. 2015), they 
might constitute a less troublesome alternative to AChE inhibitors, particularly when 
acetylcholine-mediated drugs are contraindicated (e.g. in patients with a history of 
bradycardia, peptic ulcer disease, asthma or seizures). (Akhondzadeh 2006) 
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1.6 Anti-inflammatory bioassays and their principles 
 
1.6.1 Nitric oxide quantitation via Griess method 
 
The Griess method is based on the principle of chromophore formation from 
diazotization of sulphanilamide by nitrite in acidic conditions followed by coupling 
with bicyclic amines, i.e. N-1-napthyl-ethylenediamine (NED).  The concentration of 
nitrate is calculated as a function of the reduction rate, which is in proportion to the 
yield of the Griess dye (Fig.1.10).  (Miranda, Espey and Wink 2001, Beda and 
Nedospasov 2005). 
 
Fig.1.10 Griess-reagent principles in nitrite quantification 
(http://www.biotek.com/resources/articles/reactive-oxygen-species.html 2014) 
 
 
1.6.2 Measuring TNF-α with enzyme linked immunosorbent assay 
 
ELISA stands for enzyme linked immunosorbent assay.  To quantify the amount 
TNF-α, avidin-horseradish peroxidase (avidin-HRP) conjugate is added to allow 
colour formation in the presence of tetramethylbenzidine (TMB). Subsequently, a 
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brilliant blue colour can be detected with spectrophotometer at 655nm.  Additionally, 
stop solution (0.5M H2SO4) turns the colour from brilliant blue to yellow, which is 
detectable at 450nm with reference wavelength of 655nm (Fig.1.11) (Lamche and 
Adolf 1990).  
 
 
 
Fig.1.11 TNF-α quantification with ELISA (http://www.cstj.co.jp/ddt/elisa_line.php) 
 
 
1.6.3 Determination of cell viability 
 
The principle assay of Alamar Blue relies on reduction of resazurin (blue colour and 
nonfluorescent) to resorufin (pink colour and highly fluorescent) and further reduced 
to hydroresorufin (uncoloured and nonfluorescent)(O'Brien et al. 2000). Alamar Blue 
assay works on the principle of measuring mitochondrial activity (Fig.1.12) 
(Gonzalez and Tarloff 2001).  
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Fig.1.12 Cell viability quantification with resazurin reduction to resozurfin 
(https://au.promega.com/resources/product-guides-and-selectors/protocols-and-applications-
guide/cell-viability/) 
 
 
Chronic inflammatory processes contribute to the pathogenesis of many age-related 
diseases. In search of anti-inflammatory activity of foods , in chapter 2-7 in this 
thesis we have systematically screened a variety of common dietary plants and 
mushrooms for their anti-inflammatory activity and identified some potent anti-
inflammatory compounds using above mentioned bioassays.  
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Chapter – 2 
Hydrogen peroxide acts as a first (intercellular) 
messenger in pro-inflammatory signalling 
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The physiological role of nitric oxide (NO) as an extracellular signalling molecule is 
now widely appreciated. NO, synthesized by NO synthase, typically acts in a 
paracrine fashion, where NO synthesized in one cell diffuses through the 
extracellular space and acts on a target in an adjacent cell. However, NO’s mode of 
action appears not to be unique. Here, we present evidence that hydrogen peroxide 
acts in a very similar fashion – it mediates cell-to-cell communication and can thus 
be classified as a true first messenger.   
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2.1 Introduction 
Reactive oxygen species (ROS), including superoxide (O2
–), hydrogen peroxide 
(H2O2) and hydroxyl radical (HO•), are generated under normal metabolic conditions 
through cellular respiration. ROS also participate in the bactericidal action of 
phagocytic cells of the innate immune system. The first ROS in the chain, superoxide 
(O2
-) is generated from NADPH by the membrane-bound enzyme NADPH oxidase 
(Ding 1988). O2
- is then released into the extracellular space, a phenomenon known 
as “respiratory burst” (Iles and Forman 2002).  O2- is also produced intracellularly, 
predominantly in phagosomes in order to destroy phagocytized microbes (Minakami 
and Sumimotoa 2006). O2
- is converted to H2O2 by superoxide dismutase (SOD) 
(Noor, Mittal and Iqbal 2002), and H2O2 is subsequently converted to water by 
catalase (CAT) (2). It should be noted that extracellular O2- does not easily pass the 
cytoplasmic membrane. Amphipathic H2O2 readily diffuses in and out of cells, and 
although it was long suspected to do so by simple diffusion, recent evidence points 
now at the role of aquaporin water channels (AQP) in mediating H2O2 transport 
across plasma membranes (Vieceli Dalla Sega et al. 2014a). 
H2O2 is well known to act as second messenger involved in intracellularly 
signal transduction pathways including in NF-κB-dependent gene expression, e.g. for 
pro-inflammatory mediators, including TNF-α and iNOS. (Han YJ 2001, Nakao N 
2008). Redox-sensitive, intracellular signal transduction can be down-regulated by 
various types of “anti-inflammatory” antioxidants such as α-lipoic acid and 
polyphenols (Han YJ 2001, Sen 2000, Biesalski 2007). Further support for this 
function of H2O2 comes from the fact, that exposure to exogenous H2O2 induces NF-
κB translocation (Takada et al. 2003). This ability of H2O2 to act as a second 
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messenger is termed “redox-sensitive” signal transduction (Sen 1998). On a 
molecular level, H2O2 activates a variety of redox-sensitive kinases upstream of the 
NF-κB through oxidations of critical cysteines to sulfenic acids or mixed disulfides, 
which can enhance the activity of these signaling proteins.  
Many pro-inflammatory ligands activate NADPH oxidase and lead to superoxide 
production. For this study, we have selected three ligands, LPS, IFN-ɣ and advanced 
glycation endproducts (AGEs). Bacterial endotoxins such as LPS bind to TLR4, 
activate the Src kinase/ PI3K pathway, induce activation of  p47phox, the regulatory 
subunit of NADPH oxidase, and subsequent lead to superoxide production (Hebeis 
2004, Rhee 2003, Chowdhury 2005) (Fig.2.1). IFN-γ leads to enhanced production 
of superoxide by binding  to the Interferon-ɣ receptor (IFNGR), activation of the 
JAK/STAT pathway and upregulation of the transcription of various NADPH 
oxidase subunits (MacMicking 1997).  AGEs can also induce superoxide production 
via the receptor of adcvanced glycation endproducts (RAGE) and the PI3/MAPK 
pathway, including ERK1/2 (Doublier 2003, Lal 2002, Askarovaa 2011, Abid 2001, 
Omori 2008). (Fig.2.1).  
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Fig. 2.1 Hypothesized model for the signal pathways involved in LPS, IFN-γ and AGE-
CEA induced NADPH oxidase activation, which generate intracellular ROS.  In turn, 
ROS activates PI3K/Akt and MAPK. Subsequently, MAPK (p38, ENK ½ and JNK) 
activation induces the phosphorylation of NF-κB.  
Most of the previous examples show how H2O2 can act as an intracellular signalling 
molecule. In this study we provide evidence H2O2 can diffuse through cell 
membranes and is able to transmit pro-inflammatory signals from one cell to another 
- thus acting as a true first (intercellular) messenger comparable to nitric oxide. In 
summary, the mechanisms and sequence of events behind our hypothesis (“hydrogen 
peroxide is an intercellular messenger”) are as follows:  
1. H2O2 is generated in response to a pro-inflammatory stimulus, e.g. by activated 
NADPH oxidase (“respiratory burst”) (Johnson and Sung 1987) 
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2. Hydrogen peroxide can diffuse through cell membranes into adjacent target cells, 
e.g. via aquaporin channels (Bienert, Schjoerring and Jahn 2006) 
3. Hydrogen peroxide can react with target molecules in the target cell – particularly 
reactive cysteine residues, thereby activating specific signalling pathways e.g. 
leading to the activation or enhancement of redox-sensitive transcription factors such 
as NF-κB and subsequent expression of  NF-κB-regulated cytokines or nitric oxide 
synthase (Ikeda et al. 2002). 
In support of this hypothesis, we have previously shown in a pilot study in N11 
microglial cells  that extracellular added catalase can down-regulate NO production 
almost completely – thus suggesting that H2O2 acts as a true first messenger enabling 
cell to cell communication comparable to NO (Holmquist et al. 2007).  In this 
subsequent study, we present further evidence for this hypothesis using a different 
cell line, RAW 264.7 macrophage cells, three different pro-inflammatory activators, 
and two readouts, NO and TNF-α.  
 
2.2 Materials and methods 
2.2.1 Materials 
Bovine serum albumin, lipopolysaccharide (LPS) (Salmonella serotype), N-(1-1-
napthyl) ethylenediamine dihydrochloride, resazurin sodium 10%, streptomycin, 
sulfanilamide, tetra methyl benzidine (TMB) and Trypan blue were purchased from 
Sigma-Aldrich (Castle Hill, NSW, Australia). Dulbecco’s modified Eagle’s medium 
(DMEM), Phosphate buffer saline (PBS) foetal bovine serum (FBS) and glutamine 
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were GIBCO brands purchased from Life Technologies (Mulgrave, VIC, Australia). 
Recombinant IFN-γ and TNF-α ELISA kits were purchased from PeproTech Asia 
(Rehovot, Israel).  
2.2.2 Preparation of chicken egg-albumin-derived AGEs 
Chicken egg albumin (CEA)-derived AGEs were prepared by incubating 903 mg 
glucose with 50 mg CEA in 100 mM sodium phosphate-buffered saline (PBS) (pH 
7.4). After sterilizing the samples through a 0.45 Acrodisc syringe filter into a 50 ml 
autoclaved glass jar, they were incubated for 37 days at 60°C.  The lids were 
loosened to allow air exchange.  The pH was checked every week and was adjusted 
to around 7.6 by adding sterile 100 mM NaOH. Since a steady and nearly linear 
increase in both fluorescence (370 nm excitation / 440nm emission) and absorbance 
at 400 nm was observed during the 6 weeks and the increase thereafter was only 
marginal, the CEA was assumed to be maximally modified. After incubation, 
unreacted sugars were removed before the assay by extensive dialysis against PBS. 
The AGE-CEA solutions were stored at -800C.  
2.2.3 Maintenance of RAW 264.7 macrophages 
RAW 264.7 macrophages were grown in 175 cm2 flasks on DMEM containing 5 % 
foetal bovine serum (FBS) that was supplemented with penicillin (100u/ml), 
streptomycin (100μg/ml) and L- glutamine (2mM). The cell line was maintained in 
5% CO2 at 37°C, with media being replaced every 3-4 days. Once cells had grown to 
confluence in the culture flask, they were removed using a rubber policeman, as 
opposed to using trypsin, which can remove membrane-bound receptors 
(Shanmugam et al. 2008).  
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2.2.4 Activation of RAW 264.7 macrophages 
For assays, 90 μL of each concentration of catalase (8 concentrations made by serial 
dilution from 0-4000U/mL catalase in DMEM)) were added an hour prior to addition 
of 10µL of activator.  A combination of 10 μg ml-1 LPS and 10 U ml-1 (1 unit = 
0.1ng/mL) IFN-γ, IFN-γ along (25 U ml-1) or 400 µg ml-1 AGE-CEA in DMEM were 
used for activation. After activation, the cells were incubated for 24 h at 37oC and 
then NO, TNF-α and cell viability were determined. Unactivated cells (exposed to 
media alone) were used as negative control and activated cells as positive control.  
2.2.5 Determination of NO-scavenging activity of catalase 
In a 96-well plate, 50 μL of a freshly dissolved 5 mM sodium nitroprusside solution 
in 20 mM sodium phosphate solution, pH 7.4, 0.09% NaCl was added to 50 μL of a 
solution of catalase in various concentrations ranging from 4000 U/mL to 62.5 U/mL 
for 1 h at 500C. Nitrite formed was analysed with the Griess reagent as described 
below. 
2.2.6 Determination of NO2- scavenging activity of catalase 
50 µl of freshly prepared NaNO2 (equvilant to 150 μM NO2-) was added to 50 μL of 
a solution of catalase in various concentrations ranging from 4000 U/mL to 62.5 
U/mL for 1 h at 370C. Then Nitrite in the media was analyzed with the Griess reagent 
as described below. 
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2.2.7 Determination of nitrite (as a measure of nitric oxide production) by the 
Griess assay 
Nitric oxide was determined by Griess reagent quantification of nitrite. Griess 
reagent was freshly made up of equal volumes of 1% sulfanilamide and 0.1% 
napthyethylene-diamine in 5% HCl. From each well, 50 µl of supernatant was 
transferred to a fresh 96-well plate and mixed with 50 µl of Griess reagent and 
measured at 540 nm in a POLARstar Omega microplate reader (BMG Labtech, 
Mornington, Australia). The concentration of nitrite was calculated using a standard 
curve with sodium nitrate (0-500 uM), and linear regression analysis. 
2.2.8 Determination of TNF-α by ELISA 
The diluted supernatants were used for determination of TNF-α using a commercial 
sandwich ELISA (Peprotech) according to the manufacturer’s protocol. In brief,  the 
capture antibody was used at a concentration of 1.5 μg ml-1 in PBS (1.9 mM 
NaH2PO4, 8.1 mM Na2HPO4,154 mM NaCl) (pH 7.4). Serial dilutions of TNF-α 
standard from 0 to 10000 pg mL-1 in diluent (0.05% Tween-20, 0.1% BSA in PBS) 
were used as internal standard. TNF-α was detected with a biotinylated second 
antibody and an Avidin peroxidase conjugate with TMB as detection reagent. The 
colour development was monitored at 655 nm, taking readings every 5 min. After 
about 30 min the reaction was stopped using 0.5 M sulphuric acid and the absorbance 
was measured at 450 nm using a POLARstar Omega microplate reader (BMG 
Labtech, Mornington, Australia) and expressed as a percentage of that in control 
cells after conversion of the concentrations by using a standard curve constructed 
with defined concentrations of TNF-α. Curve fitting of this standard curve and 
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extrapolation of experimental data were performed using non-linear regression 
analysis. 
2.2.9 Determination of cell viability by the Alamar Blue assay 
100 µl of Alamar Blue solution (10% Alamar Blue (Resazurin) in DMEM media) 
was added to each well, incubated at 370C for 2 h. After incubation, fluorescence 
intensity was measured with the microplate reader (excitation at 530 nm and 
emission at 590 nm) and results were expressed as a percentage of the intensity of 
that in control cells, after background fluorescence was subtracted. 
2.2.10. Statistical analysis 
Data calculations were performed using MS-Excel 2010 software. IC50 values were 
obtained by using the sigmoidal dose–response function in GraphPad Prism. The 
results were expressed as mean ± standard deviation (SD). 
 
2.3. Results  
2.3.1 Activation patterns of different ligands (LPS/IFN-γ, IFN-γ alone and AGE-
CEA) 
To establish the activation pattern of different ligands, RAW264.7 macrophages 
were activated with three different ligands, LPS, IFN-ɣ and AGEs. In this and similar 
cell lines, H2O2 production by the ligands of choice has been described previously. 
For example, LPS activated RAW 264.7 macrophages have been shown to produce 
H2O2 at concentrations up to 120ng/mL after 20 hours. Furthermore, IFN-γ was 
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shown to increase the production of H2O2 in RAW 264.7 cells with maximal effects 
being observed at 8 to 32 ng/ml (Ji GE1 1998). Moreover, ovalbumin-AGE-activated 
induces H2O2 production as shown in human umbilical vein endothelial cells 
(HUVEC).  
In a first experiment, RAW264.7 macrophages were activated in a dose dependent 
manner with LPS (up to 10 μg/mL) + IFN-γ (up to10U/mL, (1 unit = 0.1ng/mL)), 
IFN-γ (25 U/mL) or AGE-CEA (up to 400 μg/mL). NO and TNF-α production (as 
readouts for activation) as well as cell viability were determined after 24 hours (Fig. 
2.2).  All pro-inflammatory ligands produced similar maximal amounts of NO 
(corresponding to 80μM nitrite).  For TNF-α, AGE-CEA and the combination of LPS 
+ IFN-γ produced about 80ng/mL TNF-α, while IFN-γ alone only produced about 
60ng/mL TNF-α at the maximum concentrations (Fig.2.2). LPS alone did produced > 
5uM NO and >5 mg/ml TNF-α (data not shown) and was therefore not used for 
further experiments as a sole activator.  
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Fig.2.2 Concentration response curves for (a) LPS/IFN-γ, (b) IFN-γ and (c) AGE-CEA 
for NO production and (c) LPS/IFN-γ, (d) IFN-γ and (e) AGE-CEA for TNF-α 
production with cell viability.  RAW264.7 macrophages were activated with LPS (10 
μg/mL) + IFN-γ (10U/mL, (1 unit = 0.1ng/mL)), IFN-γ (25 U/mL) or AGE-CEA (400 
μg/mL) in a dose dependent manner and measured the NO and TNF-α inhibition and Cell 
viability after 24 hours. 
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2.3.2 Extracellular added catalase inhibits NO and TNF-α production  
According to our hypothesis, H2O2 acting as a first messenger would travel through 
the extracellular space and diffuse into and activate adjacent cells. Extracellular 
added catalase converts H2O2 to water and oxygen in the extracellular space and 
therefore the pro-inflammatory signal would not reach the next cell, leading to an 
overall reduction of the readouts, NO and TNF-α. Having established that activation 
of RAW 264.7 macrophages with different ligands leads to the production of NO and 
TNF-α, we investigated if increasing concentrations of catalase to would lead to 
lower NO and TNF-α production. If H2O2 travels between cells propagating the pr-
inflammatory signal, then the pro-inflammatory readouts should be inhibited by 
catalase in a dose-dependent manner.  
RAW 264.7 macrophages were activated with LPS (10 μg/mL) + IFN-γ (10U/mL, (1 
unit = 0.1ng/mL)), IFN-γ (25 U/mL) or AGE-CEA (400 μg/mL) in the presence of 
increasing concentrations of catalase (ranging from 0 to 4000 U/mL) for 24 h after 
which NO and TNF-α production were determined. The experiment showed a 
concentration-dependent inhibition of NO and TNF-α production by catalase, in 
response to the three ligands / ligand combinations (IFN-γ, LPS, and AGE-CEA).  
Addition of catalase to LPS/IFN-γ and IFN-γ activated RAW264.7 macrophages 
showed considerable NO inhibition (IC50 values were 400 ± 25 U/mL and 555 ± 28 
U/mL, respectively), compared to the AGE-CEA activated RAW 264.7 cells (IC50 
>4000 U/mL) (Table 2.1 and Fig.2.3).   
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Table 2.1 Nitric oxide and TNF-α production by RAW 264.7 macrophages 
activated with LPS/IFN-γ , IFN-γ along and AGE-CEA in the presence of 
catalase. 
 
TNF-α production was less affected by addition of catalase with IC50 > 4000 U/mL 
for all three ligands / ligand combinations. The percentage of TNF-α inhibition of 
LPS/IFN-γ, IFN-γ and AGE-CEA activated RAW264.7 macrophages at maximum 
concentration of catalase (4000 U/mL) were 64 ± 9, 59 ± 1 and 57 ± 1 % respectively 
(Table 2.1 and Fig.2.3). The decrease in NO and TNF-α production was not caused 
by cell death, since catalase had no significant effect on cell viability (Fig.2.3).  
 
 
Activator Inhibition of NO 
production  
(IC
50
 in U/ml ± 
SD) 
 
Inhibition of TNF-α  
Production  
(IC
50
 in U/ml ± SD) 
 
% inhibition of 
TNF-α at maximum 
concentration (4000  
U/ml ± SD) 
LPS/IFN-γ 400 ± 25 >4000 64 ± 9 
IFN-γ  555 ± 28 >4000 59 ± 1 
AGE-CEA >4000 >4000 57 ± 1 
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Fig. 2.3 Nitric oxide and TNF-α production with cell viability of RAW 264.7 
macrophages activated with (a) LPS + IFN-γ, (b) IFN-γ and (c) AGE-CEA. RAW 264.7 
macrophages were activated with LPS (10 μg/mL) + IFN-γ (10U/mL, (1 unit = 0.1 ng/mL), 
IFN-γ (25 U/mL) or AGE-CEA (400 μg/mL) and nitric oxide (NO) production and TNF-α 
production were measured in the media after 24 hours of incubation with increasing 
concentrations of catalase. More than six replicate were used for the each test.  
2.3.3 Investigation of a potential direct NO or nitrite scavenging effect of 
catalase 
As the down-regulation of NO was particularly strong, it could be hypothesized that 
catalase scavenges NO or nitrite directly and that this reactivity is the main reason 
for its inhibitory effects on nitrite levels. To investigate if direct NO scavenging is 
the cause for lower nitrite levels in the presence of catalase, a control experiment in a 
cell free system was performed.  
NO was released by the NO donor sodium nitroprusside (SNP) (Roncaroli 2005). NO 
in aqueous solution containing oxygen is oxidized primarily to nitrite  (Ignarro 1993), 
which allows the Griess assay to be used to indirectly measure NO production 
similar to the cellular assays.   
To investigate if direct NO2
- scavenging is the cause for lower nitrite levels in the 
presence of catalase in our experiments, 50 µl of freshly prepared NaNO2 (equivalent 
to 150 μM NO2-) was added to 50 μL of a solution of catalase in various 
concentrations ranging from 4000 U/mL to 62.5 U/mL for 1 h at 370C. After 
incubation of the NO generating system with catalase, Griess reagent was added and 
the concentration of nitrite was determined. 
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Under these assay conditions, catalase did not scavenge NO or NO2
-, indicating that 
direct NO or NO2
- scavenging is not the major mode of action of catalase (Fig. 2.4). 
 
  
Fig.2.4 Direct NO and NO2- scavenging activity of catalase.  
(a) NO production was measured as the concentration of nitrite present in the media after 1 h 
of incubation of the catalase with 5 mM SNP at 500C. Data points were expressed as % of 
control and represent the mean of four replicates. (b) The concentration of nitrite present in 
the media after 1 h of incubation of the catalase with 150 μM NO2- at 370C. Data points were 
expressed as % of control and represent the mean of four replicates. 
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2.4 Discussion 
Here, we present evidence that hydrogen peroxide travels through the extracellular 
space and activate adjacent cells and extracellular added catalase would convert 
hydrogen peroxide to water and oxygen in the extracellular space and the pro-
inflammatory signal would not reach the next cell, leading to an overall reduction of 
the readouts, NO and TNF-α. One of the previous examples also show how H2O2 can 
act as an intercellular signalling molecule which is directly relevant to the work we 
performed in this chapter. In that study they provide evidence that specific 
aquaporins facilitate Nox-produced hydrogen peroxide transport through plasma 
membrane in leukaemia cells (Vieceli Dalla Sega et al. 2014b).   
Having established that activation of RAW 264.7 macrophages with different ligands 
(LPS (10 μg/mL) + IFN-γ (10U/mL, (1 unit = 0.1ng/mL)), IFN-γ (25 U/mL) or 
AGE-CEA (400 μg/mL)) leads to production of NO and TNF-α, we used different 
concentration of catalase to investigate whether it can inhibit NO and TNF-α 
production. If hydrogen peroxide travels between cells propagating the signal, then 
certain percentage of the readout might be inhibited by catalase and this should be 
dose-dependent. To investigated that, RAW 264.7 macrophages were activated with 
LPS (10 μg/mL) + IFN-γ (10U/mL, (1 unit = 0.1ng/mL)), IFN-γ (25 U/mL) or AGE-
CEA (400 μg/mL) and nitric oxide (NO) production and TNF-α production were 
measured in the media after 24 hours of incubation with increasing concentrations of 
catalase ranging from 0 to 4000 U/mL.  
Membrane-bound NADPH oxidase of phagocytes generates H2O2 into extracellular 
spaces, which dismutates spontaneously or enzymatically to H2O2. Exposure to 
exogenous H2O2 enhanced IFN-γ induced NO production by macrophages and 
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activated NF-κB (Fig.2.1). LPS also acts in a synergistic manner to increase IFN-γ 
induced NO production through the activation of NF-κB (Held 1999).  
LPS activates the NF-κB family of transcription factors (Muller J. M. 1993). In 
resting cells, NF-κB is complexed in the cytoplasm by an inhibitory protein, IκB. 
Signal-induced phosphorylation and subsequent proteolytic degradation of IκB frees 
NF-κB from such complexes. Following this, NF-κB rapidly translocates to the 
nucleus, binds to the κB element of target genes, and activates the expression of 
iNOS genes. In contrast, IFN-γ employs the JAK-STAT pathway for its signal 
transduction (Darnell J. E. J. 1994). Binding of IFN-γ to its receptor results in 
recruitment of two Janus tyrosine kinases, JAK1 and JAK2, which induce the 
tyrosine phosphorylation of a dormant cytoplasmic protein, signal-transducing 
activator of transcription 1 (STAT1). STAT1 then migrates to the nucleus and binds 
to the IFN-γ-activated site of cellular genes whose products mediate IFN-γ effects 
(Darnell J. E. J. 1994). Although they activate different sets of genes, IFN-γ and LPS 
both are known to induce IFN-γ regulatory factor 1, which is essential for induction 
of inducible nitric oxide synthase (iNOS) (Kamijo R. 1994). The identical 
transcription factors, NF-κB (Iwashima 1999), AP-1 (Simm 1997) and Stat-1 (Huang 
1999) are also activated by AGEs and caused an up-regulation in the expression of 
iNOS (Wong A 2001).  
Our results showed that catalase down-regulated nearly 100% of NO, but only 40% 
of TNF-α production, suggesting that intercellular messaging by H2O2 is more 
relevant for NO than for TNF-α. In summary, our results demonstrate that H2O2 is 
able to travel between cells and induce a signal in an adjacent cell, and that it is 
indeed a true first messenger for pro-inflammatory signalling. These data might also 
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have interesting consequences for the design of anti-inflammatory drugs.  Catalase 
mimetics might be able to broadly influence inflammatory processes, and it might 
not even be required to for them to enter a cell to be active. 
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Chapter – 3 
Determination of anti-inflammatory activities 
of standardized preparations of plant and 
mushroom based foods 
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Chronic inflammatory processes contribute to the pathogenesis of many age-related 
diseases. One of the possible strategies to suppress inflammation is the employment 
of functional foods with anti-inflammatory properties. In search of anti-inflammatory 
foods, we have systematically screened a variety of common dietary plants and 
mushrooms for their anti-inflammatory activity. 
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Abstract
Purpose Chronic inflammatory processes contribute to
the pathogenesis of many age-related diseases. In search of
anti-inflammatory foods, we have systematically screened
a variety of common dietary plants and mushrooms for
their anti-inflammatory activity.
Methods A selection of 115 samples was prepared by a
generic food-compatible processing method involving
heating. These products were tested for their anti-inflam-
matory activity in murine N11 microglia and RAW 264.7
macrophages, using nitric oxide (NO) and tumour necrosis
factor-a (TNF-a) as pro-inflammatory readouts.
Results Ten food samples including lime zest, English
breakfast tea, honey-brown mushroom, button mushroom,
oyster mushroom, cinnamon and cloves inhibited NO
production in N11 microglia, with IC50 values below
0.5 mg/ml. The most active samples were onion, oregano
and red sweet potato, exhibiting IC50 values below 0.1
mg/ml. When these ten food preparations were retested in
RAW 264.7 macrophages, they all inhibited NO production
similar to the results obtained in N11 microglia. In addi-
tion, English breakfast tea leaves, oyster mushroom, onion,
cinnamon and button mushroom preparations suppressed
TNF-a production, exhibiting IC50 values below 0.5 mg/ml
in RAW 264.7 macrophages.
Conclusion In summary, anti-inflammatory activity in
these food samples survived ‘cooking’. Provided that
individual bioavailability allows active compounds to
reach therapeutic levels in target tissues, these foods may
be useful in limiting inflammation in a variety of age-
related inflammatory diseases. Furthermore, these foods
could be a source for the discovery of novel anti-inflam-
matory drugs.
Keywords Food  Inflammation  Cinnamon  Oregano 
Oyster mushroom
Introduction
The increase in both the absolute number and relative
proportion of the elderly is arguably one of the most
important developments facing human society in the next
decades [1]. Age is the leading risk factor for many dev-
astating diseases such as acute and chronic neurodegener-
ative diseases, degenerative musculoskeletal diseases,
cardiovascular diseases, diabetes, asthma, rheumatoid
arthritis and inflammatory bowel disease. Increasing evi-
dence suggests that systemic low-grade inflammation is a
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contributing factor in these age-related diseases [2–6]. To
date, pharmacotherapy of inflammatory conditions is based
on the use of non-steroidal anti-inflammatory drugs
(NSAIDs). However, NSAIDs can cause serious gastroin-
testinal toxicity such as gastric bleeding and the formation
of stomach ulcers [7, 8]. Even more ominously, some
NSAIDs, particularly COX-2 inhibitors, have been linked
to increased blood pressure, greatly increased risk of con-
gestive heart failure, occurrence of thrombosis and myo-
cardial infarction [9–11]. Together, these findings provide
the motivation for the development of anti-inflammatory
treatments with fewer adverse effects.
Herbal medicines derived from plants rich in the sec-
ondary metabolite salicylic acid, such as the bark of the
willow tree (Salix alba), have been used for the treatment
for diseases with a prominent inflammatory component for
thousands of years. Many other medicinal plants are known
to have anti-inflammatory activity, but neither the under-
lying mechanisms nor their potential for the development
of new drugs has been fully explored. Several mechanisms
are proposed to explain their anti-inflammatory action,
including inhibition of cyclooxygenases and lipoxygenases
or modulation of pro-inflammatory gene expression such
as inducible nitric oxide synthase, and several pivotal
cytokines including tumour necrosis factor-a (TNF-a)
[12, 13].
However, very few studies have attempted a systematic
comparison of a large number of commercially available
plant and mushroom foods in search of those with the
highest degree of anti-inflammatory activities. To close this
knowledge gap, we have screened 115 dietary plants and
mushrooms for in vitro anti-inflammatory activities using a
generic food-compatible sample processing method
involving heating in water or in the presence of glucose.
Materials and methods
Materials
Plant and mushroom samples in the screening library were
obtained from retail suppliers in Melbourne, Australia.
DMSO, 95 % ethanol, bovine serum albumin, lipopoly-
saccharide (LPS) (Escherichia coli serotype 0127:B8),
EDTA, N-(1-1-napthyl) ethylenediaminedihydrochloride,
penicillin G sodium benzyl, resazurin sodium, streptomy-
cin, sulphanilamide, tetramethylbenzidine (TMB) and try-
pan blue were purchased from Sigma-Aldrich (Castle Hill,
NWS, Australia). Antibiotics, Dulbecco’s modified Eagle’s
medium (DMEM), foetal bovine serum (FBS) and gluta-
mine were purchased from Invitrogen (Mulgrave, Vic,
Australia). Murine IFN-c and TNF-a ELISA kits were
purchased from Peprotech (Rocky Hill, NJ, USA).
Methods
Preparation of the food and plant library samples
Plant and mushroom library samples were prepared by
methods usually employed with food preparation, involv-
ing heating (i.e. ‘cooking’), mechanical dispersion and
treatments intended to solubilise both hydrophobic and
hydrophilic solutes. Samples were prepared by blending in
a food processor with water (1:2 ratio w/v) before heating
in a microwave for 10 min under control conditions or
including 1 % glucose, to enhance Maillard reaction
products. After cooling to room temperature, ascorbic acid
(0.1 % of initial solids) and ethanol (1 % of initial solids)
were added for microbial stabilisation. Samples were
ultrasonicated using a 400-W probe at 100 % power for
2 min (Hielscher 400UPS) before freeze drying.
Maintenance of N11 microglia and RAW 264.7
macrophages
Cells were cultured in 175-cm2 flasks in DMEM containing
5 % FBS, supplemented with glutamine (2 mM), penicillin
(200 U/ml), streptomycin (200 lg/ml) and fungizone
(2.6 lg/ml). The cell lines were maintained in 5 % CO2 at
37 C.
Pro-inflammatory activation of cells
Cells were seeded at a density of 75,000/well into each
well of a 96-well plate. After 24 h, a combination of 25
lg/ml LPS and 10 U/ml IFN-c diluted in DMEM was used
for activation. The food samples were dissolved in DMEM,
and insoluble solids were removed by centrifugation at
16,9009g for 2 min. Samples were added to the cells an
hour prior to the addition of the inflammatory activation
mix at a maximal concentration of 2.5 mg/ml, from which
6 doses were made by serial 1:2 dilutions. Cells were
incubated for 24 h at 37 C with the inflammatory activa-
tion mix before NO and TNF-a levels were measured.
Measurement of nitrite levels by the Griess assay
NO release was measured through the quantification of
nitrite by the Griess assay. The Griess reagent was made up
of equal volumes of 1 % sulphanilamide and 0.1 % napthyl
ethylenediamine in 5 % HCl. From each well, 80 ll of cell
culture medium was transferred to a fresh 96-well plate and
mixed with 80 ll of Griess reagent, and after 30 min at
room temperature, absorbance was measured at 540 nm in
a POLARstar Omega microplate reader (BMG Labtech,
Mornington, Australia) and expressed as a percentage of
that in control cells.
336 Eur J Nutr (2014) 53:335–343
123 62
Measurement of TNF-a levels by enzyme-linked
immunosorbent assay (ELISA)
Determination of TNF-a was performed by ELISA,
according to the manufacturer’s instructions (Peprotech)
with minor modifications. Briefly, the capture antibody
was diluted to 0.5 lg/ml in phosphate-buffered saline
(PBS; 1.9 mM NaH2PO4, 8.1 mM Na2HPO4, 154 mM
NaCl pH 7.4), and 100 ll of diluted capture antibody was
added to each well of a 96-well plate, sealed with parafilm
and incubated overnight at room temperature. The plate
was washed 4 times with washing buffer (0.05 % Tween-
20 in PBS), 250 ll of blocking buffer (1 % BSA in PBS)
was added to each well, and the plate was covered and
incubated for 1 h at room temperature. The plate was
again washed 4 times in washing buffer. TNF-a standard
was serially diluted from 0 to 10,000 pg/ml in diluent
(0.05 % Tween-20, 0.1 % BSA in PBS). To each well,
50 ll of cell supernatant or TNF-a standard in duplicate
was added; the plate was covered and incubated for 2.5 h
at room temperature. Each well was washed 4 times with
washing buffer. Detection antibody was diluted to
0.125 lg/ml in diluent (supplied by the manufacturer), and
100 ll of diluted detection antibody was added to each
well. The plate was covered and incubated for 2.5 h before
being washed 4 times with washing buffer. Avidin–per-
oxidase conjugate was diluted to a ratio of 1:4,000 in
diluent, and 100 ll of diluted Avidin–peroxidase conju-
gate solution was added to each well; the plate was cov-
ered and incubated for 30 min before being washed 4
times with washing buffer. To each well, 100 ll of
3,30,5,50-tetramethylbenzidine (TMB) liquid substrate
solution (0.5 mg TMB dissolved in 1 ml DMSO, supple-
mented with 9 ml phosphate-citrate buffer and 1 ll 30 %
H2O2) was added. Absorbance was measured at 655 nm in
a POLARstar Omega microplate reader (BMG Labtech,
Mornington, Australia), taking readings every 5 min. After
25 min, the reaction was stopped using 0.5 M sulphuric
acid, and then the absorbance was measured at a wave-
length of 455 nm.
Determination of cell viability
The Alamar Blue assay is a colorimetric assay involving
the cellular reduction of resazurin to resorufin. Resazurin
was dissolved in PBS to give a concentration of 0.001 %
(w/v), sterile-filtered (0.22 lm), protected from light with
aluminium foil and stored at 4 C for up to 6 months. To
determine cell viability, incubation media were aspirated
from wells and replaced with 100 ll of resazurin solution
and incubated at 37 C for 1 h. After incubation for 1 h,
fluorescence of formed resorufin was measured with
excitation at 530 nm and emission at 590 nm in a PO-
LARstar Omega microplate reader (BMG Labtech, Mor-
nington, Australia) and expressed as a percentage of that
in control cells, after background fluorescence was
subtracted.
Data calculation and statistics
Data calculations were performed using MS Excel 2010
software. IC50 values were obtained by using the sigmoidal
dose–response function in GraphPad Prism. IC50 values
from three experiments were averaged (all performed in
triplicate). The results were expressed as mean ± standard
deviation. Differences between the same sample heated in
water or glucose were analysed by t-tests using GraphPad
Prism.
Results
Primary screen of 115 food and mushroom samples
using nitric oxide as pro-inflammatory readout
A total of 115 commercially available dietary plants and
mushrooms were selected (Table 1). Samples were pre-
pared using a generic food-compatible sample processing
method involving heating in water or in the presence of
1 % glucose (to allow modification by the Maillard reac-
tion to form Maillard reaction products, MRPs).
These 115 samples (including 115 identical samples
heated with glucose) were then tested for their ability to
down-regulate LPS ? IFN-c-induced NO production in
N11 microglia (Table 1). Ten food preparations demon-
strated significant anti-inflammatory activity, with IC50
values below 0.5 mg/ml (Table 2). Seven of these food
preparations, including lime zest, English breakfast tea,
honey-brown mushroom, button mushroom, oyster
mushroom, cinnamon and cloves, demonstrated potent
anti-inflammatory activity, with IC50 values between 0.1
and 0.5 mg/ml (Table 2). However, the most active food
samples were onion, followed by oregano and red sweet
potato, exhibiting IC50 values below 0.1 mg/ml (Table 3).
Furthermore, the MRP-modified samples showed IC50
values in the same order of magnitude as the unmodified
samples, and despite significant differences in some
samples between the unmodified and MRP-modified
samples, no general increase in anti-inflammatory activity
by the inclusion of glucose in the heating mixture could
be detected. All of the active preparations were non-toxic
at the IC50 values (cell viability [75 %), suggesting that
the reduction in NO production was not simply caused by
a decrease in cell number or cell viability.
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Table 1 List of food and mushroom samples tested for their anti-inflammatory activity
Category Foods Botanical name Plant part used Plant family or class of organism
Herbs Continental parsley Petroselinium crispum Dried aerial parts Apiaceae/Umbelliferae
Tarragon Artemisia dracunculus Dried leaf Asteraceae/Compositae
Oregano Origanum vulgare Dried leaf Lamiaceae/Labiatae
Rosemary Rosmarinus officinalis Dried leaf Lamiaceae/Labiatae
Sage Salvia officinalis Dried leaf Lamiaceae/Labiatae
Thyme Thymus vulgaris Dried leaf Lamiaceae/Labiatae
Spices Fennel Foeniculum vulgare Seeds Apiaceae/Umbelliferae
Condiments Coriander Coriandrum sativum Seeds Apiaceae/Umbelliferae
Yellow mustard Brassica hirta Seeds Cruciferae
Bay leaves Laurus nobilis Leaves Lauraceae
Cinnamon Cinnamomum zeylanicum Bark Lauraceae
Garlic Allium sativum Bulb Lilliaceae
Brown linseed Linum Usitatissimum Seeds Linaceae
Cloves Syzygium aromaticum Flower buds Myrtaceae
Cardamom Elattaria cardamomum Fruit Zingiberaceae
Ginger Zingiber officinale Rhizome Zingiberaceae
Turmeric Curcuma longa Rhizome Zingiberaceae
Vegetables Spinach Spinacia oleracea Aerial parts Amaranthaceae
Silver beet Beta vulgaris Tuber Amaranthaceae
Rainbow silver beet Beta vulgaris Tuber Amaranthaceae
Beet root Beta vulgaris Tuber Amaranthaceae
Carrot Daucus carota Tuber Apiaceae/Umbelliferae
Coriander Coriandrum sativum Leaves Apiaceae/Umbelliferae
Black carrot Daucus carota Tuber Apiaceae/Umbelliferae
Asparagus Asparagus officinalis Asparagaceae
Radiccio Cichorium intybus Asteraceae/Compositae
Red coral lettuce Lactuca sativa Aerial parts Asteraceae/Compositae
Bok Choi Brassica chinensis var.parachinensis Fresh herb Cruciferae
Brussel srouts Brassica oleracea gemmifera? Fresh herb Cruciferae
Chinese Broccoli Brassical oleracea Fresh herb Cruciferae
Chinese cabbage Brassica rapa Fresh herb Cruciferae
Choi sum Brassica chinenssis Fresh herb Cruciferae
Red cabbage Brassica oleracea var.capitata rubra Aerial parts Cruciferae
Savoy cabbage Brassica oleracea var savoy Cruciferae
Water cress Nasturtium officinale Cruciferae
Red Sweet Potato Ipomoea batatus Tuber Convolvulaceae
Choko flesh Sechium edule Fruit flesh Cucurbitaceae
Pumpkin Cucurbita maxima Fruit Cucurbitaceae
Squash Cucurbita moschata Fruit Cucurbitaceae
Choko skin Sechium edule Skin Cucurbitaceae
Basil green Ocimum basilicum Fresh herb Lamiaceae/Labiatae
Basil purple Ocimum basilicum Fresh herb Lamiaceae/Labiatae
Basil Thai Ocimum basilicum var. thrysiflora Fresh herb Lamiaceae/Labiatae
Green peas Pisum sativum Seeds Leguminosae
Green beans
Chives Allium schoenoprasum Bulb Lilliaceae
Leek Allium porrum Herb Lilliaceae
Onion Allium cepa Buld Lilliaceae
Shallot Allium cepa var. aggregatum Bulb Lilliaceae
Spring onion Allium fistulosum Bulb Lilliaceae
Red onion Allium cepa Bulb Lilliaceae
Corn Zea mays Seeds Poaceae
Lemon grass Cimbopogon citratus Aerial parts Poaceae
Rhubarb Rheum palmatum Polygonaceae
White potato Solanum tuberosum Tuber Solanaceae
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Table 1 continued
Category Foods Botanical name Plant part used Plant family or class of organism
Marine algae Spirulina Arthrospira platensis Whole organism Cyanobacteria
Fruits Kiwi Gold Actinidia chinensis Actinidiaceae
Kiwi green Actinidia chinensis Actinidiaceae
Cucumber Cucumis sativus Cucurbitaceae
Zucchini white Cucurbita peop Cucurbitaceae
Blueberries Vaccinium corymbosum Ericaceae
Avocado Persea americana Lauraceae
Coconut Cocos nucifera Palmae
Quince Pyrus cydonia Rosaceae
Raspberries Rubus idaeus Rosaceae
Strawberries Fragaria X ananassa Rosaceae
Apples Red delicious Malus domestica Rosaceae
Ruby grapefruit Citrus paradisi Rutaceae
Lime Citrus aurantifolia Rutaceae
Mandarine (imperial) Citrus reticulata Rutaceae
Lemon flesh Citrus limon Rutaceae
Lime zest Citrus aurantifolia Rutaceae
Oranges Navel Citrus sinensis Rutaceae
Oranges Valencia Citrus sinensis Rutaceae
Orange zest Citrus sinensis Rutaceae
Lemon zest Citrus limon Rutaceae
Citrus yellow flesh Citrus limon Rutaceae
Citrus red skin Citrus limon Rutaceae
Citrus red flesh Citrus limon Rutaceae
Citrus yellow skin Citrus limon Rutaceae
Citrus green Citrus limon Rutaceae
Tomato Lycoperisicon esculentum Solanaceae
Grapes M48-42 Vitis vinifera Vitaceae
Grapes Chambourcin Vitis vinifera Vitaceae
Grapes Cabernet Sauvignon Vitis vinifera Vitaceae
Grapes M12-41 Vitis vinifera Vitaceae
Grapes Sanmuscat Vitis vinifera Vitaceae
Grapes Concord Vitis vinifera Vitaceae
Grapes CR101-13 Vitis vinifera Vitaceae
Grapes CR101-10 Vitis vinifera Vitaceae
Mushrooms Maitake Grifola frondosa Fruit body Polyporaceae
Jew’s ear Auricularia auricula-judae Fruit body Auriculariaceae
Oyster Pleurotus ostreatus Fruit body Pleurotaceae
Honey brown Agaricus bisporus Fruit body Agaricaceae
Button Agaricus bisporus Fruit body Agaricaceae
Enoki Flammulina veluptipes Fruit body Physalacriaceae
Shiitake Lentinus edodes Fruit body Tricholomataceae
Beverages Coffee beans dark columbia Coffea arabica Rubiaceae
Coffee beans mocha Coffea arabica Rubiaceae
Cocoa beans Theobroma cocoa Malvaceae
Tea leaves English breakfast Camellia sinensis Theaceae
Sencha tea leaves Japanese Camellia sinensis Theaceae
Eur J Nutr (2014) 53:335–343 339
12365
Table 2 Food samples with
anti-inflammatory activity
(IC50: 0.1–0.5 mg/ml)
Food sample Heated in IC50 for inhibition of
NO production (mg/ml)
Cell viability at
IC50 for NO (%)
Oyster mushroom Water 0.47 ± 0.28 96 ± 6
Oyster mushroom Glucose 0.27 ± 0.10 98 ± 8
Lime zest Water 0.36 ± 0.06 108 ± 4
Lime zest Glucose 0.13 ± 0.04 93 ± 10
Honey-brown mushroom Water 0.16 ± 0.13 106 ± 12
Honey-brown mushroom Glucose 0.11 ± 0.04 104 ± 14
Button mushroom Water 0.14 ± 0.01 105 ± 15
Button mushroom Glucose 0.35 ± 0.01 124 ± 2
English breakfast tea leaves Water 0.24 ± 0.13 94 ± 3
English breakfast tea leaves Glucose 0.30 ± 0.21 92 ± 2
Cinnamon Water 0.21 ± 0.10 88 ± 12
Cinnamon Glucose 0.29 ± 0.14 89 ± 14
Cloves Water 0.28 ± 0.06 83 ± 5
Cloves Glucose 0.15 ± 0.01 95 ± 9
Table 3 Food samples with
anti-inflammatory activity
(IC50 \ 0.1 mg/ml)
Food sample Heated in IC50 for inhibition of
NO production (mg/ml)
Cell viability at
IC50 for NO (%)
Onion Water 0.087 ± 0.030 99 ± 5
Onion Glucose 0.075 ± 0.010 101 ± 1
Oregano Water 0.066 ± 0.020 96 ± 2
Oregano Glucose 0.083 ± 0.030 96 ± 3
Red sweet potato Water 0.067 ± 0.020 95 ± 7
Red sweet potato Glucose 0.054 ± 0.020 90 ± 5
Table 4 Food samples retested in RAW 264.7 macrophages
Food sample IC50 for NO production (mg/ml) IC50 for TNF-a production (mg/ml) LC50 (mg/ml)
Onion 0.13 ± 0.02 0.30 ± 0.01 [2.5
Oregano 0.13 ± 0.01 0.73 ± 0.06 [2.5
Oyster mushroom 0.07 ± 0.01 0.23 ± 0.02 [2.5
Red sweet potato 1.54 ± 0.10 0.51 ± 0.03 [2.5
Lime zest (glucose) 0.41 ± 0.05 1.02 ± 0.11 [2.5
Honey-brown mushroom 0.81 ± 0.03 1.0 3 ± 0.14 [2.5
Button mushroom 0.73 ± 0.01 0.39 ± 0.04 [2.5
Cinnamon 0.10 ± 0.01 0.45 ± 0.01 [2.5
Cloves 0.12 ± 0.01 2.12 ± 0.02 [2.5
English breakfast tea leaves 0.40 ± 0.01 0.30 ± 0.02 [2.5
Anti-inflammatory drug
Prednisone 0.25 ± 0.09 (0.69 ± 0.26 mM) 0.7 ± 0.07 (1.95 ± 0.21 mM) 1.36 ± 0.21 (3.81 ± 0.59 mM)
Ibuprofen 0.79 ± 0.08 (3.83 ± 0.43 mM) 0.42 ± 0.16 (1.19 ± 0.16 mM) 0.34 ± 0.09 (1.63 ± 0.44 mM)
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Secondary screen using a second cell line
(RAW 264.7 macrophages) and nitric oxide plus
TNF-a as pro-inflammatory readouts
The 10 most active samples (defined as having an IC50
value of \0.5 or 0.1 mg/ml, respectively) with demon-
strated anti-inflammatory properties from the primary
screen were retested in a second cell line with an additional
pro-inflammatory readout, TNF-a. Since the previous
experiment did not show any striking difference between
the original and glucose-modified preparations, no glucose-
modified samples were used in the second screen, except
for lime zest, where the availability of the unmodified
sample was limited.
These 10 active samples (English breakfast tea leaves,
onion, oregano, oyster mushroom, red sweet potato, lime
zest, honey-brown mushroom, button mushroom, cinna-
mon and cloves) were tested by measuring their ability to
down-regulate LPS ? IFN-c-induced release of NO and,
as a second marker of inflammation, TNF-a (Table 4).
Of the 10 products, oyster mushroom and cinnamon
demonstrated the most significant anti-inflammatory activi-
ties (with IC50 values below 0.1 mg/ml), followed by cloves,
oregano, onion, English breakfast tea leaves and lime zest
(with IC50 values below 0.5 mg/ml) in terms of suppression of
LPS- and IFN-c-induced NO production. In addition, English
breakfast tea leaves, oyster mushroom, onion, cinnamon and
button mushroom preparations also suppressed TNF-a release
(with IC50 values below 0.5 mg/ml). Oyster mushroom was
the most active anti-inflammatory sample for both NO inhi-
bition and TNF-a inhibition, with IC50 values 0.067 and
0.23 mg/ml, respectively (Table 4).
In addition, two anti-inflammatory drugs, including
prednisone and the non-steroidal anti-inflammatory drug
(NSAID) ibuprofen, were tested in the same assay systems.
Ibuprofen was toxic to cells at concentrations of
1.63 ± 0.44 mM, and NO and TNF-a production were
down-regulated at the same concentrations (Table 4).
Prednisone inhibited LPS ? IFN-c-induced NO and TNF-a
production, with IC50 values of 0.25 ± 0.09 mg/ml (0.69 ±
0.26 mM) and 0.7 ± 0.07 mg/ml (1.95 ± 0.21 mM),
respectively (Table 4).
Discussion
The activation of macrophages and microglia leads to
secretion of inflammatory molecules such as the pro-
inflammatory cytokine TNF-a and the free radical NO,
which play an important role in inflammation and nitroxi-
dative stress in many age-related diseases, including Alz-
heimer’s disease (AD) [14]. In the assay systems used here,
the bacterial surface molecule lipopolysaccharide and the
cytokine IFN-c were used to activate microglia, and NO
and TNF-a release were used as readouts [15].
As control substances, the synthetic corticosteroid
prednisone and the non-steroidal anti-inflammatory drug
(NSAID) ibuprofen were also tested in the same assay
systems. As expected, ibuprofen as a selective COX-1 and
COX-2 inhibitor did not specifically inhibit LPS- and IFN-
c-induced NO and TNF-c production. Interestingly, pred-
nisone was quite a weak inhibitor of LPS ? IFN-c-induced
NO and TNF-a production, since in many other inflam-
matory paradigms, corticosteroids are effective at low
micromolar, and in some instances at nanomolar, concen-
trations [13]. However, it appears that macrophages treated
with a combination of LPS and IFN-c (compared to LPS
alone) are insensitive to anti-inflammatory corticosteroids
such as dexamethasone [14, 15], which is consistent with
our observations.
Among the food samples, one hundred and fifteen dis-
tinct plants and mushroom preparations were screened for
anti-inflammatory properties by employing in vitro cell-
based bioassays. The extracts of several plants including
onion, oregano, red sweet potato, lime zest, cinnamon and
cloves exhibited the strongest capacity to suppress NO and
TNF-a. Interestingly, oyster mushroom, honey-brown
mushroom and button mushroom also showed significant
anti-inflammatory potential.
Interestingly, a differential effect of MRP modification
on the activity of the food preparations was observed,
depending on the sample. Since high molecular MRPs (also
termed advanced glycation end products, AGEs) are known
to increase inflammation [16, 17] and low molecular MRPs
(MW \ 1 kDa) have been shown to possess anti-inflam-
matory potential [18], it might be the balance between
these species that shift the IC50 value up or down
depending on the composition of the sample.
Some of our data are in accordance with published
studies on anti-inflammatory properties of the foods iden-
tified as potent in this study. For example, onions have
been shown to exhibit anti-inflammatory properties, for
example down-regulation of adipokine expression in the
visceral adipose tissue of rats or attenuation of vascular
inflammation and oxidative stress in fructose-fed rats [19,
20]. Among the polyphenols in onions, quercetin was
suggested to be the responsible anti-inflammatory ingre-
dient, as evidenced by the down-regulation of COX2
transcription in human lymphocytes [21]. Furthermore, the
anti-inflammatory activity of the onion has been studied
also in relation to the presence of thiosulphinates and
cepaenes [22, 23].
Anti-inflammatory properties of cinnamon have been
demonstrated for Cinnamomum osmophloeum kaneh [24,
25], but less is known about the ‘true’ cinnamon of India,
Cinnamomum zeylanicum. Some authors reported
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significant inhibitory effects of inflammatory signalling by
the extracts of C. cassia [26]. Sodium benzoate appears to
be one of the active ingredients in cinnamon, since it
inhibits LPS-induced expression of inducible NO synthase
(iNOS), pro-inflammatory cytokines (TNF-a and IL-1b)
and surface markers for inflammatory activation such as
CD11b, CD11c and CD68 in mouse microglia [27].
Clove (Syzygium aromaticum) extracts have been iden-
tified as having potent free radical (including superoxide
anion) scavenging properties and metal chelating activities,
which may be due to the presence of flavonoids. Cloves
contain considerable concentrations of eugenol, beta-caryo-
phyllene, quercetin and kaempferol as well as rhamnetin and
kaempferol and their glycosides [28]. Our study is in line
with studies showing that eugenol suppresses NF-jB acti-
vation, thereby down-regulating cyclooxygenase-2 expres-
sion in lipopolysaccharide-stimulated macrophages [29–31].
Red sweet potato (Ipomoea batatas), a species rich in
b-carotene and anthocyanins [32], has been demonstrated
to have anti-inflammatory properties for the first time by
our study. Lime (Citrus aurantifolia) rich in flavonol gly-
cosides, especially of kaempferol-type, is known for their
antioxidant properties [33]; however, our study is also the
first to report on its anti-inflammatory activities.
The anti-inflammatory properties of the various mush-
room species were quite surprising, since there are only a
handful studies showing such activity. For example, oyster
mushroom concentrate (OMC) was shown to suppress
LPS-induced secretion of TNF-a, IL-6 and IL-12p40 in
RAW 264.7 macrophages and also suppressed PGE2 and
NO by down-regulation of COX-2 and iNOS expression,
respectively. OMC also inhibited LPS-dependent DNA
binding activity of AP-1 and NF-jB in RAW 264.7 cells
[34]. Our results correlate with these observations as oyster
mushroom extracts inhibited LPS ? IFN-c-induced pro-
duction of NO. In mushrooms, water-soluble polysaccha-
rides, especially the b-glucans, are most likely to be the
substances responsible for the anti-inflammatory proper-
ties. For example, b-glucans isolated from Pleurotus os-
treatus were able to potentiate the anti-inflammatory
effects of methotrexate in rat models of experimental
arthritis or colitis [35, 36]. A further potential anti-
inflammatory compound in mushrooms could be ergothi-
oneine (ET), a sulphur-containing amino acid that func-
tions as an antioxidant and is present in mushrooms at a
concentration of up to 2.0 mg/g [37]. In acute respiratory
distress syndrome (ARDS), ergothioneine given intrave-
nously 1 h before or 18 h after cytokine (IL-1 and IFN-c)
insufflation decreased lung injury and lung inflammation in
cytokine-insufflated rats [38].
In summary, it is suggested that foods having anti-
inflammatory properties might be useful in the prevention
of age-related inflammatory conditions, provided that dose
and individual bioavailability lead to therapeutic concen-
trations in affected tissues. Bioavailability of plant sub-
stances including polyphenols is highly variable and will
depend on the nature of the compound [39, 40]. Therefore,
validation of the active samples in animal models should
eventually follow. Furthermore, we speculate that these
natural sources could lead to the discovery of potent novel
anti-inflammatory compounds.
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Considering the stability of activity during processing stages (patented processing 
methods of the CSIRO plant and food library), anti-inflammatory activity in both the 
cell lines and suppression of both NO and TNF-α without cytotoxicity, cinnamon was 
been selected as most interesting extract for further chemical analysis. 
In chapter 4, a literature riview was performed to find the previously reported anti-
inflammatory properties of different cinnamon species and their polyphenols.  
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1. INTRODUCTION 
 
 
An increase in both the absolute number as well as 
relative proportion of the elderly is one of the most 
important developments facing human society in the 
next decades. Chronic inflammation is a contributing 
factor for many age-related diseases including neuro- 
degenerative diseases, degenerative musculoskeletal 
diseases, cardiovascular diseases, diabetes, cancer, 
asthma, rheumatoid arthritis, and inflammatory bowel 
disease. To date, pharmacotherapy of inflammatory 
conditions is based on the use of non-steroidal anti- 
inflammatory drugs (NSAIDs). Considering the preva- 
lence of degenerative and inflammatory conditions,  it 
is not surprising that NSAIDs are among the most 
commonly used drugs. However, the prolonged use of 
NSAIDs comes at a price. NSAIDs can cause serious 
gastrointestinal toxicity. Even more ominously, some 
NSAIDs have been linked to increased blood pressure, 
greatly increased risk of congestive heart failure, stroke 
and myocardial infarction.1 
Plants have long been an important source for the dis- 
covery of new drugs. Herbal medicines derive secondary 
metabolites such as salicylic acid from the bark of the 
willow tree (Salix alba) and have been used for the treat- 
ment of inflammatory diseases in the past. In fact, the 
development of acetylsalicylic acid, commonly known as 
aspirin, as an anti-inflammatory drug at the German 
drug and dye firm Bayer at the end of the nineteenth cen- 
tury was motivated by the desire to find a less   irritating 
replacement for the traditional salicylate-based medi- 
cines. Many other medicinal plants are known to have 
anti-inflammatory activity but neither the underlying 
mechanisms nor their potential for the development of 
new drugs have been fully explored.2 
Inflammation is recognized as  a  biological process 
in response to tissue injury. The defining clinical fea- 
tures of inflammation are known in Latin as rubor 
(redness), calor (warmth), tumor (swelling) and dolor 
(pain). Hallmarks of inflammation were first described 
by Aurelius Cornelius, a Roman physician and medical 
writer who lived from about 30 BC to AD 45.3,4 At the 
site of injury, an increase in blood vessel wall perme- 
ability followed by the movement of serum proteins 
and leukocytes (neutrophils, eosinophils and macro- 
phages) from the blood to the extra-vascular tissue is 
observed. 
The inflammatory response is a complex self- 
limiting process precisely regulated to prevent exten- 
sive damage to the host. When the self-limiting nature 
of this protective mechanism is inappropriately regu- 
lated, it results in chronic inflammation, which is asso- 
ciated with a number of chronic inflammatory diseases, 
including asthma, rheumatoid arthritis, inflammatory 
bowel disease, atherosclerosis, Alzheimer’s disease 
(AD), and cancer. 5,6 Intracellular antioxidant mechan- 
isms against inflammation-induced oxidative stress 
involve antioxidant enzymes, including superoxide dis- 
mutase (SOD), catalase (CAT), and glutathione peroxi- 
dase (GPx) in tissues. 
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2. CINNAMON,  A  MEDICINAL SPICE 
 
 
The genus Cinnamomum belongs to the family 
Lauraceae, comprising over 250 species, and is found 
distributed in tropical and subtropical regions of 
America, Central America, Asia, Oceania and 
Australasia. During the middle ages, the Arabs carried 
cinnamon and other spices along the old caravan trade 
routes to Alexandria, Egypt and then shipped to 
Europe. They constructed many exotic stories  about 
the great difficulty of harvesting cinnamon to account 
for its scarcity and justify the high price of this  spice.7 
There are two main species of cinnamon: 
Cinnamomum verum (true or Ceylon cinnamon) grown 
in Sri Lanka, and Cinnamomum aromaticum (also called 
cassia), which is grown in China. True cinnamon has 
a yellowish-brown color8,9 and tends  to  produce  a 
finer powder than cassia, which has a greyish-brown 
color. There are two other common species of cinna- 
mon: C. loureiroi (Saigon cinnamon, Vietnamese cassia, 
or Vietnamese cinnamon) grown in Vietnam, and C. 
burmannii (Korintje, Padang cassia, or Indonesian cin- 
namon) grown in Indonesia.10 
Cinnamon has been used  since  ancient  times both 
as a culinary spice and for medicinal purposes. The 
medicinal values of cinnamon were utilized by ancient 
health practitioners such as Dioscorides and Galen in 
their various treatments. In medieval times, cinnamon 
was an ingredient of medicines for sore throats and 
coughs. 
Cinnamon has also been used to alleviate indiges- 
tion,10 stomach  cramps,7  intestinal  spasms,  nausea, 
and flatulence, to improve the appetite, and to treat 
diarrhea.11 It is reported to be beneficial for the control 
of blood glucose levels in diabetes,12,13 reduction in the 
levels of low-density lipoprotein (bad cholesterol),14,15 
lessening of arthritic pain,16 and for healing open 
wounds and small cuts.17 The positive health effects 
associated with the consumption  of  cinnamon could, 
in part, be attributed to its phenolic  composition.18—20 
 
 
3. POLYPHENOLS, THEIR MONOMERIC 
PRECURSORS  AND INFLAMMATION 
 
 
Polyphenols are one of the major non-nutrient consti- 
tuents of most common culinary herbs. The most recent 
definition of polyphenols includes “secondary metabo- 
lites derived exclusively from the shikimate derived phe- 
nylpropanoids and/or the polyketide pathways 
featuring more than one phenolic ring and being devoid 
of any nitrogen-based functional group in their most 
basic structural expression.”21 For the sake  of brevity, 
we  have  included  cinnamon  polyphenols  and    their 
monomeric biogenetic precursors in this discussion. 
Polyphenols with varying phenolic structures are found 
enriched in vegetables, fruits, grains, bark, roots, tea, and 
wine.22 Several hundred polyphenolic structures are 
known, with edible plants containing far fewer polyphe- 
nolic structures. The monomeric precursors of polyphe- 
nols include flavan-3-ols (forming pro-anthocyanidin 
polyphenols), gallic acid derivatives (forming gallo- and 
ellagitannin polyphenols) and phloroglucinol derivatives 
(forming phlorotannin polyphenols), which may contain 
several hydroxyl groups23 and with one or more sugar 
residue (glycoside). Flavonoids are the most important 
among monomeric phenolic compounds. Categories of 
flavonoids include flavonols (e.g., quercetin), flavones 
(e.g., apigenin, luteolin), flavonones (e.g., hesperetin), 
flavan-3-ols (e.g., epicatechin, epigallocatechin-3-gallate 
(EGCG)) and anthocyanins (e.g., cyanidin).24 
Multiple studies, both epidemiological and experi- 
mental, suggest that polyphenols and their monomeric 
precursors possess anti-inflammatory and antioxidant 
activities that may contribute, via the diet, to the pre- 
vention of chronic inflammatory diseases such as can- 
cer, cardiovascular disease, inflammatory bowel 
disease, and AD.25 Recent data suggest that polyphe- 
nols can work as modifiers of signal transduction path- 
ways to elicit their beneficial effects. These natural 
compounds express anti-inflammatory activity by 
modulation of pro-inflammatory gene expression such 
as cyclooxygenase, lipoxygenase, nitric oxide synthases 
(NOS) and several pivotal cytokines, mainly by acting 
through nuclear factor-kappa B (NF-κB) and mitogen- 
activated protein kinase signaling.26 The potential 
molecular mechanisms of their anti-inflammatory 
activities have also been suggested to include the inhi- 
bition of enzymes related to inflammation, such as 
cyclooxygenase and lipoxygenase, and many others 
including PPAR, NOS, NF-κB, and  NAG-1.27 
There are two molecular aspects: the arachidonic acid 
(AA)-dependent pathway and the AA-independent 
pathway. Cyclooxygenase, lipoxygenase, and PLA2 are 
discussed as AA-dependent pathway proteins, whereas 
NOS, NF-κB, PPAR, and NAG-1 are discussed as AA-
independent pathway proteins. 
 
 
3.1 Arachidonic Acid-Dependent Pathway 
3.1.1 COX Inhibition 
Non-steroidal anti-inflammatory drugs act by inhi- 
biting the formation of prostaglandins by prostaglan- 
din H synthase (COX, also called cyclooxygenase), 
which converts AA released by membrane phospholi- 
pids into prostaglandins. Two isoforms of prostaglan- 
din H synthase, COX-1 and COX-2, have been 
identified,  and one variant form  (COX-3) has   recently 
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also been reported.28 COX-1 is constitutively expressed 
in many tissues, while the expression of COX-2 is reg- 
ulated by cytokines, mitogens, tumor promoters, and 
growth factors. Non-steroidal anti-inflammatory drugs, 
at low therapeutic doses, inhibit the activity of COX-1 
and COX-2 and the subsequent formation of prosta- 
glandins, mainly prostaglandin 2 (PGE2). However, 
many NSAIDs cause serious gastrointestinal and car- 
diovascular side effects; consequently, there has been a 
need for new and safer anti-inflammatory agents. 
Several compounds that are consumed daily in various 
foods may provide alternative tools for treating inflam- 
matory diseases by acting as COX inhibitors. 
In  1980,  Baumann  et  al.29   were  the  first  to  report, 
in a study that assessed rat  medullar  COX  activity, 
that some dietary polyphenols, such as galangin and 
luteolin, inhibit AA peroxidation. Since then, research- 
ers have reported that  dietary  polyphenols inhibit 
COX activity at the transcriptional level as well as at 
the enzyme level. The green tea catechin EGCG 
displayed COX inhibition activity in LPS-induced 
macrophages30 and the stilbene trans-resveratrol pos- 
sessed anti-inflammatory activity because it sup- 
pressed carragenen-induced pedal edema via the 
inhibition  of  COX   activity.31   Furthermore,  Landolfi 
et al.32 found that the flavones, chrysin, apigenein, and 
phloretin depressed COX activity and inhibited plate- 
let aggregation. The flavonoids 6-hydroxykaempferol 
and quercetagenin, isolated from T. parthenium (fever- 
few), and 6-hydroxyluteolin and scutellarein, isolated 
from T. vulgaris (tansy), were all shown to inhibit COX 
activity in leukocytes.33 
Although many studies have reported that polyphe- 
nols inhibit COX-1 or COX-2, it has not yet been 
reported that polyphenols inhibit COX-3.34 
3.1.2 Lipoxygenases Inhibition 
Lipoxygenases (LOXs) are the enzymes responsible 
for generating leukotrienes (LTs) from AA. There are 
three distinct LOX isozymes in different cells and 
tissues. 15-LOX synthesizes anti-inflammatory 15-
hydroxyeicosa-tetraenoic acid (HETE), 5-LOX and 12-
LOX are involved in provoking inflammatory/aller- 
gic disorders; and 5-LOX produces 5-HETE and LTs, 
which are potent chemoattractants and lead to the 
development of asthma. 12-LOX synthesizes 12-HETE, 
which aggregates platelets and induces the inflamma- 
tory response. Therefore, the effect of polyphenols  on 
5- and 12-LOXs has been extensively studied in order 
to elucidate the anti-inflammatory properties.35 
Flavonols, including kaempferol, quercetin, morin 
and myricetin, were found to be 5-LOX inhibitors.36 
Hamamelitannin and the galloylated proanthocyani- 
dins were found to be the most potent inhibitors of 5-
LOX   with   the   IC50     values   ranging   from   1.0  to 
18.7 μM.37 Some prenylated flavonoids, such as artonin 
E, are the most effective inhibitors of porcine eukocyte 
5-LOX.38 There are few reports regarding 12-LOX inhi- 
bition; kuwanson C and quercetin potently inhibit 12-
LOX activity with IC50 values of 19 and 12 μM, 
respectively, using bovine PMNs (polymorphonuclear 
neutrophil leukocytes) and 12-LOX from bovine plate- 
lets.39 In comparison, the IC50 value of the known LOX 
inhibitor nordihydroguaiaretic acid (NDGA) is 2.6 μM. 
 
3.1.3  Phospholipase A2 Inhibition 
Phospholipase A2 (PLA2), which cleaves phospholi- 
pids producing lysophospholipids and free fatty acids, 
was originally identified as an intracellular protein 
involved in cell signaling and in the production of free 
fatty acids, such as arachidonic acid. It is known that 
PLA2 plays an important role in the inflammation pro- 
cess.40 The inhibition of PLA2 could be a potential tar- 
get for lowering the production of AA and therefore 
decreasing prostaglandin synthesis.  Phospholipases 
are mainly classified into three large groups: secretory 
PLA2 (sPLA2), cytosolic PLA2 (cPLA2), and calcium- 
independent PLA2 (iPLA2). It is now known that this 
family is comprised of at least 10 members with dis- 
tinct cellular distributions and growing therapeutic 
potential. Specifically, sPLA2-V and sPLA2-X are selec- 
tively expressed in the epithelium of the human air- 
way. SPLA2-IIA (group II phospholipase A2)  is  low 
but becomes highly expressed during  inflammation 
and sepsis as a result of LPS, cytokine, and NF-κB 
induction. This enzyme is now associated with allergic 
rhinitis, rheumatoid arthritis, and septic shock. Finally, 
the selective expression of sPLA2-V and sPLA2-X sug- 
gests that these enzymes should be evaluated as tar- 
gets for airway dysfunction. Thus, the PLA2 family 
represents a therapeutic target with ever-increasing 
potential. It is likely that PLA2 is an important intra- 
and extracellular mediator of inflammation. The mod- 
ulation  of sPLA2 and/or cPLA2 activity is  important 
in controlling the inflammatory process.4 
Quercetin was found to be an effective inhibitor of 
PLA2 in rabbit41 and human42 leukocytes. It was also 
demonstrated that quercetin selectively inhibited 
sPLA2-II, compared to its lower inhibition of sPLA2- 
IB.43 Quercetagetin, kaempferol-3-O-galactoside, and 
scutellarein inhibited human recombinant synovial 
PLA2 with IC50  values ranging from 12.2 to 17.6  μM.
44
 
 
3.2 AA-Independent Pathway 
3.2.1 Nitric Oxide Synthase 
Nitric oxide (NO), a gaseous free radical, is released 
by a family of enzymes, including endothelial NOS 
(eNOS),  neuronal  NOS  (nNOS)  and  inducible    NOS 
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(iNOS), with the formation of stoichiometric amounts 
of L-citrulline from L-arginine. Compounds able to 
reduce NO production by iNOS may thus be attractive 
as anti-inflammatory agents and, for this reason, the 
effects of polyphenols on iNOS activity have been 
intensively studied. Current results suggest that poly- 
phenols inhibit NO release by suppressing NOS 
enzymes expression and/or NOS activity.45 
3.2.2 Cytokine System 
Cytokines are the major mediators of local, intercellu- 
lar communications required for an integrated response 
to a variety of stimuli in immune and inflammatory pro- 
cesses. Numerous cytokines have been identified in tis- 
sues across a range of immuno-mediated inflammatory 
diseases.46 Also, a “balance” between the effects of pro- 
inflammatory (e.g., IL-1β, IL-2, TNF-α, Il-6, IL-8 and IFN- 
γ) and anti-inflammatory cytokines (e.g., IL-10, IL-4, 
TGF-β) is thought to determine the outcome of disease, 
whether in the short- or long-term. It has been observed 
that several flavonoids are able to decrease the expression 
of different pro-inflammatory  cytokines/chemokines 
such as TNF-α, IL-1β, IL-6, IL-8, MCP-1 in LPS-activated 
mouse primary macrophages, PMA or phytohemaggluti- 
nin (PHA) stimulated human peripheral blood mononu- 
clear cells, activated human astrocytes, human synovial 
cells, activated human mast cell line HMC-1, nasal muco- 
sal fibroblasts and A549 bronchial epithelial cells.47 In 
fact, polyphenols, such as quercetin and catechins, cou- 
pled their inhibitory action on TNF-α and IL-1β to the 
enhancement of IL-10 release.47,48 
3.2.3 Peroxisome Proliferator Activated Receptors 
The expression of many inflammatory cytokines is 
regulated at the transcriptional level, which can either 
enhance or inhibit the inflammation process. 
Peroxisome proliferator-activated receptors (PPARs) 
are nuclear hormone receptors that are activated by 
specific endogenous and exogenous ligands.49 Three 
isoforms (α, β/δ, and γ) have been identified, and are 
encoded by separate genes. Among these, PPARα acti- 
vation is responsible for the pleiotropic effects of per- 
oxisome proliferators, such as enzyme induction, 
peroxisome proliferation and amelioration of inflam- 
mation. PPARα also plays a critical role in the regula- 
tion of cellular uptake and β-oxidation of fatty acids. 
Furthermore, PPARδ (also known as PPARβ) is widely 
expressed with relatively higher levels in the brain, 
colon, and skin. Although there have been extensive 
studies on PPARα and inflammation, very little is 
known about the effect of PPARδ on inflammation.27 
Few studies have regarded polyphenols as PPAR 
ligands, but it is probable that polyphenols may also 
affect PPAR protein expression, which results in the 
activation  of  the  PPAR  pathway,  as  PPAR pathways 
are closely connected to other inflammatory pathways 
including NF-κB, COX-2 expression, and pro- 
inflammatory cytokines. 
 
3.2.4 Nuclear Transcription Factor Kappa  B 
NF-κB is a ubiquitous factor that resides in the cyto- 
plasm. When it becomes activated, it is translocated to 
the nucleus, where it induces gene transcription. NF- 
κB is activated by free radicals, inflammatory stimuli, 
carcinogens, tumor promoters, endotoxins, γ-radiation, 
ultraviolet (UV) light, and X-rays. Therefore,  agents 
that can suppress NF-κB activation have the  potential 
to suppress cytokine expression and,  therefore, 
decrease inflammatory response. Recent data suggest 
that dietary polyphenols can work as modifiers of sig- 
nal transduction pathways to elicit beneficial effects. 
Polyphenols have been shown to exert their anti- 
inflammatory activity by modulating NF-κB activation 
and act on multiple steps of the activation  process.26 
The influence of EGCG on NF-κB pathway has been 
extensively studied demonstrating its inhibitory effects 
on NF-κB obtained by counteracting the activation of 
IKK and the degradation of IκBα.50,51 An  interesting 
in vivo study carried out on rats showed that EGCG 
markedly attenuated the myocardial injury after ische- 
mia and reperfusion.37,52—57 
 
 
4. ANTI-INFLAMMATORY ACTIVITY OF 
CINNAMON  EXTRACTS 
 
 
4.1  Cinnamomum zeylanicum 
C. zeylanicum polyphenol extract has been found to 
affect immune responses by regulating anti- and pro- 
inflammatory and GLUT gene expression in mouse 
macrophages.58 Another laboratory study found  that 
the water-soluble C. zeylanicum extract reverses TNF- α-
induced overproduction of intestinal apoB48 by 
regulating gene expression involving inflammatory, 
insulin, and lipoprotein signaling pathways,59 and con- 
cluded that the water-soluble extract improves inflam- 
mation related intestinal dyslipidemia. Of interest is a 
recent  study  that  found  that  an  aqueous  extract    of 
C. zeylanicum inhibited tau aggregation and filament 
formation, hallmarks of AD.60 
The anti-inflammatory effect of Cinnamomum zeyla- 
nicum was also investigated using ethanol extract 
obtained from bark. In vitro and in vivo experiments 
were performed targeting TNF-α using flow cytome- 
try. Ethanol extract of C. zeylanicum showed suppres- 
sion of intracellular release of TNF-α in murine 
neutrophils as well as leukocytes in pleural fluid. The 
extract was found to inhibit TNF-α  gene expression   in 
 
 
5.  INFLAMMATION AND POLYPHENOLS 
76 
 
 
5. CINNAMON POLYPHENOLS AND THEIR MONOMERIC PRECURSORS 413 
 
LPS-stimulated human blood mononuclear cells 
(PBMCs) at 20 μg/mL concentration.61 
 
4.2  Cinnamomum cassia 
Cinnamomi Ramulus (CR), the young twig of C. cassia 
and other Cinnamomum species, has been shown to 
have anti-inflammatory properties.62 CR reduced the 
increased expression of iNOS and COX-2 caused by 
lipopolysaccharide (LPS) stimulation in  RAW264.7 
cells, which are macrophages in the periphery. CR has 
also exhibited anti-inflammatory activities that sup- 
press the release of NO and PGE2.63 Furthermore, a 
more recent study suggested that the  components of 
CR inhibit inflammatory responses in the CNS in vitro 
and in vivo.64 
A study conducted on mice with 70% ethanolic 
extract of C. cassia bark gave promising  results  on 
acute inflammation.65 The extract  inhibited  the 
increase in vascular permeability induced by acetic 
acid. It inhibited the paw oedema induced by carra- 
geen as well as seratonin, while it was ineffective 
against bradykinin and histamine produced during 
inflammation. Little effect was observed on secondary 
lesions in the development of adjuvant-induced arthri- 
tis. It is also useful in pulmonary  inflammations. 
Ninety-five   percent   ethanol   extract   of   C.   cassia 
inhibitory activity. The 50% effective concentration 
(EC50) for essential oil was 18.68  μg/mL.
70
 
 
4.5 Cinnamomum camphora 
C. camphora Sieb has long been prescribed in tradi- 
tional medicine for the treatment of inflammation- 
related diseases such as rheumatism, sprains, 
bronchitis, and muscle pains. The inhibitory effects    of 
C. camphora were investigated on various inflammatory 
phenomena to explore its potential anti-inflammatory 
mechanisms under non-cytotoxic (less than 100 μg/mL) 
conditions. 
The total crude extract (100 μg/mL) prepared with 
80%  methanol  (MeOH   extract)   and   its fractions 
(100 μg/mL) obtained by solvent partition with hexane 
and ethyl acetate (EtOAc) significantly blocked the 
production of interleukin (IL)-1β, IL-6 and the tumor 
necrosis factor (TNF)-α from RAW264.7 cells stimu- 
lated by lipopolysaccharide (LPS) up to 20—70%. 
The hexane and EtOAc extracts (100 μg/mL) also 
inhibited NO production in LPS/interferon (IFN)- γ-
activated macrophages by 65%. 
The MeOH extract (100 μg/mL) as well as two frac- 
tions (100 μg/mL) prepared by solvent partition with 
n-butanol (BuOH) and EtOAc strongly suppressed 
prostaglandin   E2   (PGE2)   production   in   LPS/IFN- 
71 
exerted strong anti-inflammatory activity by suppres- 
sing Src and spleen tyrosine kinase-mediated NF-κB 
activation.66 
 
4.3 Cinnamomum  osmophloeum 
The constituents of C. osmophloeum twigs sup- 
pressed NO production by LPS-stimulated macro- 
phages.67 In the presence of 25 μg/mL essential oil, the 
inhibition of NO production was 68.8%. The IC50 value 
was 11.2 μg/mL. Tung et al.67 demonstrated that essen- 
tial oil of C. osmophloeum twigs has excellent anti- 
inflammatory activity in HepG2 (human hepatocellular 
liver carcinoma) cells and Kirtikar and Basu and  others 
have also reported that cinnamon extract relieves 
pulmonary inflammation.68,69 
 
4.4 Cinnamomum insularimontanum 
The NO inhibitory activity of fruit essential oil of C. 
insularimontanum was evaluated by using a LPS- 
stimulated RAW264.7 cell assay. The  fruit’s essential 
oil  revealed   the   significant   inhibitory   effects on 
NO production in LPS-stimulated RAW264.7 cells. 
RAW264.7 cells treated with fruit essential oil at 
dosages of 1—50 μg/mL caused a dose-dependent  NO 
γ-activated macrophages up to 70%. 
 
4.6 Cinnamomum  massoiae 
Twelve alcoholic extracts and twelve hexane extracts 
of plant materials selected on the basis of medicinal 
folklore for asthma treatment in Indonesia were stud- 
ied for their activity in inhibiting histamine  release 
from RBL-2H3 cells (rat basophilic leukemia cell   line), 
a tumor analog of mast cells. The results of screening 
indicated that alcoholic extract of C. massoiae cortex 
inhibited IgE-dependent histamine release from RBL- 
2H3 cells. The inhibitory effects were found to be more 
than 80% for extract concentrations of 0.5 mg/mL. 
That result indicates that the extracts contain active 
compounds that inhibit mast-cell degranulation, and 
provides insight into the development  of  new drugs 
for treating asthma and/or allergic disease.72 
 
5. CINNAMON POLYPHENOLS AND 
THEIR  MONOMERIC PRECURSORS 
 
 
5.1 Cinnamon Polyphenols 
Proanthocyanidins (PA) are the major polyphenolic 
component in commercial cinnamon,  and  are known 
to occur widely in common foods such as apple skin, 
 
 
5.  INFLAMMATION AND POLYPHENOLS 
77 
 
 
414 30.  ANTI-INFLAMMATORY PROPERTIES OF CINNAMON POLYPHENOLS AND THEIR MONOMERIC PRECURSORS 
 
broccoli, olives, onions, green and black tea, cinnamon, 
parsley, grapefruit, oranges and their juices, dark choc- 
olate, cocoa, and red  wine.73 
Proanthocyanidins are mixtures of oligomers and 
polymers composed of flavan-3-ol units, linked mainly 
through C4—C8 bonds; however, C4—C6 bonds also 
exist. The flavan-3-ol units can also  be  doubly linked 
by an additional ether bond between C2 and O7 (e.g., 
cinnamtannin B1). Proanthocyanidins containing the 
single interflavan linkage are known  as B-type, 
whereas those containing double interflavan linkages 
are known as A-type (Figure 30.1). The size of the 
proanthocyanidin molecule is determined  by the 
degree of polymerization (DP). 52,74 They are divided 
into three major classes (procyanidins, propelargoni- 
dins, and prodelphinidins) according to the type of 
their monomeric precursors. 
Cinnamomum zeylanicum bark contains dimeric, tri- 
meric, and oligomeric proanthocyandins with doubly 
linked bis-flavan-3-ol units (A-type procyanidins) 
(Figure 30.2). Among the several cinnamon species, 
only the bark of C. zeylanicum contained, as major phe- 
nolic metabolites, a series of proanthocyanidins with 
the doubly linked (A-type) unit, while the barks of C. 
burmanni and C. cassia, and the root bark of C. camphora 
consisted of linearly linked proanthocyanidins (B- 
type).75 
 
5.2 Monomeric Precursors 
The cinnamon monomeric precursors are the  pheno- 
acid derivatives. The common flavan-3-ols in 
proanthocyanidins are shown in Figure 30.3. The 
proanthocyanidins that consist exclusively of (epi)cate- 
chin are procyanidins. Proanthocyanidins containing 
(epi)afzelechin or (epi)gallocatechin as subunits are 
called propelargonidin or prodelphinidin, respectively. 
Propelargonidin or prodelphinidin are mostly hetero- 
geneous in their constituent units and co-exist with the 
procyanidins.76 
 
5.3 Other Cinnamon Phenolics 
Anti-inflammatory cinnamon monophenolic com- 
pounds include protocatechuic acid, urolignoside, 
quercetin, rutin, kaempferol, isorhamnetin, cinnamald- 
hyde, 2-hydroxycinnamaldehyde, and eugenol. 
One laboratory study investigated the proximate 
composition, minerals, amino acids, polyphenolic com- 
pounds, and presence of some  anti-nutritional factors 
in Sri Lankan cinnamon (C. zeylanicum) and Chinese 
cinnamon (C. cassia) barks. The results showed that the 
tannins levels (0.65—2.18 %) were high in these two 
bark samples, compared to other plant sources and 
there were no significant differences observed in the 
amounts of catechin and isorhamentin  between  the 
two barks; whereas rutin, quercetin and kaempferol 
were significantly higher in Sri Lankan cinnamon than 
that in Chinese cinnamon (Table  30.1).77 
Water extracts of cinnamon fruits have  been 
reported to contain high levels of phenolics, i.e., proto- 
catechuic  acid,  urolignoside, rutin,  and quercetin-3-O- 
78 
lic subunits that  produce  the condensed   polyphenols. α-L-rhamnopyranoside (Figure 30.4). 
The common monomeric precursors (flavan-3-ols) of 
the cinnamon proanthocyanidins are afzelechin, 
epiafzelechin,   catechin,   epicatechin,   and   their gallic 
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6. ANTI-INFLAMMATORY ACTIVITY OF 
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6.1 Proanthocyanidins 
6.1.1 Proanthocyanidins and COX  Inhibition 
In vitro studies of prodelphinidins (the proanthocya- 
nidins that consists of (epi)gallocatechin as subunits) 
showed a decrease in the secretion of prostaglandin  E2 
FIGURE 30.1  Structure of cinnamon polymeric polyphenols. (PGE2)  from  human  chondrocytes  as  well  as     their 
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FIGURE 30.2 Cinnamon  polyphenols. 
A, procyanidin B; B, procyanidin A; C, cin- 
namtannin B; D, procyanidin C; E, parameri- 
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inhibition potential on COX-1 and COX-2  in  vitro.82 
The  synthesis  of  PGE2  was   significantly   reduced 
by gallocatechin dimer (GC—GC), gallocatechin- 
epigallocatechin  (GC—EGC)  and   GC—GC—GC   at 
10 and 100 μg/mL. Moreover, these compounds inhib- 
ited purified cyclooxygenase-1 (COX-1) and 
cyclooxygenase-2 (COX-2).82 GC showed a preferential 
inhibition  of  COX-2  compared  to  COX-1  at  1024 M. 
This selectivity was enhanced by a reduction of the 
concentration tested (1025 M). The same pattern was 
observed with the dimer. 
 
6.1.2 Proanthocyanidins and LOX-1 [Lectin-like 
Oxidized LDL Receptor-1] Inhibition 
Procyanidin is one of the components that inhibits 
oxidized LDL (oxLDL) uptake since nearly half of the 
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FIGURE 30.3    Structures of the flavan-3-ol monomers in  proanthocyanidins. 
 
TABLE 30.1 Polyphenol Content of Sri Lankan and Chinese 
Cinnamon Barks (mg/100 g)77 
 
 
 
 
 
 
 
 
 
 
potent hit extracts. Purified procyanidins inhibited 
oxLDL binding in LOX-1-CHO (Chinese  hamster 
ovary) cells. Furthermore, oligomeric procyanidins 
(OPC) suppressed lipid accumulation in the vascular 
wall of stroke-prone spontaneously hypertensive rats 
(SHR-SP) in which an anti-LOX-1 antibody was also 
effective.83,84 
LOX-1-inhibiting properties were almost identical 
among procyanidins $ trimer and the dimer also potently 
inhibited LOX-1. Moreover, four different isomers of tri- 
mer procyanidins almost equally inhibited oxLDL bind- 
ing to LOX-1. These results implicate that intake of 
procyanidin-rich foods potentially inhibits LOX-1; regard- 
less  of  food  source  since  the  polymerization  levels    of 
procyanidins significantly differ among foods.52 Out of 
more than 400 foodstuff extracts derived from various 
sources, more than half of those displaying potent LOX-1 
inhibition are known to contain a large amount of 
procyanidin.84 
 
6.1.3 Proanthocyanidins, NOS and Cytokines 
The anti-inflammatory effects of a grape seed extract 
containing a rich amount of dimeric and oligomeric 
procyanidins were demonstrated  by  the decreasing 
NO and prostaglandin E2 levels, avoidance of translo- 
cation of NF-κB p65 to the nucleus, and by the 
downregulation of the expression of iNos and IκBα in 
RAW264.7 macrophages (mouse leukemic monocyte 
macrophage cell line) stimulated with LPS and 
interferon-γ.85 
Proanthocyanidins isolated from Ribes nigrum leaves 
interfered with the accumulation of circulating leuko- 
cytes, associated with a reduction of pro-inflammatory 
factors such as TNF-α, IL-1β and CINC-1, a decrease of 
NOx level, and a decrease in plasma  exudation.86 
In a recent study, it was shown that proanthocyani- 
dines (PA) significantly suppressed the content of lipo- 
peroxidation product malondialdehyde (MDA) in 
carrageenan-induced    inflamed    paws    of    rats   and 
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FIGURE 30.4  Some phenolic compounds present in cinnamon. 
 
markedly lessened the activity of NOS and the content 
of NO in exudates of carrageenan-induced paw edema 
in rats. These results demonstrated that inhibition of 
lipoperoxidation and NO formation was one of the 
anti-inflammatory mechanisms of PA.76 
Pro-inflammatory cytokines TNF-α, IL-1β and IL-6 
are sequentially released in the pleural exudates 
induced by carrageenin in rats.87 These cytokines cause 
chemotaxis to attract granulocytes and monocytes and 
then, migrating leukocytes produce, in turn, further 
cytokines, such as TNF-α and IL-1β, and other pro- 
inflammatory mediators. IL-6 has been proposed as a 
crucial mediator for the development of carrageenin- 
induced pleurisy and for the accumulation of leuko- 
cytes in the inflammatory site. Indeed, in carrageenin- 
induced pleurisy in IL-6 knock-out mice, the degree of 
plasma exudation, leukocyte migration and the release 
of TNF-α and IL-1β were greatly reduced. Moreover, a 
positive feedback plays an important part in the devel- 
opment of the oedema as levels  of  TNF-α  and IL-1β 
are attenuated in IL-6 knock-out  mice.88 
Inhibitory activity of proanthocyanidins isolated 
from peanut skin tested on inflammatory cytokine pro- 
duction and melanin synthesis in cultured cell  lines 
and   administration   of   peanut   skin   extract (PSE, 
200 μg/mL) decreased melanogenesis in cultured 
human melanoma HMV-II co-stimulated with phorbol- 
12-myristate-13-acetate.  It also decreased production  of 
inflammatory cytokines (PSE at 100 μg/mL), tumor 
necrosis factor-α and interleukin-6, in cultured human 
monocytic THP-1 cells in response to lipopolysaccha- 
ride. The isolated compounds from PSE also showed 
anti-inflammatory activities. They showed suppressive 
activities against melanogenesis and cytokine produc- 
tion at concentrations ranging from 0.1—10 μg/mL. 
Among the tested compounds,  suppressive  activities 
of proanthocyanidin dimers or trimers in two assay 
systems were stronger than those obtained with mono- 
mer or tetramers. These data indicate that proantho- 
cyanidin oligomers have the potential to reduce 
dermatological conditions such as inflammation and 
melanogenesis.89 
Recent studies have demonstrated that proanthocya- 
nidins reduce the expression of soluble adhesion mole- 
cules, intercellular adhesion molecule-1 (ICAM-1), 
vascular cell adhesion molecule-1 (VCAM-1), and E- 
selectin in the plasma of systemic sclerosis patients.90 
The same compounds have been shown to inhibit TNF-
α-induced VCAM-1 expression in human umbili- cal 
vein endothelial cells cultures.91 A possible mecha- 
nism of the anti-inflammatory effect of PACs would be 
an interference with the expression or the effect of 
adhesion molecules. This interference  would result   in 
a reduction of polymorphonuclear cell migration and 
subsequently in a reduction of the release of pro- 
inflammatory factors such as TNF-α and  IL-1β.86 
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7. ANTI-INFLAMMATORY ACTIVITY OF 
MONOMERIC PRECURSORS 
 
 
7.1 (2)-Catechin,(2)-Epicatechin and 
Gallocatechins 
Several foods of plant origin such as grapes, cocoa, 
cinnamon and apples are rich in oligomeric procyani- 
dins (OPCs) and the monomeric flavan-3-ols epicate- 
chin and catechin. 
There is substantial evidence that the anti- 
inflammatory effects of catechins may be due, in part, 
to their NO and peroxynitrite scavenging ability and 
inhibition of NOS activity. However, catechins have 
varying effects on the three different isoforms of NOS. 
The neuronal NOS (nNOS) isoform produces toxic 
effects through NO, and catechin inhibition of nNOS 
may be a mechanism of anti-inflammatory activity. 
Stevens et al.92 showed that EGCG and oligomeric 
proanthocyanidins (which are made up of esterified 
catechins) inhibited nNOS activity in BL21 (DE3) 
Escherichia coli cells. In addition, in mouse peritoneal 
cells, nNOS activity was inhibited by EGCG after stim- 
ulation with lipopolysaccharide (LPS) and interferon g 
(IFN-δ).93 
EGCG, an extensively studied, potent antioxidant, 
has been shown to inhibit LPS-induced TNF-α produc- 
tion and to induce inducible NOS in mouse macro- 
phages. Several studies have focused on the potential 
anti-inflammatory and anticarcinogenic mechanisms of 
EGCGs through the inhibition of activation of NF-κB 
and thus impairment of the induction of inflammatory 
cytokines and immune  responses.94,95 
Catechins, especially epicatechin gallate (ECG), 
almost completely blocked TNF-α induced NF-κB 
activity and consequently strongly diminished the 
secretion of IL-8 and uPA following TNF-α treatment. 
Both IL-8 and uPA are proteins overexpressed in pan- 
creatic cancer cells and linked to invasion, angiogene- 
sis  and metastasis.96—100 
 
 
7.2 Epiafzelechin 
(2)-Epiafzelechin is a COX inhibitor and it  exhib- 
ited a dose-dependent inhibition on the COX activity 
with an IC50 value of 15 μM. (2)-Epiafzelechin exhib- 
ited about a 3-fold weaker inhibitory potency on the 
enzyme activity than indomethacin as a positive con- 
trol. (2)-Epiafzelechin exhibited significant anti- 
inflammatory activity on carrageenin-induced mouse 
paw edema when the compound (100 mg/kg) was 
orally administrated 1 hour before carrageenin 
treatment.101 
8. ANTI-INFLAMMATORY ACTIVITY OF 
OTHER CINNAMON PHENOLICS 
 
 
8.1 Quercetin 
Quercetin is an excellent scavenger of ROS and reac- 
tive nitrogen species, and an excellent candidate for 
reducing oxidative stress, i.e., an important contributor 
to inflammation. Quercetin inhibits NF-κB activation, 
thereby directly reducing the cytokine production via 
this  transcription factor.102—107 
Quercetin is able to downregulate the inflammatory 
response   of   bone    marrow-derived    macrophages 
in vitro. Quercetin also inhibits cytokine and inducible 
NOS expression through the inhibition of the NF-κB 
pathway both in vitro and in  vivo.108—110 
Quercetin suppressed LPS-induced activation of 
STAT-1 in macrophages suggesting that its effects on 
STAT-1 are stimulus and cell-type independent. 
Quercetin inhibited LPS-induced STAT-1  activation 
and inhibited iNOS expression and NF-κB activation.56 
Quercetin also inhibited IFN-γ-induced signal trans- 
ducer and activator of transcription 1 (STAT-1) activa- 
tion in mouse BV-2 microglia. 
 
8.2 Protocatechuic Acid 
Protocatechuic acid (PCA) (3,4-dihydroxybenzoic 
acid) was shown to inhibit low-density lipoprotein 
(LDL)  oxidation   mediated   by   macrophage   in   an 
in vitro cell model.111 Min et al.112 found that black rice 
Cy-3-G as well as its metabolites, including PCA, 
exerted anti-inflammatory effects  in  vitro  as  well  as 
in vivo. 
PCA reduced monocyte adhesion and NF-κB activa- 
tion in vitro, decreased VCAM-1 and ICAM-1 in vitro 
and in vivo, and inhibited the formation of early ath- 
erosclerotic lesions in the ApoE-deficient mouse 
model.113 
PCA treatment significantly lowered serum marker 
enzymes and liver antioxidants of diabetic rats in 
inflammatory conditions. Furthermore, it also reduced 
plasma C-reactive proteins and von Willebrand factor 
levels, interleukin-6, tumor necrosis factor-α, and 
monocyte chemoattractant protein-1 levels in heart and 
kidney.114 It was suggested that PCA was able to ame- 
liorate complications in metabolic  disorders  through 
its beneficial effects like triglyceride-lowering, anticoa- 
gulatory, antioxidative and anti-inflammatory activi- 
ties. PCA was shown to inhibit cyclooxygenase-2, NOS 
(in vitro) in the expression  of cyclo-oxygenase,    myelo- 
peroxidase, as well as nitrite and nitrate levels in CCl4- 
induced hepatic damage.115,116 The hepatoprotective 
activity    of    PCA    against    tert-butyl  hydroperoxide 
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(t-BHP)-induced liver injury has been attributed to its 
antioxidant and anti-inflammatory properties.117 
Tyrosinase-derived reactive quinone intermediate(s) of 
PCA was shown to bind nucleophilic residues of pro- 
teins and sulfhydryl group including oxygen radical- 
generating leukocytes.118,119 Several  recent  studies 
have, however, revealed that PCA is a major metabo- 
lite of anthocyanins in humans.120 Extensive investiga- 
tions have shown that anthocyanins reduce the 
development of atherosclerosis in different atheroscle- 
rotic animal models121,122 and the risk of  atherosclero- 
sis in human studies.14,123 In a recent human study, it 
has been shown that after the consumption of antho- 
cyanins, the maximal level of PCA in the blood 
(approximately 492 nmol/L) is far higher than that of 
anthocyanins themselves (approximately 1.9 nmol/ 
L).120 This made  us  hypothesize  that anthocyanins 
may exert their protective effects at least partially 
through this important and major metabolite. 
 
8.3 Rutin 
Rutin, quercetin-3-O-rhamnosylglucoside, is a natu- 
ral flavone derivative. The  anti-inflammatory activity 
of rutin was investigated in vivo and in vitro. The IC50 
value of the rutin and other flavonols on NO produc- 
tion inhibitory activity in LPS-activated mouse 
peritoneal macrophages124 is shown in Table 30.2. The 
anti-inflammatory effect of rutin may be explained, at 
least in part, by the inhibition of production of inflam- 
matory mediators, which play an important role in 
neutrophil recruitment and activation. Indeed, it has 
been reported that rutin inhibited PLA2 activity, an 
important enzyme in arachidonic acid cascade, from 
human  synovial fluid.40,125 
The anti-inflammatory activity of equimolar rutin 
and quercetin was compared using the TNBS rat colitis 
model. Rutin treatment resulted in amelioration of coli- 
tic status, based on reductions in colonic damage score, 
weight:length ratio, myeloperoxidase and alkaline 
phosphatase activities. Quercetin gavages had no sub- 
stantial  effect  on  inflammation.  Mechanistically, rutin 
 
TABLE 30.2 Effects of Flavonols on Nitric Oxide Production in 
LPS-activated Mouse Peritoneal  Macrophages124 
Compound IC50  (µM) 
Kaempferol 29 
Quercetin 36 
Rhamnetin 42 
Rutin .100 (1)* 
Isoquercitrin .100 (3)* 
had a strong inhibitory effect on IL-2 secretion by con- 
canavalin A-treated mesenteric node cells ex vivo. 
Similarly, the colonic mRNA levels of IL-1β, TNF-α, 
MCP-1 and especially IL-17 were generally lower in 
rutin-treated animals. Preliminary results from the 
genomic analysis applied to the rutin anti- 
inflammatory effect indicate that B cell markers are 
upregulated compared to the TNBS colitic group. 
Neither oral rutin nor intraperitoneal quercetin  had 
any effect on splenocytes or mesenteric node cells in 
normal animals.126 
It is well known that the early phase of carrageenan-
induced oedema is related to the produc- tion of 
inflammatory mediators such as arachidonic acid 
metabolites, while the delayed phase of inflamma- tory 
response has been linked to neutrophil migration and 
accumulation within the inflammatory site where they 
release reactive oxygen species and proteolytic 
enzymes.127 The results showed that rutin exhibited a 
significant (p , 0.05) inhibitory effect on rat paw 
oedema formation effectively.128 
 
 
8.4 Kaempferol 
Kaempferol, a phytoestrogen and a flavonoid, pro- 
tects against various oxidative stresses and inflamma- 
tory age-related chronic disorders.129,130 The IC50 value 
of kaempferol and other flavonols on NO production 
inhibitory activity in LPS-activated mouse peritoneal 
macrophages124  is provided in Table  30.2. 
Oxidative stress plays an important role in the path- 
ogenesis of many diseases, including inflammatory 
diseases.131 Kidney is especially vulnerable to oxida- 
tive stress during aging, as shown by oxidant-induced 
nephritis, vasculitis, toxic nephropathies, pyelonephri- 
tis, and acute renal failure.132—134 These diseases are 
likely to be mediated in part by age-related oxidative 
insults due to redox imbalance. 
The anti-inflammatory effects of kaempferol on NF- 
κB activity and its related gene expressions in the 
presence of oxidative stress in aged kidney were eluci- 
dated. The data show that treatment with kaempferol 
inhibited accumulated oxidative stress  and  restored 
the GSH/GSSG ratio. In aged rats, kaempferol modu- 
lated redox status and exerted potent antioxidative 
capacity. The results from western blot,  EMSA,  and 
the reporter assay demonstrated that kaempferol inhib- 
ited proteolytic degradation of IκB, binding of the 
p50/p65 heterodimer, and NF-κB-dependent gene 
expressions in aged rat   kidney.34,135—138 
Kaempferol significantly suppressed the NIK/IKK 
and MAPK pathways that lead to NF-κB activation in 
   aged   kidney   tissues.   This   study   documented   that 
*Value in parentheses represents the inhibition (%) at 100  µM. kaempferol   restored   redox   imbalance   through     its 
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efficient RS scavenging capacity and modulated pro- 
inflammatory NF-κB activation via the NIK/IKK and 
MAPK pathways in aging. These studies demonstrated 
that kaempferol as an efficient anti-inflammatory com- 
pound with the ability to attenuate oxidative stress- 
induced inflammation in aged rat  kidney.138 
 
8.5 Isorhamnetin 
30-Methoxy-3,40 ,5,7-tetrahydroxyflavone (isorhamne- 
tin) is an abundant flavonoid found in many dietary 
plants.139 Isorhamnetin inhibits NO production and 
iNOS protein and mRNA expression; it also reduces 
iNOS expression, and that effect may well be mediated 
by inhibition of NF-κB activation.56 The IC50 value of 
isorhamnetin and other flavonols on NO production 
inhibitory activity in LPS-activated mouse peritoneal 
macrophages124  is provided in Table  30.2. 
 
8.6 Cinnamaldehyde 
Cinnamaldehyde suppressed NF-B activation within 
macrophage-like RAW264.7 cells.140 It has been dem- 
onstrated that CA is capable of blocking  inducible 
nitric oxide synthase (iNOS) and NO production by 
mediation of NF-B activation blockade in LPS- 
stimulated RAW264.7 cells.141 Cinnamaldehyde, iso- 
lated from the leaves of C. osmophloeum, was reported 
to inhibit the secretion of IL-1β and TNF-α within LPS 
or lipoteichoic acid (LTA) stimulated murine J774A.1 
macrophages. Cinnamaldehyde also suppressed the 
production of these cytokines from LPS-stimulated 
human blood monocytes derived primary macro- 
phages and human THP-1 monocytes.142 These find- 
ings demonstrated the anti-inflammatory (Table 30.3) 
potential of cinnamaldehyde. 
 
8.7 20-Hydroxycinnamaldehyde (HCA) and 20- 
Benzoyloxycinnamaldehyde  (BCA) 
20-Hydroxycinnamaldehyde (HCA) from the stem 
bark of C. cassia and its derivative 20-benzoyloxycinna- 
maldehyde    (BCA)    were    reported    to    show  anti- 
 
TABLE 30.3 Effects of Cinnamaldehyde and 2-hydroxycinnamalde- 
hyde on NO Production Inhibitory Activity in LPS-activated 
RAW264.7   Macrophages5,149,150 
inflammatory  effects143  in  RAW264.7  macrophage 
cells. 
A potential anti-inflammatory effect of HCA/BCA 
was assessed in  LPS-stimulated  microglial cultures 
and microglia/neuroblastoma co-cultures. HCA/BCA 
significantly decreased the production of NO and TNF-
α in microglial cells. HCA/BCA also attenuated the 
expression of iNOS and pro-inflammatory cyto- kines 
such as interleukin-1β (IL-1β) and TNF-α at mRNA 
level via blockade of ERK, JNK,  p38 MAPK, and NF-κB 
activation. Moreover, HCA/BCA was neuroprotective 
by reducing microglia-mediated neu- roblastoma cell 
death in a microglia-neuroblastoma co- culture. 
Affinity chromatography and LC-MS/MS analysis 
identified low-density lipoprotein receptor- related 
protein 1 (LRP1) as a potential molecular target of 
HCA in microglial cells. Studies using the receptor- 
associated protein (RAP) that blocks a ligand binding 
to LRP1 and the siRNA-mediated LRP1 gene silencing, 
showed that HCA inhibited LPS-induced microglial 
activation via LRP1 suggesting that HCA/BCA is anti- 
inflammatory and neuroprotective in the CNS by 
targeting LRP1, and may have a therapeutic potential 
against neuroinflammatory diseases.144 
 
8.8 Eugenol   (4-Allyl-2-Methoxyphenol) 
Eugenol is a major component of cinnamon leaves 
and has been reported to show potent antioxidant and 
anti-inflammatory actions,145—147 and it effectively 
improved functional and  structural  pulmonary 
changes induced by LPS, modulating lung inflamma- 
tion and remodeling in an in vivo model of acute lung 
injury (ALI), through a mechanism involving inhibi- 
tion of TNF-α release and NF-κB activation. This may 
lead to potential new therapies for ALI as well as other 
chronic lung inflammatory  diseases.148 
Effect of eugenol on the production of NO by 
RAW264.7 macrophages showed anti-inflammatory 
effect; both eugenol and isoeugenol inhibited LPS- 
dependent production of NO, through the inhibition of 
protein synthesis of iNOS. Isoeugenol was shown to be 
the more effective than eugenol (Table 39.3) by inhibit- 
ing LPS-dependent expression of cyclooxygenase-2 
(COX-2).149 
 
 
9. CONCLUSION 
 
 
 
Dietary polyphenols comprise a vast array of biolog- 
ically active compounds that are ubiquitous in plants, 
many of which have been used in traditional Oriental 
medicine  for  thousands  of  years.  In  this  review,  we 
   summarized   the   current   findings   of   the molecular 
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Cinnamaldehyde 45.56 
2-Hydroxycinnamaldehyde 8 
Eugenol 100 
Isoeugenol 10 
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targets of cinnamon polyphenols, their monomeric pre- 
cursors and other phenolics as anti-inflammatory com- 
pounds. Better knowledge of the consumption and 
bioavailability of dietary polyphenols will be essential 
in the future to properly evaluate their role in the pre- 
vention of diseases. After the consumption of a given 
source of polyphenols or of a given diet, we should be 
able to evaluate the contribution to the prevention of 
oxidative stress with regard to other dietary antioxi- 
dants. We should also be able to predict the  tissue 
levels of specific metabolites that may bind to specific 
receptors and trigger the responses beneficial for our 
health, and this should lead to some dietary recom- 
mendations that are optimized for particular popula- 
tion groups and to the design of new food products 
that will satisfy future needs. 
Moreover, there is great potential for dietary poly- 
phenols to become the next generation of dietary fac- 
tors to confer health effects for inflammation beyond 
synthetic drugs. Further, dietary polyphenols may pro- 
vide an excellent model system for the development of 
more effective drugs in the future. 
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As only little has been published about the anti-inflammatory activity of the most 
common cinnamon species used as food, C. zeylanicum and C. cassia, the anti-
inflammatory activities of C. zeylanicum (Sri Lankan cinnamon) and C. cassia 
(Chinese cinnamon) extracts and their chemical constituents were examined using 
RAW 264.7 and J774A.1 macrophages. 
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Chronic inflammation is a contributing factor in many age-related diseases. In a previous study, we have
shown that Sri Lankan cinnamon (C. zeylanicum) was one of the most potent anti-inflammatory foods
out of 115 foods tested. However, knowledge about the exact nature of the anti-inflammatory com-
pounds and their distribution in the two major cinnamon species used for human consumption is limited.
The aim of this investigation was to determine the anti-inflammatory activity of C. zeylanicum and
C. cassia and elucidate their main phytochemical compounds. When extracts were tested in LPS and IFN-γ
activated RAW 264.7 macrophages, most of the anti-inflammatory activity, measured by down-regulation
of nitric oxide and TNF-α production, was observed in the organic extracts. The most abundant com-
pounds in these extracts were E-cinnamaldehyde and o-methoxycinnamaldehyde. The highest concen-
tration of E-cinnamaldehyde was found in the DCM extract of C. zeylanicum or C. cassia (31 and 34 mg
g−1 of cinnamon, respectively). When these and other constituents were tested for their anti-inflammatory
activity in RAW 264.7 and J774A.1 macrophages, the most potent compounds were E-cinnamaldehyde
and o-methoxycinnamaldehyde, which exhibited IC50 values for NO with RAW 264.7 cells of 55 ± 9 µM
(7.3 ± 1.2 µg mL−1) and 35 ± 9 µM (5.7 ± 1.5 µg mL−1), respectively; and IC50 values for TNF-α of
63 ± 9 µM (8.3 ± 1.2 µg mL−1) and 78 ± 16 µM (12.6 ± 2.6 µg mL−1), respectively. If therapeutic concen-
trations can be achieved in target tissues, cinnamon and its components may be useful in the treatment
of age-related inflammatory conditions.
1. Introduction
Chronic inflammation plays an important role in the patho-
genesis of a wide variety of acute and chronic diseases includ-
ing cardiovascular and neurodegenerative diseases, obesity,
type 2 diabetes and even ageing in general.1–5 To date, phar-
macotherapy of inflammatory conditions is predominantly
based on the use of non-steroidal anti-inflammatory drugs
(NSAIDs). NSAIDs are commonly used to manage pain and
inflammation (swelling and redness) associated with some
types of arthritis (such as rheumatoid arthritis) and other mus-
culoskeletal disorders. While NSAIDs are effective in relieving
pain, fever and inflammation, they can cause unwanted side
effects including serious gastrointestinal toxicity such as the
formation of stomach ulcers and gastric bleeding.6,7 Some
NSAIDs, particularly COX-2 inhibitors, have been linked to
increased blood pressure, greatly increased risk of congestive
heart failure, occurrence of thrombosis and myocardial infarc-
tion.8 Together, these findings provide the motivation for the
development of anti-inflammatory treatments with fewer
adverse effects.
Cinnamon has been used in Asia as a food additive and has
a long history in traditional Indian and Chinese medicine.9
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Cinnamon bark (Cinnamomum zeylanicum Syn C. zeylanicum,
family: Lauraceae) is one of the oldest herbal medicines for
treating inflammation and pain.10 In traditional Chinese medi-
cine, for example, cinnamon is used as an analgesic and anti-
pyretic for colds, fever, headache, myalgia, arthralgia, and
amenorrhea.11
A variety of cinnamon species have been studied for their
anti-diabetic and anti-microbial properties as well as for their
anti-cancer and anti-arthritis properties in cell and animal
models.12 However, the major focus of the medical use of cin-
namon has been the treatment of diabetes.13 A significant
number of clinical trials indicate that cinnamon appears to be
an effective option for lowering blood sugar in uncontrolled
type 2 diabetics. The consumption of cinnamon at doses of
120 mg per day to 6 g per day was reported to be associated
with a statistically significant decrease in levels of fasting
plasma glucose, total cholesterol, LDL-C, and triglyceride
levels, and an increase in HDL-C level.13
We have previously shown that, out of 115 foods tested,
Cinnamomum zeylanicum displayed among the highest anti-
inflammatory activity.14 However, so far, only a few studies
have been conducted examining the inflammatory effects of
cinnamon. Moreover, most studies on anti-inflammatory pro-
perties of cinnamon were conducted with the species Cinnamo-
mum osmophloem kaneh (Lauraceae) from Taiwan.15,16 This
species was chosen generally for analysis because the chemical
constituents of its oil are similar to those of Cinnamomum
cassia bark oil,15 which is the common additive to foods and
beverages referred to simply as ‘cinnamon’. However, so far,
only a few studies have investigated the anti-inflammatory
activity of the most common cinnamon species used as food,
C. zeylanicum and C. cassia. In one study, Kanuri et al. showed
that pre-challenge with an alcohol extract of cinnamon bark
suppressed lipopolysaccharide (LPS)-induced MyD88, iNOS,
and TNF-α expression as well as NO formation almost comple-
tely. The authors further showed that this cinnamon extract
might protect the liver from acute alcohol-induced steatosis.17
In a further study, the efficacy of the polyphenol fraction from
C. zeylanicum bark (CPP) was evaluated in animal models of
inflammation and rheumatoid arthritis. Dose–response
studies of CPP (50, 100, and 200 mg kg−1) were conducted in
acute (carrageenan-induced rat paw edema), subacute (cotton
pellet-induced granuloma), and sub-chronic (AIA, adjuvant-
induced established polyarthritis) models of inflammation in
rats. CPP showed a significant reduction in elevated serum
TNF-α concentration in the AIA model in rats. CPP also
demonstrated mild analgesic effects during acute treatment as
evidenced by the reduction in the writhing and paw withdra-
wal threshold of the inflamed rat paw during the acetic acid-
induced writhing model and Randall–Selitto test. In con-
clusion, the authors suggest, that CPP has a beneficial action
in animal models of inflammation and arthritis and therefore
can be considered as a potential anti-rheumatic agent with
disease-modifying action.18
However, it is not widely known, which compounds except
cinnamaldehyde exert these anti-inflammatory properties in
cinnamon. Therefore, in this study, we have examined the
anti-inflammatory activities of C. zeylanicum and C. cassia
extracts and identified all the chemical constituents contribut-
ing to this activity using RAW 264.7 and J774A.1 macrophages,
and determined their potency.
2. Results
2.1. Comparison of the yields of different extraction
procedures
Four grams of C. zeylanicum or C. cassia powder was extracted
using a sequential extraction procedure with solvents of
increasing polarity, starting with DCM followed by EtOAc,
EtOH, MeOH and water in order to separate the lipophilic (for
GC-MS analysis) from the hydrophilic compounds. In a second
experiment, a direct extraction using a single polar solvent,
either EtOH or water, was conducted to allow comparison with
the sequential extraction procedure. The sequential extraction
provided a higher overall yield compared to the direct extrac-
tion procedure for C. zeylanicum and C. cassia (1.48 ± 0.70 g
and 1.64 ± 0.54 g, respectively), compared to 1.09 ± 0.35 g and
1.07 ± 0.44 g (for EtOH), and 0.338 ± 0.032 g and 0.530 ±
0.170 g (for water, Table 1).
2.2. Determination of the anti-inflammatory activity of the
cinnamon extracts
Nitric oxide (NO) and tumour necrosis factor are key mediators
of the inflammatory response. After exposure to bacterial lipo-
polysaccharide (LPS) and Interferon gamma (IFN-γ), macro-
phages respond with release of NO and TNF-α,19,20 which can
trigger a number of pathophysiological consequences includ-
ing tissue damage. Hence, measuring inhibition of NO and
TNF-α production in LPS or LPS and IFN-γ stimulated cells rep-
resents a widely used experimental model for examining the
anti-inflammatory effects of chemical compounds.20
Sequential and direct extracts of both cinnamon species
were tested in LPS + IFN-γ activated 264.7 macrophages using
NO and TNF-α production as readouts to determine their anti-
inflammatory activity. Due to insolubility of the low polarity
Table 1 Yield of cinnamon extracts after extraction and freeze-drying
derived from 4 g cinnamon powder
Extraction solvent
Yield of extracts (g)
C. zeylanicum C. cassia
Sequential
Dichloromethane 0.162 ± 0.026 0.165 ± 0.008
Ethyl acetate 0.151 ± 0.091 0.149 ± 0.065
Ethanol 0.361 ± 0.164 0.396 ± 0.141
Methanol 0.450 ± 0.190 0.521 ± 0.126
Water 0.364 ± 0.228 0.404 ± 0.195
Total 1.48 ± 0.70 1.64 ± 0.54
Direct
Ethanol 1.09 ± 0.35 1.07 ± 0.44
Water 0.338 ± 0.032 0.530 ± 0.170
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extracts in the cell culture media, they were diluted in DMSO
or EtOH, leading to final concentrations of up to 0.5% DMSO
or EtOH in cell culture medium. This concentration of organic
solvents did not affect cell viability by more than 10% (data
not shown).
In the sequential extracts of C. zeylanicum, the DCM, EtOAc
and EtOH extracts contained the majority of the anti-inflam-
matory activity compared to the methanol and water extracts
(Table 2). The ethyl acetate extract was the most potent, as it
inhibited both NO and TNF-α production with IC50 values of
14.0 ± 4.0 μg mL−1 and 66.2 ± 5.6 μg mL−1 respectively (Fig. 1A,
Table 2). Interestingly, the ethyl acetate extract was also rela-
tively toxic with an LC50 value of 120.2 ± 13.3 µg ml
−1. The
sequential organic extracts of C. cassia showed similar results,
the DCM, EtOAc and EtOH fractions also contained most of
the anti-inflammatory activity (IC50 values for NO: 22.8 ± 1.4 μg
mL−1, 19.7 ± 6.0 μg mL−1 and 47.4 ± 0.4 μg mL−1, respectively)
(Fig. 1B, Table 3). The sequential ethyl acetate extract showed
the highest activity in regards to inhibition of TNF-α pro-
duction with an IC50 value of 78.4 ± 1.5 μg mL−1 (Fig. 1B,
Table 3).
The direct EtOH and water extracts of both cinnamon
species inhibited the LPS + IFN-γ induced production of NO
and TNF-α but mostly with lower potency (Tables 2 and 3). For
example, the direct EtOH extract of C. zeylanicum demon-
strated stronger inhibition of NO and TNF-α production (with
the IC50 values of 122 ± 21 μg mL−1 and 36.4 ± 1.6 μg mL−1,
respectively) than the water extract (Table 2). Interestingly,
direct ethanolic extracts of both cinnamon species showed
potent activity in regards to inhibition of TNF-α production
(IC50: 36.4 ± 1.6 and 51.2 ± 0.7 μg mL−1, respectively) (Tables
2 and 3).
2.3. Identification of the major constituents of the cinnamon
extracts by GC-MS
Our data showed that the lipophilic extracts, i.e. the DCM,
EtOAc and EtOH fractions of the sequential extracts of both
cinnamon species showed considerably higher anti-inflamma-
tory activity than the hydrophilic extracts, indicating that the
most potent anti-inflammatory compounds were lipophilic
and/or volatile. We therefore used GC-MS to identify the major
constituents in these extracts.
Table 2 Summary of anti-inflammatory activity and toxicity of C. zeyla-
nicum extracts
C. zeylanicum
Extraction solvent
Inhibition of
NO production
(IC50 in µg
mL−1 ± SD)
Inhibition
of TNF-α
production
(IC50 in µg
mL−1 ± SD)
Cytotoxicity
(LC50 in µg
mL−1 ± SD)
Sequential extraction
Dichloromethane 24.3 ± 1.3 76.4 ± 12.8 194.8 ± 26.0
Ethyl acetate 14.0 ± 4.0 66.2 ± 5.6 120.2 ± 13.3
Ethanol 32.6 ± 4.3 87.4 ± 15.8 646 ± 46
Methanol 482 ± 10 310 ± 14 >500
Water 20.8 ± 2.2 91.2 ± 13.3 606 ± 16
Direct extraction
Ethanol 122 ± 21 36.4 ± 1.6 866 ± 56
Water 245 ± 12 270 ± 29 607 ± 7
Fig. 1 Down regulation of LPS and IFN-γ induced production of pro-inflammatory markers by a sequential EtOAC extract of C. zeylanicum and C.
cassia. RAW264.7 macrophages were activated with LPS and IFN-γ in the presence of increasing concentrations of C. zeylanicum (A) or C. cassia (B)
EtOAc extracts derived from the sequential extraction. Nitric oxide and TNF-α production as well as cell viability were determined after 24 h. Results
represent the mean ± SD of 3 experiments (in triplicate).
Table 3 Summary of anti-inflammatory activity and toxicity of C. cassia
extracts
C. cassia
extraction solvent
Inhibition of
NO production
(IC50 in µg
mL−1 ± SD)
Inhibition
of TNF-α
production
(IC50 in µg
mL−1 ± SD)
Cytotoxicity
(LC50 in µg
mL−1 ± SD)
Sequential extraction
Dichloromethane 22.8 ± 1.4 121 ± 3.0 204 ± 30
Ethyl acetate 19.7 ± 6.0 78.4 ± 1.5 140 ± 9.0
Ethanol 47.4 ± 0.4 117 ± 3 620 ± 115
Methanol 322 ± 1 358 ± 19 >500
Water 103 ± 4 83.6 ± 25.3 600 ± 30
Direct extraction
Ethanol 157 ± 39 51.2 ± 0.7 501 ± 147
Water 180 ± 56 354 ± 24 629 ± 31
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Five major compounds were identified and quantified from
C. zeylanicum (as an example, the EtOAc extract of C. ceylani-
cum is shown in Fig. 2) and 4 major compounds were identi-
fied and quantified from C. cassia. These compounds
were E-cinnamaldehyde, o-methoxycinnamaldehyde, eugenol,
benzyl benzoate, coumarin and cinnamyl alcohol (Table 4).
The highest concentration of E-cinnamaldehyde was found in
the DCM extract of either C. zeylanicum or C. cassia (125 and
135 mg per 4 g of cinnamon, respectively; Table 4).
2.4. Identification of the major constituents of the cinnamon
extracts by UPLC-PDA/MS
In the GC-MS analysis of methanol and water extracts, only
E-cinnamaldehyde could be identified in methanolic extracts
and no compounds in water extracts. Therefore, UPLC-PDA/MS
was additionally employed to identify the constituents in the
MeOH and water extracts of both C. zeylanicum and C. cassia.
Five major compounds were identified by UPLC-MS and then
quantified by UPLC-PDA (Table 4).
2.5. Anti-inflammatory activities of cinnamon constituents
In order to identify which of the constituents was responsible
for the anti-inflammatory activity of the extracts, individual
compounds (Fig. 4) were tested for their anti-inflammatory
activity in the same manner as the extracts using two different
cell lines, RAW 264.7 and J774A.1 macrophages as described
previously.21 All compounds except coumarin demonstrated
considerable anti-inflammatory activity, determined as inhi-
bition of LPS + IFN-γ induced NO and TNF-α production
(Fig. 3, Tables 5 and 6). The most potent compounds were
E-cinnamaldehyde and o-methoxycinnamaldehyde, which
exhibited IC50 values for NO with RAW 264.7 cells of 55 ± 9 µM
(7.3 ± 1.2 µg mL−1) and 35 ± 9 µM (5.7 ± 1.5 µg mL−1), respecti-
vely; and IC50 values for TNF-α of 63 ± 9 µM (8.3 ± 1.2 µg mL−1)
and 78 ± 16 µM (12.6 ± 2.6 µg mL−1), respectively (Table 5).
Similar results were obtained with the J774A.1 cell line. Again,
the most potent compounds were E-cinnamaldehyde and
o-methoxycinnamaldehyde, which exhibited IC50 values for NO
of 51 ± 2 µM (6.7 ± 0.3 µg mL−1) and 38 ± 2 µM (6.2 ± 0.3 µg
mL−1), respectively and IC50 values for TNF-α of 51 ± 5 µM
(6.7 ± 0.7 µg mL−1) and 79 ± 7 µM (12.8 ± 1.1 µg mL−1), respect-
ively (Table 6).
3. Discussion and experimental
Cinnamon has been reported to be beneficial for the ameliora-
tion of many inflammatory diseases including control of blood
glucose levels in diabetes arthritic pain.22 In spite of its wide-
spread use, research on its anti-inflammatory properties has
been limited. The pioneering work by the group of Chang
et al. has demonstrated anti-inflammatory activity from the
essential oil of Cinnamomum osmophloeum Kaneh. (Laura-
ceae).15 However, less is known about the compounds respon-
sible for the anti-inflammatory activity of the ‘true’ cinnamon
of Sri Lanka, Cinnamomum zeylanicum and the ‘Chinese’ cinna-
mon, C. cassia, and our study was aimed at identifying the
amount and potency of the major anti-inflammatory com-
pounds in these foods.
The highest level of anti-inflammatory bioactivity was
observed in the organic fractions which were more potent than
the methanol and water extracts (Tables 2 and 3), suggesting
that the majority of anti-inflammatory activity is exerted by
lipophilic compounds. The organic fractions (DCM, EtOAc) of
both C. zeylanicum and C. cassia showed anti-inflammatory
activity comparable to the data reported by Tung et al.,15 who
reported an IC50 value for NO inhibition for the essential oil
isolated from C. osmophloeum twigs of 11.2 μg mL−1. For TNF-
α, our results are comparable to data reported by Chao et al.,16
who showed that the essential oil from the leaves of C. osmo-
phloeum had inhibitory effects on LPS-induced TNF-α pro-
duction. They showed that 52 ng mL−1 TNF-α was released
from LPS-stimulated cells and that this TNF-α secretion was
reduced to 35 ng mL−1 (67% of control) by 60 μg mL−1 essen-
tial oil from C. osmophloeum leaves. When cytotoxicity was
investigated, the sequential DCM and EtOAc extracts of both
cinnamon species caused some degree of cell death, with an
LC50 value of 120–200 μg mL−1, values much lower than the
extracts from the polar solvents EtOH, MeOH and water
(Tables 2 and 3). However, none of the major compounds
identified appear to be the responsible for cytotoxicity, indicat-
ing that minor constituents might be responsible for the cyto-
toxicity in this fraction.
Cinnamon bark extracts are complex mixtures and therefore
we identified and quantified all major compounds in the two
cinnamon species using GC-MS and UPLC-PDA/MS. E-cinna-
maldehyde, o-methoxycinnamaldehyde, cinnamyl alcohol,
benzyl benzoate, eugenol, and cinnamic acid demonstrated
considerable anti-inflammatory activity in terms of inhibition
of NO production, whereas only cinnamaldehyde, o-methoxy-
cinnamaldehyde and benzyl benzoate were potent inhibitors
of TNF-α production. In detail, the most potent compounds
were E-cinnamaldehyde and o-methoxycinnamaldehyde which
Fig. 2 Gas chromatogram of the C. zeylanicum EtOAc extract derived
from the sequential extraction. E-cinnamaldehyde, cinnamyl alcohol,
eugenol, o-methoxycinnamaldehyde and benzyl benzoate could be
identified and quantified. The magnified insert (top right) shows the four
minor peaks.
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exhibited IC50 values for NO (RAW 264.7 cells) at concen-
trations of 55 µM and 35 µM respectively and IC50 for TNF-α
of 63 µM and 78 µM, respectively (Table 5). The data were
confirmed in J774A.1 cells, where E-cinnamaldehyde and
o-methoxycinnamaldehyde emerged as the most potent com-
pounds (Table 6).
These results are comparable to results reported by Tung
et al. who reported an IC50 value of 88.4 µM for NO inhibition
for E-cinnamaldehyde in LPS-activated RAW 264.7 macro-
phages.15 Our results indicate that E-cinnamaldehyde and
o-methoxycinnamaldehyde are the principal anti-inflammatory
compounds in C. zeylanicum and C. cassia. Our in vitro data
suggest that cinnamon and its components may be used as for
the amelioration of age-related inflammatory conditions, if
therapeutic concentrations can be achieved in target tissues.
As most active cinnamon compounds are aldehydes, it was
suggested safety might pose some limitations for the use of
cinnamon and its components as therapeutic drugs. In
chronic toxicity studies, oral doses of E-cinnamaldehyde
>2620 mg kg−1 per day in mice and >940 mg kg−1 per day in
rats produced nearly 100% mortality.23 However, these doses
appear to be much higher than used in human consumption.
For humans, the World Health Organization (WHO 1984)
suggested an acceptable daily intake level of cinnamaldehyde
of 0.7 mg kg−1 body weight, and cinnamon doses ranged from
1 to 6 grams (corresponding to approximately 400 mg E-cinna-
maldehyde) per day have been used in human clinical trials
without major side effects.13,24 For coumarin, the German
Table 4 Compounds identified from C. zeylanicum and C. cassia by GC and UPLC-PDA analysis (mean ± SD, n = 3)
Solvent
C. zeylanicum C. cassia
Concentrations of the
compounds in extractb
(mM)
Weight of the
compounds in
extractc (mg)
Concentrations
of the compounds
in extractb (mM)
Weight of the
compounds in
extractc (mg)
Dichloromethane (GC)
E-Cinnamaldehyde 948 ± 74 125 ± 9.8 1019 ± 89 135 ± 12
Cinnamyl alcohol 7.5 ± 1.2 1.0 ± 0.2 9.7 ± 0.8 1.3 ± 0.1
Eugenol 25.8 ± 3.0 4.2 ± 0.5 n.d. n.d.
Coumarin n.d.a n.d. 1.7 ± 0.3 0.25 ± 0.04
o-Methoxy cinnamaldehyde 130 ± 17 21.1 ± 2.8 171 ± 22 27.8 ± 3.4
Benzyl benzoate 10.3 ± 1.7 2.2 ± 0.4 n.d n.d.
Ethyl acetate (GC)
E-Cinnamaldehyde 601 ± 62 79.4 ± 8.2 425 ± 42 56.2 ± 5.5
Cinnamyl alcohol Trace Trace 2.4 ± 0.3 0.35 ±
Eugenol 9.5 ± 1.5 1.6 ± 0.3 n.d. n.d
Coumarin n.d. n.d. 2.4 ± 0.2 0.35 ± 0.03
o-Methoxy cinnamaldehyde 210 ± 12 34.1 ± 1.9 467 ± 35 75.7 ± 5.7
Benzyl benzoate 8.0 ± 1.0 1.7 ± 0.2 n.d. n.d.
Ethanol (GC)
E-Cinnamaldehyde 493 ± 98 65.1 ± 12.9 356 ± 33 47.1 ± 4.3
o-Methoxy cinnamaldehyde Trace Trace 44.9 ± 4.2 7.3 ± 0.7
Methanol (UPLC)
E-Cinnamaldehyde 8.66 ± 0.03 1.14 ± 0.01 1.78 ± 0.02 1.78 ± 0.02
o-Methoxy cinnamaldehyde 1.24 ± 0.02 0.20 ± 0.01 n.d. n.d.
Cinnamic acid 0.94 ± 0.01 0.14 ± 0.01 0.68 ± 0.01 0.68 ± 0.01
Eugenol 1.25 ± 0.18 0.20 ± 0.03 1.09 ± 0.44 1.09 ± 0.44
Coumarin 2.64 ± 0.03 0.39 ± 0.01 0.90 ± 0.25 0.90 ± 0.25
Water (UPLC)
E-Cinnamaldehyde 0.35 ± 0.01 0.05 ± 0.01 0.28 ± 0.02 0.04 ± 0.01
o-Methoxy cinnamaldehyde 0.26 ± 0.01 0.04 ± 0.01 0.50 ± 0.01 0.08 ± 0.01
Cinnamic acid 3.24 ± 0.01 0.48 ± 0.01 2.91 ± 0.01 0.43 ± 0.01
Coumarin 1.50 ± 0.03 0.22 ± 0.01 0.92 ± 0.11 0.14 ± 0.02
Direct extracts
Ethanol
E-Cinnamaldehyde 706 93.3 741 97.9
Eugenol Trace Trace 239 38.8
Coumarin 0.94 0.14
o-Methoxy cinnamaldehyde Trace Trace n.d. n.d.
Water
E-Cinnamaldehyde 7.46 0.99 6.79 0.90
a n.d. = not detectable. b Concentrations of the compounds in each extract extracted from 4 g of cinnamon powder redissolved at a concentration
of 1 mg ml−1. cWeights of the compounds in each extract extracted from 4 g of cinnamon powder.
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Federal Institute for Risk Assessment has established a toler-
able daily intake (TDI) of 0.1 mg coumarin per kg body weight.
Furthermore, European health agencies and researchers have
warned against consuming high amounts of C. cassia, because
of its coumarin content.25 However, without detailed in vivo
studies with an inflammatory readout in animals or humans,
it is difficult to calculate if the TDI of coumarin would be
exceeded if a therapeutic dose of cinnamon extract is con-
sumed. However, our data demonstrate that coumarin is not
one of the major anti–inflammatory compounds, and therefore
C. zeylanicum which contains little coumarin would be a safer
option in this regard.
An important issue for clinical efficacy of cinnamon com-
pounds is also their bioavailability, as the compound needs to
be present in therapeutic concentrations in the target tissue.
Orally applied (radiolabelled) cinnamaldehyde (up to 500 mg
kg−1 bw) undergoes nearly complete absorption as demon-
strated in rats and mice. One of the studies demonstrated that
Fig. 3 Dose-dependent effects of cinnamon compounds on LPS and IFN-γ induced production of nitric oxide and TNF-α. RAW264.7 macrophages
were activated with LPS and IFN-γ in the presence of increasing concentrations of cinnamon compounds (A) E-cinnamaldehyde, (B) o-methoxy-
cinnamaldehyde, (C) cinnamyl alcohol, (D) benzyl benzoate, (E) eugenol, (F) coumarin and (G) E-cinnamic acid. Nitric oxide and TNF-α production
as well as cell viability were determined after 24 h. Results represent the mean ± SD of 3 experiments (in triplicate).
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94% of the administered dose could be recovered in the
excreta in 72 h in both species, with most (75–81%) present in
urine after 24 h. Surprisingly, plasma concentrations of cinna-
maldehyde are quite low (0.2 µg ml−1), when rats are given an
oral dose of 500 mg kg−1.26 This apparent discrepancy can be
explained by the large volume of distribution (2392 ± 52 l kg−1)
which indicates that E-cinnamaldehyde is trapped in certain
compartment, such as adipose tissue.26
In summary, due to the unique pharmacokinetic para-
meters of cinnamon aldehydes, it is difficult to predict directly
from pharmacokinetic data if their tissue concentrations are
high enough to lead to an anti-inflammatory effects in vivo,
and further animal and human studies will be required to
prove their clinical efficacy.
3.1. Materials
3.1.1. Plant material. Cinnamomum zeylanicum Breyn
(Lauraceae) (Sri Lankan cinnamon) and Cinnamomum cassia
Nees & T. Nees J. Presl (Lauraceae) (Chinese cinnamon) were
supplied in powder form by Sunrise Botanicals, Uralla, NSW,
Australia.
3.1.2. Chemicals and reagents. DMSO, 95% ethanol,
bovine serum albumin, lipopolysaccharide (LPS) (E. coli sero-
type 0127:B8), EDTA, N-(1-1-napthyl) ethylenediamine dihy-
drochloride, penicillin G sodium benzyl, resazurin sodium
10%, streptomycin, sulfanilamide, tetra methyl benzidine
(TMB), trypan blue 0.4%, benzyl benzoate, furfural, E-cinna-
maldehyde, p-cymene, β-caryophyllene, o-methoxycinnamalde-
hyde, eugenol, cinnamyl alcohol, citral, cinnamic acid,
estragole, coumarin and cinnamyl acetate were purchased
from Sigma-Aldrich (Castle Hill, NSW, Australia). Dulbecco’s
modified Eagle’s medium (DMEM), fetal bovine serum (FBS)
and glutamine were GIBCO brands purchased from Life
Technologies (Mulgrave, VIC, Australia). IFN-γ (murine) and
TNF-α ELISA kits were purchased from PeproTech Asia
(Rehovot, Israel). Diatomaceous earth was the Dionex brand
purchased from Thermo Fisher Scientific Australia (Scoresby,
VIC, Australia).
Fig. 4 Structures of the identified cinnamon compounds. A total of
seven compounds were identified in cinnamon by GC-MS and UPLC-MS
analysis, including E-cinnamaldehyde, o-methoxycinnamaldehyde, cin-
namyl alcohol, benzyl benzoate, eugenol, coumarin and E-cinnamic
acid.
Table 5 Anti-inflammatory activity and toxicity of cinnamon compounds determined in RAW 264.7 macrophages
Cinnamon compound
Inhibition of NO production
(IC50 in µM ± SD)
Inhibition of TNF-α production
(IC50 in µM ± SD)
Cytotoxicity
(LC50 in µM ± SD)
E-Cinnamaldehyde 55 ± 9 63 ± 9 1191 ± 226
o-Methoxycinnamaldehyde 35 ± 9 78 ± 16 1142 ± 134
Cinnamyl alcohol 82 ± 12 >2500 1311 ± 103
Benzyl benzoate 123 ± 17 142 ± 27 117 ± 186
Eugenol 670 ± 95 529 ± 89 >2500
Coumarin >2500 >2500 >2500
E-Cinnamic acid 102 ± 21 1256 ± 369 >2500
Table 6 Anti-inflammatory activity and toxicity of cinnamon compounds determined in J774A.1 macrophages
Cinnamon compound
Inhibition of NO production
(IC50 in µM ± SD)
Inhibition of TNF-α production
(IC50 in µM ± SD)
Cytotoxicity
(LC50 in µM ± SD)
E-Cinnamaldehyde 51 ± 2 51 ± 5 546 ± 89
o-Methoxycinnamaldehyde 38 ± 2 79 ± 7 539 ± 86
Cinnamyl alcohol 61 ± 5 1933 ± 487 1564 ± 160
Benzyl benzoate 195 ± 31 209 ± 24 1646 ± 157
Eugenol 475 ± 82 450 ± 37 >2500
Coumarin 2010 ± 245 >2500 >2500
E-Cinnamic acid 147 ± 19 1204 ± 158 >2500
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4. Methods
4.1. Sequential extraction of cinnamon samples
Four grams of each cinnamon sample were mixed in a 4 : 1
ratio with diatomaceous earth and sequentially extracted using
the following solvents of increasing polarity: dichloromethane
(DCM), ethyl acetate (EtOAc), ethanol (EtOH), methanol
(MeOH) and water. Extractions were performed at a specific
temperature for each solvent on a Dionex Accelerated Solvent
Extractor 350 using 5 min static time and 2 cycles. Tempera-
tures and extraction times were varied according to the solvent
of extraction. DCM was heated to 100° C for 5 min, EtOAc to
100° C for 5 min. EtOH to 120° C for 6 min, MeOH to 120° C
for 6 min, water to 180° C for 9 min. The extracts were sub-
sequently evaporated using a Büchi Syncore Polyvap R6 evapor-
ator at 60 °C using 130 rpm speed, until all the solvents were
removed. The pressure was varied according to the solvent of
evaporation. DCM and EtOAc were evaporated at 350 mbar,
EtOH and MeOH at 200 mbar and water at 50 mbar. The
resulting extracts were then freeze dried using a Telstar
vacuum freeze drier with Edwards XDS10 Scroll pump for 24 to
48 hours. Dried extracts were stored in a freezer at −20 °C. For
GC-MS and UPLC-MS analysis, dried extracts (1 mg) were redis-
solved in 1 mL of EtOH, MeOH or water. For cell culture appli-
cations, dried extracts (1 mg) were dissolved in 1 mL DMEM
media (DCM and EtOAC extracts in 1% DMSO in 99% DMEM,
EtOH and MeOH extracts in 1% EtOH in 99% DMEM and
water extracts in 100% DMEM water), respectively.
4.2. Direct extraction of cinnamon with EtOH or water
Each cinnamon species sample (4 g) was extracted in a 4 : 1
ratio with diatomaceous earth with EtOH and water. EtOH was
heated to 120° C for 6 min and water was heated to 180° C for
9 min. The extracts were freeze dried using a vacuum freeze
dryer as described previously. The dried extracts (1 mg) were
resuspended in 1 mL of EtOH, MeOH or water for chemical
analysis using GC-MS and 1 mg of dried extracts were dis-
solved in 1 mL of DMEM media (EtOH extract in 1% EtOH in
99% DMEM and water extract in 100% DMEM water) for cell
culture applications.
4.3. Analysis of cinnamon extracts by GC-MS
GC-MS analysis was performed on an Agilent 7890A gas chro-
matograph with 5975C inert XL EI/CI mass selective detector
(MS) and CombiPral autosampler. Gas chromatography separ-
ation was performed on J&W scientific HP-5MS column (30 m ×
0.25 mm ID, 0.25 μm). Stock solutions of each extract (1 mg
ml−1) were used for the injection. The injection volume of
sample was 1 μL, using a split ratio of 10 : 1, at a temperature
of 250 °C. The syringe was then rinsed with ethanol five times
after each injection. Separation was performed at a constant
carrier gas flow rate of 1 mL min−1. The oven temperature was
initially 80 °C for 1 min and then increased at a rate of 4 °C
min−1 until 200 °C was reached. The MS transfer line was set
to a temperature of 250 °C, the EI source to 230 °C and the
quadrupole at 150 °C. We employed a solvent delay of 3 min
and the acquisition mode was set to scan 40–500 m/z.
The components in each fraction were identified using
comparison of their GC retention times, interpretation of their
mass spectra and confirmation by mass spectral library search
using the National Institute of Standards and Technology
(NIST) database. The relative concentration of each compound
in cinnamon extracts were quantified based on the peak area
integrated by the analysis program. Hence stock solutions of
the standards containing trans-cinnamaldehyde; eugenol,
benzyl benzoate, o-methoxy cinnamaldehyde, cinnamyl
alcohol and coumarin (500 μM) were prepared in EtOH. The
mass spectrometer detector response was calibrated by injec-
tion of a solution of a mixture of the standards in ethanol.
Sample solutions were then analysed at concentrations of
1 mg mL−1 in the solvent of extraction. Concentrations of each
analyte were calculated using respective peak areas and detec-
tor response factors.
4.4. Analysis of cinnamon extracts by UPLC-PDA/MS
Chromatography was performed using a Waters Acquity UPLC
instrument. A Waters Acquity UPLC BEH C18 column was
used, of dimensions 2.1 × 150 mm, with stationary phase par-
ticle diameter of 1.7 μm. A column temperature of 35 °C was
used. Injections of 10 μL were made in full loop mode (loop
overfill factor × 4) using a method run time of 20 min and
solvent flow rate of 0.2 mL min−1. Solvent A consisted of 0.1%
(v/v) formic acid in ultrapure water and solvent B was 0.1%
(v/v) formic acid in LC-MS grade methanol. The chromatographic
method consisted initially of 5% solvent B, ramped linearly to
100% solvent B over 15 min. At 17 min, the solvent compo-
sition returned to 5% B and maintained this composition
until completion of the run. Mass spectrometry was performed
in order to positively confirm the identity of each of the chro-
matographic peaks in question by mass spectrum. Detection
of analytes was accomplished with photodiode array detector
(PDA) and mass spectrometry. 3D spectra were obtained over
the wavelength range 190–500 nm with resolution of 1.2 nm
and sampling rate of 20 points s−1. 2D spectra were measured
at 254 nm with resolution of 4.8 nm.
Mass spectrometry was performed using a Waters Xevo
TQ-MS triple quadrupole mass spectrometer with the follow-
ing settings: desolvation gas temperature 300 °C; desolvation
gas flow 500 L h−1; cone gas 0 L h−1; and source temperature
of 150 °C. In positive mode the capillary voltage was 3.5 kV
and the cone voltage 30 V. In negative ion mode the capillary
voltage was 2.5 kV and cone voltage 30 V. Negative and positive
spectra were recorded simultaneously over the m/z range
100–500 using a scan time of 1 second. Solutions of the stan-
dard analytes were prepared at a concentration of 50 mM in
30% (v/v) aqueous methanol.
Samples were run using triplicate injections and peak inte-
gration of the compounds separated by UPLC was performed
by UV-Vis spectrophotometry in two different ways: a) at
254 nm and b) in the wavelength range 100–500 nm. Agree-
ment between the two methods was excellent. Quantification
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of each compound was accomplished by division of the peak
area of a compound of unknown concentration by the peak
area of the same compound of known concentration (stan-
dard), multiplied by the concentration of the standard.
4.5. Maintenance of RAW 264.7 and J774A.1 macrophages
RAW 264.7 and J774A.1 macrophages were grown in 175 cm2
flasks on DMEM containing 5% fetal bovine serum (FBS) that
was supplemented with Penicillin (100 u ml−1), Streptomycin
(100 μg ml−1) and L-Glutamine (2 mM). The cell line was
maintained in 5% CO2 at 37 °C, with media being replaced
every 3–4 days. Once cells had grown to confluence in the
culture flask, they were removed using a rubber policeman, as
opposed to using trypsin, which can remove membrane-bound
receptors.27 The cell suspension was concentrated by centrifu-
gation for 3 min at 900 rpm and resuspended in a small
volume of fresh DMEM (with 1% antibiotics and 5% FBS), cell
density was estimated using a Neubauer counting chamber.
The cell concentration was adjusted with DMEM (with 1%
antibiotics and 5% FBS) to obtain 60 000 cells/100 μl cell sus-
pension. 100 μl of this cell suspension was dispensed into the
wells of 96-well plates. Plates were incubated at 37 °C; 5% CO2
for 24 h before the activation experiments were carried out.
4.6. Activation of macrophages
From each well, the medium was removed and replaced with
fresh DMEM containing 0.1% FBS. For assays with extracts,
50 μL volumes of the dilutions in DMEM were added an hour
prior to addition of activator. A combination of 10 μg ml−1 LPS
and 10 U ml−1 (1 unit = 0.1 ng mL−1) IFN-γ, both in DMEM,
was used for activation. Maximum concentrations of 1.25 mg
mL−1 (direct extracts) and 0.5 mg mL−1 (sequential extracts)
were used and a minimum of 6 doses (made by serial dilution)
were employed. After activation, the cells were incubated for
24 h at 37 °C and then NO, TNF-α and cell viabilities were
determined. Unactivated cells (exposed to media alone) were
used as negative control and activated cells as positive control.
The effects of solvents on readouts were initially determined,
but as the anti-inflammatory or cytotoxic effects of the solvents
were <10% even at the highest concentration used, parameters
were compared to the “no solvent” controls.
4.7. Determination of nitric oxide by the Griess assay
Nitric oxide was determined by the quantification of nitrite
using the Griess reagent as described previously.28 In detail,
Griess reagent was freshly made up of equal volumes of 1%
sulfanilamide and 0.1% naphthylethylene-diamine in 5% HCl.
From each well, 50 µl of supernatant was transferred to a fresh
96-well plate and mixed with 50 µl of Griess reagent and
measured at 540 nm in a POLARstar Omega microplate reader
(BMG Labtech, Mornington, Australia). The concentration of
nitrite was calculated using a standard curve with sodium
nitrate (0–250 μM), and linear regression analysis.
4.8. Determination of TNF-α by ELISA
The diluted supernatants were used for determination of TNF-
α using a sandwich ELISA according to manufacturer’s instruc-
tions as described previously (Peprotech Asia, Rehovot, Israel)
with small modifications.27 In detail, the capture antibody was
used at a concentration of 0.5 μg ml−1 in PBS (1.9 mM
NaH2PO4, 8.1 mM Na2HPO4, 154 mM NaCl) (pH 7.4). Serial
dilutions of TNF-α standard from 0 to 10 000 pg mL−1 in
diluent (0.05% Tween-20, 0.1% BSA in PBS) were used as
internal standard. TNF-α was detected with a biotinylated
second antibody and an Avidin peroxidase conjugate with TMB
as detection reagent. The colour development was monitored
at 655 nm, taking readings every 5 min. After about 30 min the
reaction was stopped using 0.5 M sulphuric acid and the
absorbance was measured at 450 nm using a POLARstar
Omega microplate reader (BMG Labtech, Mornington, Austra-
lia) and expressed as a percentage of that of control cells after
conversion of the concentrations by using a standard curve
constructed with defined concentrations of TNF-α. Curve
fitting of this standard curve and extrapolation of experimental
data were performed using non-linear regression analysis.
4.9. Determination of cell viability by the Alamar Blue assay
100 µl of Alamar Blue solution (10% Alamar Blue (Resazurin)
in DMEM media) was added to each well, incubated at 37 °C
for 1–2 h. After incubation, fluorescence intensity was
measured with the microplate reader (excitation at 530 nm
and emission at 590 nm) and results were expressed as a per-
centage of the intensity of that in control cells, after back-
ground fluorescence was subtracted.
4.10. Data presentation and analysis
Six experiments were combined to determine the IC50 (for NO
and TNF-α inhibition) and LC50 (for cell viability) values using
the four parameter sigmoidal dose–response function in
GraphPad Prism 5 (GraphPad Software, La Jolla, CA, USA).
5. Conclusion
In summary, our findings indicate that in both cinnamon
species, E-cinnamaldehyde and o-methoxycinnamaldehyde are
responsible for most of the inflammatory activity of cinnamon.
If therapeutic concentrations (e.g. by using advanced delivery
methods such as microencapsulation) can be achieved in
target tissues without toxicity, cinnamon and its components
may be of use as a treatment for the amelioration of age-
related inflammatory conditions.
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NF-κB Nuclear factor kappa-light-chain-enhancer of acti-
vated B cells
iNOS Inducible nitric oxide synthase
DCM Dichloromethane
EtOAc Ethyl acetate
EtOH Ethanol
MeOH Methanol
NOS Nitric oxide synthase
ASE Accelerated solvent extraction
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According to our previous study described in chapter-3, oyster mushroom and honey 
brown mushroom showed strong anti-inflammatory activity out of 115 foods tested 
and edible mushrooms are attracting more and more attention as functional foods 
since they are rich in bioactive compounds, but their anti-inflammatory properties 
and the effect of food processing steps on this activity has not been systematically 
investigated. In the present study, White Button and Honey Brown (both Agaricus 
bisporus), Shiitake (Lentinus edodes), Enoki (Flammulina velutipes) and Oyster 
mushroom (Pleurotus ostreatus) preparations were tested for their anti-inflammatory 
activity in lipopolysaccharide (LPS) and interferon-γ (IFN-γ) activated murine RAW 
264.7 macrophages. 
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a b s t r a c t
Inflammation is a well-known contributing factor to many age-related chronic diseases. One of the pos-
sible strategies to suppress inflammation is the employment of functional foods with anti-inflammatory
properties. Edible mushrooms are attracting more and more attention as functional foods since they are
rich in bioactive compounds, but their anti-inflammatory properties and the effect of food processing
steps on this activity has not been systematically investigated. In the present study, White Button and
Honey Brown (both Agaricus bisporus), Shiitake (Lentinus edodes), Enoki (Flammulina velutipes) and Oyster
mushroom (Pleurotus ostreatus) preparations were tested for their anti-inflammatory activity in
lipopolysaccharide (LPS) and interferon-c (IFN-c) activated murine RAW 264.7 macrophages. Potent
anti-inflammatory activity (IC50 < 0.1 mg/ml), measured as inhibition of NO production, could be
detected in all raw mushroom preparations, but only raw Oyster (IC50 = 0.035 mg/ml), Shiitake
(IC50 = 0.047 mg/ml) and Enoki mushrooms (IC50 = 0.099 mg/ml) showed also potent inhibition of TNF-
a production. When the anti-inflammatory activity was followed through two food-processing steps,
which involved ultrasonication and heating, a significant portion of the anti-inflammatory activity was
lost suggesting that the anti-inflammatory compounds might be susceptible to heating or prone to
evaporation.
 2013 Elsevier Ltd. All rights reserved.
1. Introduction
Age is the leading risk factor for many devastating diseases,
such as acute and chronic neurodegenerative diseases,
degenerative musculoskeletal diseases, cardiovascular diseases,
diabetes, asthma, rheumatoid arthritis and inflammatory bowel
disease. Increasing evidence suggests that systemic low grade
inflammation is a contributing factor in these age-related diseases
(Badolato & Oppenheim, 1996; Brod, 2000; Gu, Luchsinger, Stern, &
Scarmeas, 2010; Perry, 2004).
To date, pharmacotherapy of inflammatory conditions is based
on the use of non-steroidal anti-inflammatory drugs (NSAIDs).
However, NSAIDs can cause serious gastrointestinal toxicity and
have been linked to increased blood pressure, greatly increased
risk of congestive heart failure and occurrence of thrombosis
(Aisen, Schafer, Grundman, Thomas, & Thal, 2003; McMurray &
Hardy, 2002).
Together, these findings provide the motivation for the develop-
ment of anti-inflammatory treatments with fewer adverse effects.
Herbalmedicines derived fromplants, such as the bark of thewillow
tree (Salix alba), have been used for the treatment of diseases with a
prominent inflammatory component for thousands of years. Several
mechanisms are proposed to explain their anti-inflammatory ac-
tion, including inhibition of cyclooxygenases and lipoxygenases or
modulation of pro-inflammatory gene expression such as inducible
nitric oxide synthase, and several pivotal cytokines including TNF-a
(Rainsford, 2007; Wong et al., 2001; Zhang et al., 2011).
Mushrooms are a well-known source of physiologically active
agents including polysaccharides and other molecular classes
0308-8146/$ - see front matter  2013 Elsevier Ltd. All rights reserved.
http://dx.doi.org/10.1016/j.foodchem.2013.10.015
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(e.g., polysaccharo-peptides, proteins and lectins) with anti-
tumour and immunostimulatory activity (Zhong & Xiao, 2009).
The utilisation and processing of mushrooms and their bioac-
tive proteins usually include various food processing steps, such
as thermal sterilization, freezing treatment, acid and alkali pro-
cessing, and a dehydration procedure. Since the resistance of
mushroom proteins to diverse treatments in food processing and
pharmaceutical production for the regulation of cellular immune
response remained unclear, it is of great importance to understand
their remaining bioactivities after food processing steps.
Therefore, in this study, generic food-compatible methods for
processing dietary plants involving microwave heating, ultrasoni-
cation, freeze drying and change of pH were applied to a selection
of mushrooms including White Button and Honey Brown (both
Agaricus bisporus), Shiitake (Lentinus edodes), Enoki (Flammulina
velutipes) and Oyster mushrooms (Pleurotus ostreatus). These
mushroom preparations were tested for their anti-inflammatory
activity in LPS and IFN-c activated murine RAW 264.7
macrophages. The contribution of a known mushroom bioactive
compound, L-ergothioneine, was also tested in the respective
anti-inflammatory assays. L-ergothioneine is a thiourea derivative
of histidine, containing a sulfur atom in the imidazole ring. It is a
naturally occurring antioxidant and present in plants and animals.
L-ergothioneine is present in a range of cultivated mushrooms
including White Button, Shiitake and Oyster mushroom (Dubosta,
Boxin, & Robert, 2007).
2. Materials and methods
2.1. Materials
Mushrooms included in the study including White Button and
Honey Brown (both A. bisporus), Enoki (F. velutipes), Shiitake
(L. edodes), and Oyster (P. ostreatus) as well as wheat-based
cornflour (Homebrand, Woolworths) were obtained from retail
suppliers in Melbourne, Australia. L-ergothioneneine, iodo-acetic
acid, EDTA, ascorbic acid, lipopolysaccharide were obtained from
Sigma–Aldrich (St Louis, Missouri, USA). Clarase G Plus, Mannanase
and Fungal Lipase 8000 were obtained from Enzyme Solutions
(Melbourne, Victoria, Australia). Tetra sodium pyrophosphate and
methanol were obtained from Merck KGaA (Darmstadt, Germany);
Flavourzyme (EC 3.4.11.1; 1000L), and porcine pancreatic Trypsin
(EC 3.4.21.4; Novo 6.0 S, salt free), were obtained from Novozymes
(Bagsvaerd, Denmark).
2.2. Mushroom processing
The sample processing methods designated unprocessed, stages
1 and 2 processing described in detail below, were applied to five
mushroom types (White Button, Swiss (Honey) Brown, Enoki,
Shiitake, Oyster). The results presented in this study are therefore
relevant to these particular strains produced locally and bioactivi-
ties may vary compared with mushrooms of similar species
sourced elsewhere. At least two independent batches of each
mushroom product were prepared. ‘Unprocessed’ forms of mush-
rooms were prepared by washing, drying and chopping fresh
mushrooms and freeze-drying. All dried samples were stored with
desiccant at 18 C and ground by mortar and pestle to fine pow-
der before analysis. Stages 1 and 2 processing involved heating (i.e.,
‘cooking’), mechanical dispersion and treatments intended to solu-
bilise both hydrophobic and hydrophilic solutes. Successive stages
of processing (Stages 1 and 2) provided for progressive enrichment
of bioactivity. Each represented a scalable, food regulation-
compliant processing method, according to Australian standards,
in terms of use of additives and technologies. ‘Stage 1-processed’
mushrooms were prepared by washing the raw, edible mushroom
components, blending in a food processor with water (1:2 ratio w/
v) before boiling by microwave heating (9000 W, 10 min). After
cooling to room temperature, ascorbic acid (0.1% of solids) and eth-
anol (1% of solids) were added for anti-microbial stabilisation.
Samples were ultrasonicated using a 400W probe at 100% power
for 2 min (Hielscher 400UPS, Hielscher, Germany) before freeze-
drying. ‘Stage 2-processed’ mushrooms were prepared by reconsti-
tuting the stage 1 product at 2% total solids in de-ionised water and
stirring for 2 h. After addition of the following processing aids:
wheat-based cornflour (0.01% w/v); Clarase G Plus (0.001% w/v);
Fungal Lipase (0.01% w/v); tetra sodium pyrophosphate (0.01%
w/v), the pH was adjusted to 5.5 using 1.0 M NaOH or 1.0 M HCl
and samples were incubated at 45 C for 17 h with agitation at
100 rpm (OLS 200 shaking water bath, Grant, England). Enzymes
were subsequently inactivated by heating to 90 C for 30 min, then
cooled to room temperature before homogenisation for 2 min (T25
probe, Ultra-turrax, IKA, Germany). The sample was filtered
(150 lm sieve) and the filtrate centrifuged at 16,900g for 10 min
at 20 C. The supernatant was homogenised by 2 passes through
an in-house homogeniser (adapted from Milkscan, Foss, Denmark)
before freeze-drying.
2.3. Determination of anti-inflammatory activity in RAW 264.7
macrophages
Murine macrophage cells (RAW264.7) were cultured in 175 cm2
flasks in DMEM containing 5% FBS, supplemented with glutamine
(2 mM), penicillin (200 U/ml), streptomycin (200 lg/ml) and fungi-
zone (2.6 lg/ml). The cell lines were maintained in 5% CO2 at 37 C.
For assays with test inhibitor samples, cells were treated with
50 ll of sample solution in DMEM media for 1 h prior to addition
of pro-inflammatory activators (combination of LPS:25 lg/ml in
DMEM and IFN-c:10 U/ml in DMEM). Following 24 h of incubation,
NO in the culture media was measured by the Griess assay and
TNF-a by ELISA as described previously (Shanmugam et al.,
2008). Cell viability was determined by the Alamar Blue assay
involving the cellular reduction of resazurin to resorufin. Alamar
Blue (Resazurin) solution (100 ll of 10% Alamar Blue in DMEM
media) was added to each well before incubation at 37 C for
1.5 h. Fluorescence was measured in a microplate reader (545 nm
excitation, 595 nm emission).
2.4. Statistical analysis
Data calculations were performed usingMS-Excel 2010 software.
IC50 values were obtained by using the sigmoidal dose–response
function inGraphPadPrism. IC50 values fromthree experimentswere
averaged (all performed in triplicate). The results were expressed as
mean ± standard deviation (SD). Differences between control and
treated data sets were evaluated by Anova using Sigmaplot for
Windows, version 11 (Systat Software Inc., CA, USA).
3. Results
3.1. Comparison of the anti-inflammatory activity of the five
unprocessed mushroom species
In order to determine a potential anti-inflammatory bioactivity,
RAW 264.7 murine macrophage were activated with a combina-
tion of LPS and IFN-c in the presence of increasing concentration
of mushroom preparations. After 24 h, the production of NO and
TNF-a as well as the cell viability were determined.
All five mushrooms including the commercially most important
White Button and Honey Brown mushrooms led to a decrease in
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NO production with IC50 values <0.1 mg/ml (Table 1), without
significantly affecting the cell viability in the active range (Fig. 1).
However, only Oyster (IC50 = 0.04 mg/ml), Shiitake (IC50 = 0.05 -
mg/ml) and Enoki mushrooms (IC50 = 0.09 mg/ml) showed potent
inhibition of TNF-a production (Fig. 1, Table 1).
3.2. Effect of food processing steps on anti-inflammatory activity of the
mushrooms
The effect of defined generic food processing methods on the
anti-inflammatory activity of the mushroom preparations was
tested.
‘‘Stage 1-processed’’ mushrooms were prepared by washing the
raw, edible mushroom components, before boiling by microwave
heating. ‘‘Stage 2-processed’’ mushrooms were prepared by recon-
stituting the stage 1 product and addition of the processing aids.
Samples were incubated at 45 C for 17 h and then heated to
90 C for 30 min as described in detail in Section 2.
When the anti-inflammatory activity was followed through the
food processing steps, the stages 1 or 2 mushroom lost a significant
amount of anti-inflammatory bioactivity compared to the raw
mushrooms. For all mushroom species and both anti-inflammatory
readouts, the activity was gradually reduced through the process-
ing stages from unprocessed mushroom to stages 1 and 2 (Fig. 2,
Table 1). In particular, heating of the samples during the prepara-
tion of the stage 1 products led to a significant loss of anti-inflam-
matory activity in all samples (Table 1). Conversion of stage 1 into
stage 2 products did only have a minor influence on bioactivity
compared to each other, except for the Enoki mushroom. In the
Enoki mushroom the anti-Inflammatory effect for NO inhibition
from stage 1 to stage 2 reduced considerably, demonstrated by
an increase of the IC50 value from 0.09 ± 0.04 to 0.75 ± 0.09 mg/
ml) (Table 1).
Two of the most potent anti-inflammatory mushrooms,
Oyster and Shiitake, also exhibited some degree of cytotoxicity,
with an LD50 value of 0.34 ± 0.04 and 0.59 ± 0.38 mg/ml,
respectively, which is approx. 5–10 times higher than the IC50.
The best mushroom in terms of its therapeutic index was the
Enoki mushroom, which showed potent anti-inflammatory
activity in the absence of any detectable cytotoxicity. The
activity of L-ergothioneine was also tested in the respective
anti-inflammatory assays. L-ergothioneine down-regulated LPS
and IFN-c induced NO (IC50 = 0.11 mg/ml), but not TNF-a pro-
duction (IC50 > 2.5 mg/ml) (Table 1).
4. Discussion
To our knowledge, our study is the first report comparing anti-
inflammatory bioactivity of raw White Button, Honey Brown,
Shiitake and Enoki mushrooms in an established inflammation-
related assay system, and following these activities through two
food processing steps.
Previous research studies have tested the anti-inflammatory
activities of extracts for several other mushroom species but
mostly focussed on inhibition of prostaglandin synthesis. For
example, ethyl acetate extracts of Ganoderma applanata, Naemato-
loma sublateritium, Pleurotus eryngii, and Pleurotus salmoneostram-
ineus have been shown to have in vitro anti-inflammatory
activity via inhibition of both COX-2 and COX-1 activity (Elgorashi,
Maekawa, & Satoh, 2008).
Among the tested mushrooms, only Oyster mushroom concen-
trate (OMC) has been tested in a comparable manner in terms of
NO and TNF-a production. OMC has been shown to suppress LPS-
induced secretion of TNF-a, IL-6 and IL-12p40, and PGE2 andNOpro-
duction by down-regulation of COX-2 and iNOS expression in
RAW264.7macrophages. Furthermore, the previous study identified
the compound responsible for the anti-inflammatory reaction as the
non-lectin glycoprotein (PCP-3A). PCP-3A inhibited LPS-inducedpro-
ductionofNOandPGE2via thedown-regulationofpro-inflammatory
mediators, including iNOS and COX-2 via amechanism involving the
transcription factor NF-jB (Chen, de Mejia, & Wu, 2011).
The mode of action and the exact composition of the anti-
inflammatory bioactives in the different mushroom species remain
to be elucidated. The combination of LPS and IFN-c is known to be
a very potent inducer of the expression of pro-inflammatory pro-
teins including iNOS and TNF-a via redox-sensitive signalling path-
ways in which superoxide anions (or their conversion products, e.g.
hydrogen peroxide and hydroxyl radicals) act as second messen-
gers. Expression of these proteins is regulated on the transcrip-
tional level, as the mouse macrophage iNOS promoter contains
several binding sites for LPS-related and interferon (IFN)-related
response elements, including NF-kB, AP-1, IFN-c-response element
and Stat-1 (Diaz-Guerra, Velasco, Martin-Sanz, & Bosca, 1996).
Thus, membrane permeable antioxidants (i.e. polyphenols), which
inhibit the up-regulation of cytokines or radical producing en-
zymes by inhibition of redox-active signalling, could be the respon-
sible anti-inflammatory agent in the active mushrooms similar to
plant derived polyphenols. However, the nonlectin glycoprotein
(PCP-3A) with a size of 45 kDa is unlikely to enter the cell and more
likely to act via a receptor mediated mechanism.
Table 1
Summary of anti-inflammatory activity and toxicity of selected mushroom products and L-ergothioneine.
Mushroom species Product type Inhibition of NO production
(IC50 in mg/ml ± SD)
Inhibition of TNF-a production
(IC50 in mg/ml ± SD)
Cell viability
(LC50 in mg/ml ± SD)
Therapeutic index
(NO/TNF)
Oyster Unprocessed
Stage 1
Stage 2
0.077 ± 0.001
0.23 ± 0.01
0.32 ± 0.25
0.035 ± 0.01
0.37 ± 0.11
0.47 ± 0.08
0.34 ± 0.04
>2.5
>2.5
4.4/9.7
Honey Brown Unprocessed
Stage 1
Stage 2
0.063 ± 0.009
1.07 ± 0.22
1.04 ± 0.15
>2.5
>2.5
>2.5
>2.5
n/d
n/d
>40/n/a
White Button Unprocessed
Stage 1
Stage 2
0.032 ± 0.003
1.5 ± 0.1
1.25 ± 0.26
1.88 ± 0.56
>2.5
>2.5
>2.5
n/d
n/d
>78/n/a
Enoki Unprocessed
Stage 1
Stage 2
0.024 ± 0.010
0.09 ± 0.04
0.75 ± 0.09
0.099 ± 0.012
>2.5
>2.5
>2.5
n/d
n/d
>104/25
Shiitake Unprocessed
Stage 1
Stage 2
0.027 ± 0.002
0.10 ± 0.05
0.17 ± 0.11
0.047 ± 0.001
1.34 ± 0.16
2.11 ± 0.56
0.59 ± 0.38
>2.5
> 2.5
22/13
Compound
L-ergothioneine n/a 0.11 ± 0.01 >2.5 >2.5
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One other compound which might be responsible for some of
the anti-inflammatory activity in these mushrooms could be L-
ergothionine (ET) (Colognato et al., 2006). ET is a naturally
occurring thiol containing amino acid, known for its antioxidant
properties (Dubost, Beelman, Peterson, & Royse, 2006). ET is water
soluble and exerts antioxidant properties through multiple mech-
anisms, one of which is its powerful ability to scavenge free radi-
cals. Ergothioneine has been shown to inhibit both H2O2 and
TNF-a mediated activation of NF-jB. Both H2O2 and TNF-a signif-
icantly increased IL-8 release, which was inhibited by pre-treat-
ment of A549 cells with ergothioneine compared to the control
untreated cells. This indicates a redox-based molecular mechanism
for the anti-inflammatory effects of ergothioneine (Colognato et al.,
2006). In our study, the anti-inflammatory activity of the mush-
room samples was higher than that of L-ergothioneine and not only
restricted to down-regulation of NO production, suggesting that
the mushroom samples are likely to contain other anti-inflamma-
tory compounds besides L-ergothioneine.
The result of this study also shows that fresh mushrooms exhi-
bit significantly higher bioactivity than processed mushrooms. Our
results suggest that the responsible anti-inflammatory bioactive
factors degrade when the processing steps involving boiling for
10 min. However, it could be possible that other methods involved
in stage 1 processing, e.g. addition of ascorbic acid (e.g. by reduc-
tion), ethanol or ultrasonication might be involved in the disap-
pearance of the anti-inflammatory compounds.
The conversion of stage 1 into stage 2 products only had a minor
influence on anti-inflammatory bioactivity, except for the Enoki
Fig. 1. Dose-dependent effects of unprocessed mushrooms preparations on LPS and IFN-c induced production of pro-inflammatory markers. RAW264.7 macrophages were
activated with LPS and IFN-c in the presence of increasing concentrations of raw mushroom extracts of (A) Oyster, (B) Enoki, (C) Shiitake, (D) Button and (E) Honey Brown
mushrooms. Nitric oxide and TNF-a production as well as cell viability were determined after 24 h. Experiments show the mean of 3 independent experiments ± SEM.
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mushroom, indicating that substrates sensitive to the enzyme
treatment (e.g. lipids or starches) were not the responsible anti-
inflammatory species in these other four mushrooms.
In summary, we have identified that Enoki, Shiitake and Oyster
as the most potent anti-inflammatory mushroom species. Further-
more, we showed that fresh mushrooms exhibited significantly
higher bioactivity than processed mushrooms, highlighting the
susceptibility of the anti-inflammatory compounds to heating.
While our results suggest that somemushrooms would more likely
deliver higher levels of anti-inflammatory compounds when eaten
raw, consumption of rawmushrooms carries some health risks. For
example, many edible mushrooms including the button mushroom
contain various hydrazines, a group of chemical compounds gener-
ally considered carcinogenic (Friederich et al., 1986; Toth, 1975).
For the most part, these compounds are heat sensitive, readily vol-
atilized and expunged from the fungal flesh by proper cooking.
Furthermore, raw mushrooms can be contaminated with Listeria
monocytogenes responsible for listeriosis, a disease with a very high
mortality rate (Viswanath et al., 2013). In addition, raw Shiitake
mushrooms have been shown to cause contact dermatitis on rare
occasions (Tarvainen et al., 1991).
Therefore, future research could test a range of ‘cooking’
temperatures to see if mushrooms cooked on low heat retain their
bioactivity while not posing a health risk.
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In our quest for the search of novel potent anti-inflammatory compounds involved 
the screening of 72 Australian tropical rainforest plant extracts from Northern 
Queensland. This chapter highlights the bioassay guided isolation and 
characterization of new anti-inflammatory compounds from one of the most active 
plant, Cryptocarya mackinoniana. The aim of this study was the identification of 
novel anti-inflammatory compounds present in Cryptocarya mackioniana young 
leaves. 
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7.1 Introduction 
The organic world is sustained by plants through the fundamental process of 
photosynthesis.  Plants have provided all the basic needs of man ever since his birth 
and evolution.  Plants are the sources of food, medicine, fuel, fiber and others.  Even 
before the beginning of agriculture, that is about 10,000 years ago, man must have 
eaten many plants to satisfy hunger and regulate his digestive system and to cure 
different diseases.  As civilization developed people identified and used many other 
plants that yielded spices, oil and selected forage and fodder grass for the animals 
that they domesticated (Bodeker 2000). 
 
Using plants as drugs has been a goal of mankind since prehistoric times.  Many of 
the drugs in use today have their origin from plants used by healers since time 
immemorial.  It is estimated that there are about 250,000 species of flowering plant 
on this planet of which 150,000 are found in the tropical forests (Bodeker 2000).  
Less than 5% of these plants have been so far investigated for pharmacological 
activity.  Higher plants are untapped reservoirs, waiting to be investigated.  For many 
classes of drugs widely employed in humans, synthesis of novel structures has not 
yielded entities with new mechanism of action (Cragg and Newman 2013).  Due to 
this reason, initiation is taken to further explore higher plants for biologically active 
compounds that till now have eluded the imagination of synthetic chemists. 
 
For thousands of years, mankind has known about the benefit of drugs from nature.  
The drugs used by ancient civilization were extracts of plants or animal products, 
with a few inorganic salts.  In the main, plants in medicinal use have been held in 
high esteem, e.g. in India where the Ayurveda gave access to a broad variety of 
medicines from plants reported since 1000 BC.  The earliest prescriptions in Chinese 
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medicine based on natural products date back to about 500 BC, and some of the 
classical Chinese formulae handed down in the years between 25 BC and 220 BC are 
still in use (Grabley 1999).   
 
From about 800 AD, the monks of the Benedictine order have had a profound 
knowledge of herbs and their potential use in medicine.  For example, they were able 
to apply Papaver somniferum not only to treat pain but also to anaesthetize patients.  
The active principle morphine was first isolated in 1806 (Table 7.1) and the 
manufacturing of an analgesic drug was realized by E.Merck in Darmstadt, Germany 
in 1826 (Grabley 1999).  At present, substantial efforts have been undertaken to 
replace morphine by a synthetic drug with less side-effects. However, no alternative 
drug can yet be provided to patients suffering from severe pain in the late stages of 
cancer. 
 
In former centuries, malaria played a major role in European countries.  In the 17th 
century, the bark of the Peruvian Cinchona tree was imported to Europe, and an 
extract from the Cinchona cortex was often used for the treatment of malaria.  The 
pure active principle quinine was first isolated in 1820, representing the only 
effective antimalarial medicine until the introduction of the synthetic drug 
pamaquine (Fig 7.1) in 1926.  Later on, pamaquine was replaced by primaquine (Fig 
7.1) and further quinoline-type drugs, most of them with severe side effects (Michael 
2007). 
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Fig.7.1: Structures of pamaquine (a) and primaquine (b). 
 
Traditional systems of medicine continue to be widely practiced on many accounts. 
Population rise, inadequate supply of drugs, prohibitive cost of treatments, side 
effects of several  drugs and development of resistance to currently used drugs for 
infectious diseases have led to increased emphasis on the use of plant materials as a 
source of medicines for a wide variety of human ailments. Global estimates indicate 
that 80% of about 4 billion population cannot afford the products of the Western 
Pharmaceutical Industry and have to rely upon the use of traditional medicines which 
are mainly derived from plant material (Geetha 2010). This fact is well documented 
in the inventory of medicinal plants, listing over 20,000 species.  In spite of the 
overwhelming influence of, and our dependence on, modern medicine and the 
tremendous advances in synthetic drugs, a large segment of the world population still 
prefer drugs from plants. In many of the developing countries the use of plant drugs 
is increasing because modern life saving drugs are beyond the reach of three quarters 
of the third world’s population although many such countries spend 40-50% of their 
total wealth on drugs and health care. As a part of the strategy to reduce the financial 
burden on developing countries, it is obvious that an increased use of plant drugs will 
be followed in the future. 
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Table 7.1 History of commercialization of some modern drugs derived from 
nature as plant metabolites (Grabley 1999) 
Year of 
introduction 
Drug Commercialized as Indication 
1826 morphine (3) Natural compound Analgesic 
1899 Acetylsalicylic acid 
(Aspirin) (4) 
Synthetic analog Analgesic, 
Antiphlogistic, etc. 
1987 Artemisinin (5) Natural compound Antimalarial 
1993 Paclitaxel (6) 
(Taxol)  
Natural compound 
as a semi-synthetic 
derivative 
Anticancer 
1995 Docetaxel (7) 
(Taxotere)  
Semi-synthetic 
derivative 
Anticancer 
1996 Topotecan (8) 
Irinotecan (9) 
Semi-synthetic 
derivative 
Anticancer 
1996 Miglitol (10) Syntetic analog Antidiabetic 
 
Many higher plants produce economically important organic compounds such as oils, 
resins, tannins, natural rubber, gums, waxes, dyes, flavours, fragrances, 
pharmaceuticals and pesticides.  Advances in biotechnology, particularly methods for 
culturing plant cells and tissues, should provide new means for the commercial 
processing of even rare plants and the chemicals that they produce (Balandrin 1985)   
 
 The ultimate goal of ethnopharmacology should be to identify drugs to alleviate 
human illness through a thorough analysis of plants alleged to be useful in human 
cultures throughout the world. Natural products research continues to explore a 
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variety of lead structures, which may be used as templates for the development of 
new drugs by the pharmaceutical industry (Jayaweera 1981-1982).  
 
7.1.1 Australian flora 
One of Australia's greatest treasures is her flora. Australia has been isolated for 
thousands of years and thus plants have been able to develop independently to suit 
the often harsh natural conditions. It has been estimated there are about 20,000 to 
25,000 different plants native to Australia. They are varying across the many 
different natural environments of the country. In the tropical regions of north 
Queensland, Arnhem Land and the Kimberleys there are many native fruit trees, such 
as figs and green plums. Where water is scarce in central Australia, the plants are 
spread thinly over the land and Aborigines rely on fruits such as bush tomatoes and 
quandong or native peach (Wells 2013).  There are now an estimated 20 000 vascular 
and 7700 non-vascular plants, and 250 000 species of fungi in Australia. Plants 
include living fossils such as the cycad palm and the grass tree, and brilliant 
wildflowers such as the waratah, Sturt’s desert pea, banksia and kangaroo paws. 
Australia has over 1000 species of acacia, which Australians call ‘wattle’, and 
around 2800 species in the Myrtaceae family, which includes eucalyptus and 
melaleucas. Native forests are limited to wetter coastal districts, and rainforests are 
found mainly in Queensland. The high diversity of flora includes large numbers of 
species in ecologically significant genera such as Acacia, Eucalyptus, Melaleuca, 
Grevillea and Allocasuarina. Acacias tend to dominate in drier inland parts of 
Australia, while eucalypts dominate in wetter parts.  
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Australia’s unique flora includes the Proteaceae family of Banksia, Dryandra, 
Grevillea, Hakea and Telopea (waratah).  
The dominant type of vegetation in Australia is the hummock grasslands (23%) 
found in Western Australia, South Australia and the Northern Territory. In the east of 
Australia eucalypt woodlands are prevalent, and in the west there are Acacia forests, 
woodlands and shrublands. Tussock grasslands are found largely in Queensland 
(http://www.australia.gov.au/about-australia/our-country/our-natural-environment). 
7.1.2 Genus Cryptocarya 
Cryptocarya is a genus of evergreen trees belonging to the laurel family, Lauraceae. 
The genus includes more than 350 species, distributed through the Neotropic, 
Afrotropic, Indomalaya, and Australasia ecozones. Common in the canopy, they 
grow up to 60 m, or as subcanopy trees in the succession climax species in tropical, 
lower temperate, or subtropical broadleaved forests. They are found in low-elevation 
evergreen forests and littoral rainforests, on all type of soils. The seeds are readily 
dispersed by fruit-eating birds, and seedlings and saplings have been recorded from 
other habitats where they are unlikely to develop to maturity. The genus name 
Cryptocarya is from a Greek word krypto meaning to hide, karya meaning a walnut 
tree, the fruit of which was known as karyon', a word also used to describe other 
fruits. Sometimes, they are called mountain laurels or mountain walnuts. The fruits 
are succulent, partially immersed in a deep, thick cup 
(http://en.wikipedia.org/wiki/Cryptocarya 2014). 
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7.1.3. Previous bioactivity studies of Cryptocarya species 
Previous phytochemical investigations on the genus established the presence of 
numerous different classes of natural products, e.g., flavonoids ((Chou 2010, 
Dumontet 2001, Kurniadewi and Kinoshita 2010, Feng 2012, Govindachari 1972), 
pyrones ((Davis 2010, Grkovic 2011, Meragelman 2009), pavines ((Lee 1990, Lin 
2002, Wu 2001) and aporphines ((Awang 2008, Lee 1993, Wu 2001), stilbenes 
((Juliawaty 2000b), lignans (Saad) (Table 7.2-7.8). Alkaloids and pyrones are widely 
distributed in this genus in contrast to the chemical profile of Lauraceae family, in 
which lignans and neolignans are considered chemotaxonomical markers(Gottlieb 
1972).  
 Many of which exhibited cytotoxic ((Dumontet 2001, Chou 2010, Dumontet 2004),  
nuclear factor-κB (NF-κB) inhibitory ((Feng 2012, Meragelman 2009, Hexum 2012), 
antitrypanosomal (Davis 2010) activities, glucose transport inhibitory effects (Ren 
2014), tyrosine kinase inhibitory effects (Kurniadewi 2010), antituberculosis activity 
(Choua 2011) or antipoliferative activity (Huang 2014a) . Some of the pyrones and 
styrylpyrones showed larvicidal and antifertility activities, in addition to inhibition of 
breast cancer cell lines growth (Hawariah 1998) (Table 7.2-7.8). 
Table 7.2 Flavonoids isolated from Cryptocarya species 
Compound No Species and 
plant part 
Indication Ref 
(-)-rubrichalcolactone 36 C.rubra (leaves 
and twigs) 
 (Ren 2014) 
(2S)-5,7-
dihydroxyflavanone 
7 C.chingii (stem)  anti-inflammatory 
(blocked TNF-α 
induced IκBα 
degradation) 
(Wagner 
1976, Feng 
2012) 
2׳,4׳-dihydroxy-5׳,6׳-
dimethoxychalcone 
46 C.costata (bark) Cytotoxic  (Usman 
2006) 
26׳-dihydroxy-4׳-
methoxydihydrochalcone 
43 C.idenburgensis anticancer, 
antimicrobial 
(Juliawaty 
2000b) 
2׳-hydroxy chalcone 29 C.konishii 
(heartwood) 
 (Kurniadewi 
2010, 
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Kurniadewi 
2008) 
4׳,7-di-o-methyl naringenin 41 C.obovata 
(leaves) 
 (Davis 2010) 
7-hydroxy-5,6-
dimethoxyflavanone 
44 C.costata (bark)  (Usman 
2006) 
7-o-methyl naringenin 42 C.obovata 
(leaves) 
 (Davis 2010) 
bicaryanone A 12 C.chingii 
(stem), 
C.infectoria 
(trunk bark), 
C.rubra (leaves 
and twigs) 
 (Dumontet 
2001, Feng 
2012, Ren 
2014) 
bicaryanone B 14 C.infectoria 
(trunk bark) 
 (Dumontet 
2001) 
bicaryanone C 15 C.chingii 
(stem), 
C.infectoria 
(trunk bark) 
 (Dumontet 
2001, Feng 
2012) 
bicaryanone D 13 C.chingii 
(stem), 
C.infectoria 
(trunk bark) 
 (Dumontet 
2001, Feng 
2012) 
bromocryptocaryone 26 C.infectoria 
(trunk bark) 
 (Dumontet 
2001) 
chalcocaryanone A 16 C.infectoria 
(trunk bark) 
 (Dumontet 
2001) 
chalcocaryanone B 17 C.infectoria 
(trunk bark) 
 (Dumontet 
2001) 
chalcocaryanone C 18 C.chingii 
(stem), 
C.infectoria 
(trunk bark), 
C.rubra (leaves 
and twigs)  
 (Dumontet 
2001, Feng 
2012, Ren 
2014) 
chalcocaryanone D 19 C.infectoria 
(trunk bark) 
 (Dumontet 
2001) 
chartaceone A 58 C.chartacea 
(bark)  
 (Allard 
2011) 
chartaceone B 59 C.chartacea 
(bark) 
 (Allard 
2011) 
chartaceone C 60 C.chartacea 
(bark) 
dengue virus NS5 
polymerase 
inhibitors 
(Allard 
2011) 
chartaceone D 61 C.chartacea 
(bark) 
dengue virus NS5 
polymerase 
inhibitors 
(Allard 
2011) 
chartaceone E 62 C.chartacea 
(bark) 
dengue virus NS5 
polymerase 
inhibitors 
(Allard 
2011) 
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chartaceone F 63 C.chartacea 
(bark) 
dengue virus NS5 
polymerase 
inhibitors 
(Allard 
2011) 
cryptocaryanone A 28 C.infectoria 
(trunk bark), 
C.rubra (leaves 
and twigs), 
C.concinna 
(stem) 
antitumor, 
antimicrobial 
(Kurniadewi 
2008, 
Kurniadewi 
2010, 
Dumontet 
2001, Huang 
2014b, Ren 
2014) 
cryptocaryanone B 8 C.chingii (stem) 
C.infectoria 
(trunk bark) 
anti-inflammatory 
(blocked TNF-α 
induced IκBα 
degradation), 
antitumor 
(Dumontet 
2001, Feng 
2012) 
cryptocaryone 9 C.chingii (stem) 
, C.infectoria 
(trunk bark), 
C.konishii 
heartwood), 
C.chingii 
(leaves), 
C.rugulosa, 
C.rubra (leaves 
and twigs) 
 
anti-inflammatory 
blocked TNF-α 
induced IκBα 
degradation ) 
(Feng 2012), 
antitumor 
(Dumontet 2001), 
tyrosine kinase 
inhibitory activity 
(Kurniadewi 
2010), NF-κB 
inhibitory activity 
(Meragelman 
2009), glucose 
transport 
inhibitory effects 
(Ren 2014), 
antituberculosis 
activity (Choua 
2011) 
(Kurniadewi 
2008, 
Kurniadewi 
2010, 
Dumontet 
2001, 
Govindachari 
1972, Hexum 
2012, 
Meragelman 
2009, Feng 
2012, Ren 
2014, Choua 
2011)  
cryptochinone A  11 C.chingii 
(stem), 
C.concinna 
(stem), 
C.chinensis 
(leaves) 
 (Chou 2010, 
Feng 2012, 
Huang 
2014b, Lin 
2014) 
cryptochinone B 57 C.chinensis 
(leaves) 
 (Lin 2014) 
cryptochinone C 37 C.chinensis 
(leaves) 
 (Lin 2014) 
cryptochinone D 25 C.chinensis 
(leaves) 
 (Lin 2014) 
cryptoconone A 52 C.concinna 
(stem) 
 (Huang 
2014b) 
cryptoconone B 53 C.concinna  (Huang 
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(stem) 2014b) 
cryptoconone C 54 C.concinna 
(stem) 
 (Huang 
2014b) 
cryptoconone D 55 C.concinna 
(stem) 
 (Huang 
2014b) 
cryptoconone E 56 C.concinna 
(stem) 
 (Huang 
2014b) 
cryptoflavanone A 64 C.chingii 
(leaves) 
 (Choua 
2011) 
cryptoflavanone B 65 C.chingii 
(leaves) 
 (Choua 
2011) 
cryptoflavanone C 66 C.chingii 
(leaves) 
 (Choua 
2011) 
cryptoflavanone D 67 C.chingii 
(leaves) 
 (Choua 
2011) 
cryptogione A 1 C.chingii (stem)  (Feng 2012) 
cryptogione B 2 C.chingii (stem)  (Feng 2012) 
cryptogione C 3 C.chingii 
(stem), 
C.concinna 
(stem) 
 (Feng 2012, 
Huang 
2014b) 
cryptogione D 4 C.chingii (stem)  (Feng 2012) 
cryptogione E 5 C.chingii (stem)  (Feng 2012) 
cryptogione F 6 C.chingii (stem)  (Feng 2012) 
cryptogione G 20 C.maclurei 
(stem) 
 (Feng 2013) 
cryptogione H 21 C.maclurei 
(stem 
 (Feng 2013) 
cryptogione I 22 C.maclurei 
(stem 
 (Feng 2013) 
cryptogione J 23 C.maclurei 
(stem 
 (Feng 2013) 
cryptogione K 24 C.maclurei 
(stem 
 (Feng 2013) 
desmethylinfectocaryone 10 C.chingii 
(stem), 
C.konishii 
heartwood), 
C.rubra (leaves 
and twigs) 
antitumor (Kurniadewi 
2010, 
Kurniadewi 
2008, Feng 
2012, Ren 
2014) 
didymocarpin 45 C.costata (bark)  (Usman 
2006) 
hyperin 33 C.ashersoniana 
(sedlings) 
antioxidant (Ricardo 
2004) 
infectocaryone 27 C.infectoria 
(trunk bark), 
C.konishii 
heartwood) 
antitumor  (Kurniadewi 
2010, 
Kurniadewi 
2008, 
Dumontet 
2001)  
isodidymocarpin 47 C.costata (bark) Cytotoxic (Usman 
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2006) 
iso-quercitrin 32 C.ashersoniana 
(sedlings) 
antioxidant (Ricardo 
2004) 
kurzichalcolactone A 30 C.konishii 
heartwood) 
,C.lucida (stem 
bark), 
C.concinna 
(stem)  
antimicrobial (Kurniadewi 
2008, 
Kurniadewi 
2010, 
Dumontet 
2004, Huang 
2014b, 
Siallagan 
2008) 
kurzichalcolactone B 31 C.lucida (stem 
bark), 
C.obovata 
(fruits and trunk 
bark), 
C.concinna 
(stem) 
 
antimicrobial (Siallagan 
2008, 
Dumontet 
2004, Huang 
2014b) 
kurziflavolactone A 48 C.kurzii 
(leaves) 
 (Fu 1993) 
kurziflavolactone B 49 C.kurzii 
(leaves) 
 (Fu 1993) 
kurziflavolactone C 50 C.kurzii 
(leaves) 
 (Fu 1993) 
kurziflavolactone D 51 C.kurzii 
(leaves) 
 (Fu 1993) 
obochalcolactone 38 C.obovata 
(fruits and trunk 
bark) 
cytotoxic (Dumontet 
2004) 
oboflavanone A 39 C.obovata 
(fruits and trunk 
bark) 
cytotoxic (Dumontet 
2004) 
oboflavanone B 40 C.obovata 
(fruits and trunk 
bark) 
 (Dumontet 
2004) 
pinocembrin 34 C.chingii 
(leaves), 
C.konishii 
heartwood),  
C.strictifolia 
(stem bark) 
antituberculosis (Kurniadewi 
2010, 
Juliawaty 
2000a, 
Choua 2011) 
trans-N-feruloyltyramine 35 C.konishii 
heartwood) 
 (Kurniadewi 
2010) 
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Table 7.3 Pyrones isolated from Cryptocarya species 
Compound No Species and Plant 
part 
Indication Ref 
(2׳,4׳-diacetoxy)—6-
Pentyl-5,6-dihydro-2-H-
pyran-2-one 
17 C.latifolia (bark)  (Siegfried 
1995a) 
(2׳4׳6׳-triacetoxy)-6-
Heptyl-5,6-dihydro-2-H-
pyran-2-one 
18 C.latifolia (bark)  (Siegfried 
1995a) 
5,6-dihydro-6-propyl-
2H-pyran-2-one 
3 C.ashersoniana 
(sedlings) 
 (Ricardo 
2004) 
6-(4,6-dimethoxy-8-
phenyl-octa-1,7-dienyl)-
26 C.alba (fruit) cytotoxic (Schmeda 
2001) 
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4-hydroxy-tetrahydro-
pyran-2-one 
6-[4׳-ethyl-9׳-
oxabicycle[3.3.1]non-6׳-
en-3׳-yl)methyl]-5,6-
dihydro-2H-pyran-2-one. 
1 C.ashersoniana 
(sedlings) 
 (Ricardo 
2004) 
7׳8׳-dihydroobolactone 6 C.obovata (leaves) anti-
trypanosomal 
activity 
(Davis 
2010) 
7-styryl-2,6-
dioxabicyclo[3,3,1] 
nonan-3-one 
24 C.latifolia  (Siegfried 
1995b) 
cryptocaryalactone 22 C.moschata seed, 
C.bourdilloni 
(roots) 
germination 
inhibitor 
(Siegfried 
1995b, 
Govindac
hari 1971, 
Spencer 
1984) 
cryptocaryol A 7 Cryptocarya sp  (Grkovic 
2011) 
cryptocaryol B 8 Cryptocarya sp  (Grkovic 
2011) 
cryptocaryol C 9 Cryptocarya sp Pdcd4-
stabilizing 
activity 
(Grkovic 
2011) 
cryptocaryol D 10 Cryptocarya sp Pdcd4-
stabilizing 
activity 
(Grkovic 
2011) 
cryptocaryol E 11 Cryptocarya sp Pdcd4-
stabilizing 
activity 
(Grkovic 
2011) 
cryptocaryol F 12 Cryptocarya sp  (Grkovic 
2011) 
cryptocaryol G 13 Cryptocarya sp Pdcd4-
stabilizing 
activity 
(Grkovic 
2011) 
cryptocaryol H 14 Cryptocarya sp Pdcd4-
stabilizing 
activity 
(Grkovic 
2011) 
cryptocaryolone 19 C.latifolia (bark)  (Siegfried 
1995a) 
cryptocaryolone diacetate 20 C.latifolia (bark)  (Siegfried 
1995a) 
cryptofolione  16 C.latifolia (bark), 
C.myrtifolia (stem 
bark), C.alba (fruit) 
cytotoxic (Sehlapel
o 1994, 
Schmeda 
2001, 
Siegfried 
1995a) 
Cryptofolione acetate 25 C.alba (fruit)  (Schmeda 
2001) 
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cryptofolione ketone 21 C.latifolia  (Siegfried 
1995b) 
deacetyl 
cryptocaryalactone 
23 C.moschata seed, 
C.myrtifolia (stem 
bark)  
germination 
inhibitor 
(Siegfried 
1995b, 
Spencer 
1984) 
goniothalamine 2 C.ashersoniana 
(sedlings) 
antifungal (Ricardo 
2004) 
obolactone 5 C.obovata (fruits 
and trunk bark), 
C.obovata (leaves) 
Cytotoxic (Dumonte
t 2004, 
Davis 
2010) 
rugulactone 4 C.rugulosa IκB inhibitory 
activity 
(Meragel
man 
2009) 
strictifolione 15 C.strictifolia (stem 
bark) 
 (Juliawaty 
2000a) 
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Table 7.4 Coumarins isolated from Cryptocarya species 
Compound No Species and plant part Ref 
psoralen 1 C.obovata (leaves) (Davis 
2010) 
1,16-hexadecanediol-
di-p-coumaroate 
2 C.rubra (leaves and twigs) (Ren 
2014) 
          
O
O
O
O O
HO
O
OH
( )
14
1'' 16''
9'
8'8
9
 
   1      2 
7.5 Stilbenes isolated from Cryptocarya species 
Compound No Species and plant part Ref 
3-hydroxy-5-methoxystilbene 2 C.idenburgensis (Juliawaty 
2000b) 
idenburgene 1 C.idenburgensis (Juliawaty 
2000b) 
OCH3
O
OCH3
OH
 
OCH3
OH   
  1       2 
O
O
H
O
H
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Table 7.6 Polyketide isolated from Cryptocarya species 
Compound  No Indication Species and plant part Ref 
cryptomaclurone 1 moderate cytotoxicity C.maclurei (stem) (Feng 
2013) 
 
O
H
O
1 
 
Table 7.7 Alkaloids isolated from Cryptocarya species 
Compound No Species and plant 
part 
Indication Ref 
(-)-10β,13aα-antofine N-oxide 35 C.oubatchensis 
(leaves) 
 (Toribio 
2006) 
(-)-12-hydroxycrychine 22 C.chinensis (wood)  (Wu 
2001) 
(-)-12-hydroxyeschscholtzidine 23 C.chinensis (wood)  (Wu 
2001) 
(-)-13aα-6-O-desmethyl-
antofine 
33 C.oubatchensis 
(leaves) 
cytotoxic (Toribio 
2006) 
(-)-14β-hydroxy-13aα-antofine 32 C.oubatchensis 
(leaves) 
cytotoxic (Toribio 
2006) 
(-)-antofine 5 C.phyllostemon 
(whole plant), 
C.chinensis (wood) 
cytotoxic (Cave 
1989, 
Wu 
2012) 
(-)-caryachine-N-oxide 19 C.chinensis (stem 
bark) 
 (Lin 
2002) 
(-)-cryptowolidine 11 C.phyllostemon 
(whole plant) 
 (Cave 
1989) 
(-)-cryptowoline 10 C.phyllostemon 
(whole plant) 
 (Cave 
1989) 
(-)-cryptowolinol 12 C.phyllostemon 
(whole plant) 
 (Cave 
1989) 
(-)-isocaryachine-N-oxide B 17 C.chinensis (stem 
bark) 
 (Lin 
2002) 
(-)-methylisopiline 36 C.ferrea (bark)  (Saidi 
2009) 
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(-)-N-demethylcrychine 24 C.chinensis (wood)  (Wu 
2001) 
(-)-N-methylisococlaurine 45 C.rugulosa (bark)  (Saidi 
2011) 
(-)-phyllostemine 6 C.phyllostemon 
(whole plant) 
 (Cave 
1989) 
(-)-phyllosteminine 7 C.phyllostemon 
(whole plant) 
 (Cave 
1989) 
(-)-phyllostone 8 C.phyllostemon 
(whole plant) 
 (Cave 
1989) 
(+)-6-methoxy-1-(3׳-
methoxybenzyl)-N-methyl-7-
isoquinolinol 
42 C.rugulosa (bark)  (Saidi 
2011) 
(+)-8,9-dihydrostepharine 28 C.chinensis (wood)  (Wu 
2001) 
(+)-codamine 41 C.rugulosa (bark)  (Saidi 
2011) 
(+)-cryprochine 30 C.chinensis (bark)  (Lee 
1993) 
(+)-eschscholtzidine-N-oxide 21 C.chinensis (wood)  (Wu 
2001) 
(+)-isocaryachine-N-oxide 18 C.chinensis (stem 
bark) 
 (Lin 
2002) 
(+)-lirioferine 38 C.ferrea (bark)  (Saidi 
2009) 
(+)-N-methylisococlaurine 1 C.nigra (stem bark) antioxidant, 
antiplasmoidal 
(Nasrulla
h 2013) 
(+)-norcinnamolaurine 40 C.rugulosa (bark)  (Saidi 
2011) 
(+)-norlirioferine 37 C.ferrea (bark)  (Saidi 
2009) 
(+)-phyllocryptine 13 C.phyllostemon 
(whole plant) 
 (Cave 
1989) 
(+)-phyllocryptonine 14 C.phyllostemon 
(whole plant) 
 (Cave 
1989) 
(+)-reticuline 44 C.rugulosa (bark)  (Saidi 
2011) 
(+)-reticuline N-oxide 43 C.rugulosa (bark)  (Saidi 
2011) 
(±)-romneine 29 C.chinensis 
(leaves) 
 (Lee 
1993) 
2-hydroxyathersperminine 3 C.nigra (stem 
bark), 
C.crassinervia 
(bark) 
 
antiplasmoidal (Nasrulla
h 2013, 
Awang 
2008) 
6,7-methylenedioxy-N-
methylisoquinoline 
20 C.chinensis (stem 
bark) 
 (Lin 
2002) 
atherosperminine 2 C.nigra (stem bark) antioxidant, 
antiplasmoidal 
(Nasrulla
h 2013) 
dehydroantofine 9 C.phyllostemon cytotoxic, anti- (Cave 
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(whole plant), 
C.chinensis (wood) 
HIV 1989, 
Wu 
2012) 
ficuseptine C 34 C.oubatchensis 
(leaves) 
 (Toribio 
2006) 
isoamuronine 27 C.chinensis (wood)  (Wu 
2001) 
isocryprochine 25 C.chinensis (wood)  (Wu 
2001) 
lysicamine 31 C.strictifolia (stem 
bark) 
 (Juliawat
y 2000a) 
N-demethyl-2-
methoxyatherosperminine 
15 C.crassinervia 
(bark) 
 (Awang 
2008) 
neocaryachine 16 C.chinensis (bark)  (Lee 
1990) 
noratherosperminine 4 C.nigra (stem bark)  (Nasrulla
h 2013) 
papraline 39 C.rugulosa (bark)  (Saidi 
2011) 
prooxocryptochine 26 C.chinensis (wood)  (Wu 
2001) 
oubatchensine 46 C.oubatchensis 
(leaves) 
 (Toribio 
2006) 
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Table 7.8 Lignans isolated from Cryptocarya species 
 
 
 
O
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      1 
 
 
 
 
 
 
 
 
 
 
 
 
 
Compound No Species and plant 
part 
Ref 
(-)-grandisin 1 C.crassinervia 
(bark) 
(Saad) 
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7.1.4 Cryptocarya mackinoniana 
Cryptocarya mackinnoniana F.Muell (Lauraceae) is a medium sized evergreen tree, 
distributed in Cape York Peninsula and North East Queensland (The area north of 
Townsville and south of Princess Charlotte Bay), at altitudinal range from sea level to 
1100 m. The common names of this species are Laurel, Rusty; Laurel, Rusty Leaved; 
Mackinnon's Laurel; Mackinnon's Walnut; Rusty Laurel; Rusty Leaved Laurel; Rusty-
leaved Walnut (http://keys.trin.org.au/key-server/data/0e0f0504-0103-430d-8004-
060d07080d04/media/Html/taxon/Cryptocarya_mackinnoniana.htm 2010). It has little 
commercial value and the species has not been previously investigated chemically or 
biologically. 
 
www.flickriver.com 
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7.2 Materials and methods 
7.2.1 Materials  
7.2.1.1 Plant material  
Freeze dried powder of young leaves of Cryptocarya mackinoniana were supplied from 
EcoBiotics company pty.ltd Queensland, Australia. 
 
7.2.1.2 Chemicals and reagents                 
DMSO, 95% ethanol, bovine serum albumin, lipopolysaccharide (LPS) (E.coli serotype 
0127:B8), EDTA, N-(1-1-napthyl) ethylenediamine dihydrochloride, penicillin G sodium 
benzyl, resazurin sodium 10%, streptomycin, sulfanilamide, tetra methyl benzidine (TMB) 
and trypan blue 0.4% were purchased from Sigma-Aldrich (Castle Hill, NSW, Australia). 
Dulbecco’s modified Eagle’s medium (DMEM), foetal bovine serum (FBS) and glutamine 
were GIBCO brands purchased from Life Technologies (Mulgrave, VIC, Australia). IF-γ 
(murine) and TNF-α – ELISA kits were purchased from PeproTech Asia (Rehovot, Israel).  
 
7.2.2 Methods  
7.2.2.1 Sequential extraction of C. mackinoniana young leaves  
120 g of young leaves of C. mackinoniana freeze dried powder was sequentially 
extracted using the following solvents of increasing polarity: dichloromethane (DCM), 
50% dichloromethane (DCM) / 50% methanol (MeOH) and methanol (MeOH). 
Extractions were performed at 40 0C, 30 min in triplicates for each solvent using a 
sonicator. The extracts were then subsequently evaporated using a Rotary evaporator at 40 
0C, until all the solvents were removed. The resulting extracts were further dried by 
purging nitrogen gas and the yield of the extracts were determined (Table 7.9). The DCM 
(3.97 g) fraction exhibited the highest anti-inflammatory activity, which was then later 
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subjected to analytical HPLC and afforded one new compound (12) and a known, 
cryptocaryone (7C)  
Compound 12: colourless sticky solid, UV (MeOH) max (log ) 209 (4.36) nm; NMR 
data, see Table 7.12; HRMS [M +H]+ m/z 351.1553 (molecular formulae C19H26O6). 
 Compound 7C: yellow coloured solid; UV (MeOH) max (log ) 207 (4.77), 282 (4.82), 
286 (4.91), 387 (5.04) nm; 1H and 13C NMR data, see Table 7.13; MS [M +H]+ m/z 283 
(molecular formulae C17H14O4). 
 
7.2.2.2 Experimental procedure for UV, LC-MS, HPLC and NMR analyzing  
UV spectrum was recorded on an Agilent 8453 spectrophotometer. NMR spectra were 
recorded on a Bruker Ascend 400 MHz spectrometer (Bruker Biospin GmbH, Germany), 
in the solvents indicated and referenced to residual 1H signals in deuterated solvents. (ESI-
MS) were acquired using a Waters Xevo TQ-MS triple quadrupole mass spectrometer in 
both positive and negative ion modes under the following conditions (Waters Acquity 
UPLC BEH C18 column, 150  2.1 mm, eluting with 0.2 mL/min 95% H2O/MeCN to 5% 
H2O/MeCN (with isocratic 0.01% FA) over 20 mins, then held for 5 min. HRMS was 
carried out using a Waters Xevo Q-TOF mass spectrometer operating in the positive ESI 
mode. HPLC was carried out using a 2D- Agilent 1290 series. 
 
7.2.2.3 Analysis of C. mackinoniana extracts by HPLC 
The HPLC analysis of the DCM fraction was performed using a Kinetex 5 µM phenyl-
Hexyl column (250×4.6 mm), flow rate of 1 mL/min. A gradient system was applied from 
10% MeOH/water to 100% MeOH over 40 mins.  Peak detection was accomplished with 
photodiode array detector (PDA) using three detection wave lengths (210 nm, 250 nm and 
300 nm). Twelve peaks were identified and the retention times of the first and last peaks 
were 21 min and 33 min respectively (Fig.7.3A and 7.3B).  
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A second fractionation of each major fraction was performed using a Poroshell 120, 
2.7μM, SB-C18 Column (4.6×100mm), flow rate of 0.8 mL/min. A gradient system was 
applied from 10% acetonitrile/water to 100% acetonitrile over 40 mins.  Peak detection 
was accomplished with photodiode array detector (PDA) using three detection wave 
lengths (210 nm, 250 nm and 300 nm). 
 
7.2.3 Maintenance of RAW 264.7 macrophages 
RAW 264.7 macrophages were grown in 175 cm2 flasks on DMEM containing 5 % foetal 
bovine serum (FBS) that was supplemented with Penicillin (200u/ml), Streptomycin 
(200μg/ml) and L- Glutamine (2mM). The cell line was maintained in 5% CO2 at 37°C, 
with media being replaced every 3-4 days. Once cells had grown to confluence in the 
culture flask, they were removed using a rubber policeman, as opposed to using trypsin, 
which can remove membrane-bound receptors (Shanmugam et al. 2008). The cell 
suspension was concentrated by centrifugation for 3 min at 900 rpm and resuspended in a 
small volume of fresh DMEM (with 1% antibiotics and 5% FBS), cell density was 
estimated using a Neubauer counting chamber. The cell concentration was adjusted with 
DMEM (with 1% antibiotics and 5% FBS) to obtain 60000 cells / 100μl cell suspension. 
100ul of this cell suspension was dispensed into the wells of 96-well plates. Plates 
were incubated at 37oC; 5% CO2 for 18 h before the activation experiments were carried 
out.  
 
7.2.4 Activation of RAW 264.7 macrophages 
From each well, the medium was removed and replaced with fresh DMED containing 0.1 
% FBS. For assays with extracts, 50 μL volumes of the dilutions in DMEM were added 
an hour prior to addition of activator. A combination of 10 μg ml-1 LPS and 10 U ml-1 (1 
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unit = 0.1ng/mL) IFN-γ, both in DMEM, was used for activation. Maximum concentrations 
of 1.25 mg/mL (direct extracts) and 0.5 mg/mL (sequential extracts) were used and a 
minimum of 6 doses (made by serial dilution) were employed.  After activation, the cells 
were incubated for 24 h at 37oC and then NO, TNF-α and cell viability was determined. 
Unactivated cells (exposed to media alone) were used as negative control and activated 
cells as positive control.  
 
7.2.5 Determination of nitric oxide by the Griess assay 
Nitric oxide was determined by Griess reagent quantification of nitrite. Griess reagent was 
freshly made up of equal volumes of 1% sulfanilamide and 0.1% napthyethylene-diamine 
in 5% HCl. From each well, 50 µl of supernatant was transferred to a fresh 96-well plate 
and mixed with 50 µl of Griess reagent and measured at 540 nm in a POLARstar Omega 
microplate reader (BMG Labtech, Mornington, Australia). The concentration of nitrite was 
calculated using a standard curve with sodium nitrate (0-250 uM), and linear regression 
analysis. 
 
7.2.6 Determination of TNF-α by ELISA 
The diluted supernatants were used for determination of TNF-α using a commercial 
sandwich ELISA (Peprotech) according to the manufacturer’s protocol. In brief,  the 
capture antibody was used at a concentration of 1.5 μg ml-1 in PBS (1.9 mM NaH2PO4, 8.1 
mM Na2HPO4,154 mM NaCl) (pH 7.4). Serial dilutions of TNF-α standard from 0 to 
10000 pg mL-1 in diluent (0.05% Tween-20, 0.1% BSA in PBS) were used as internal 
standard. TNF-α was detected with a biotinylated second antibody and an Avidin 
peroxidase conjugate with TMB as detection reagent. The colour development was 
monitored at 655 nm, taking readings every 5 min. After about 30 min the reaction was 
stopped using 0.5 M sulphuric acid and the absorbance was measured at 450 nm using a 
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POLARstar Omega microplate reader (BMG Labtech, Mornington, Australia) and 
expressed as a percentage of that in control cells after conversion of the concentrations by 
using a standard curve constructed with defined concentrations of TNF-α. Curve fitting of 
this standard curve and extrapolation of experimental data were performed using non-
linear regression analysis. 
 
7.2.7 Determination of cell viability by the Alamar Blue assay 
100 µl of Alamar Blue solution (10% Alamar Blue (Resazurin) in DMEM media) was 
added to each well, incubated at 370C for 2 h. After incubation, fluorescence intensity was 
measured with the microplate reader (excitation at 530 nm and emission at 590 nm) and 
results were expressed as a percentage of the intensity of that in control cells, after 
background fluorescence was subtracted. 
 
7.2.8 Statistical analysis 
Data calculations were performed using MS-Excel 2010 software. IC50 values were 
obtained by using the sigmoidal dose–response function in GraphPad Prism. The results 
were expressed as mean ± standard deviation (SD). 
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7.3 Results  
7.3.1 Yields of the extracts 
120 g of freeze dried powder of C. mackinoniana young leaves was sequentially extracted 
using the following solvents of increasing polarity: dichloromethane (DCM), 50% 
dichloromethane (DCM) / 50% methanol (MeOH) and methanol (MeOH) in order to 
separate the lipophilic from the hydrophilic compounds. The 50% DCM/ MeOH extract 
provided a higher yield compared to the DCM and MeOH extracts (Table 7.9). 
 
Table 7.9: Yield of the extracts after extraction and freeze-drying derived from 120 g 
of freeze dried powder of C. mackinoniana young leaves 
Extract Yield of the extract (g) 
DCM 3.97 
50% DCM / 50% MeOH 10.00 
MeOH 2.35 
Total 16.32 
 
 
7.3.2 Determination of the anti-inflammatory activity of the extracts 
Nitric oxide (NO) and tumour necrosis factor are key mediators of the inflammatory 
response. After exposure to bacterial lipopolysaccharide (LPS) and Interferon gamma 
(IFN-γ), macrophages respond with release of NO and TNF-α (Gunawardena 2013) which 
can trigger a number of pathophysiological consequences including tissue damage. Hence, 
measuring inhibition of NO and TNF-α production in LPS or LPS and IFN-γ stimulated 
cells represents a widely used experimental model for examining the anti-inflammatory 
effects of chemical compounds. 
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DCM, 50% DCM/ MeOH and MeOH extracts of C. mackinoniana were tested in LPS + 
IFN-γ activated 264.7 macrophages using NO and TNF-α production as readouts to 
determine their anti-inflammatory activity. Due to insolubility of the low polarity extracts 
in the cell culture media, they were diluted in DMSO, leading to final concentrations of up 
to 0.5% DMSO in cell culture medium. This concentration of organic solvents did not 
affect cell viability by more than 10% (data not shown). All these extracts showed 
significant anti-inflammatory activity against the NO and TNF-α inhibition with IC50 less 
than 155 μg/mL and 42 μg/mL respectively, without any considerable cytotoxicity (Fig. 
7.2, Table 7.10). The DCM extract was the most potent, as it inhibited both NO and TNF-α 
production with IC50 values of 6.67 ± 0.32 μg/mL and 22.4 ± 6.0 μg/mL respectively (Fig. 
7.2A, Table 7.10) which was then subjected to analytical HPLC.  
 
 Table 7.10: Anti-inflammatory activity of Extracts 
Extract Inhibition of NO 
(IC50 in μg/mL ± 
SD) 
Inhibition of 
TNF-α 
(IC50 in μg/mL ± 
SD) 
Cytotoxicity 
(LC50 in μg/mL ± 
SD) 
DCM 6.67 ± 0.32 22.4 ± 6.0 98.5 ± 13.0 
50% DCM / 50% MeOH 155 ± 17 41.9 ± 12.0 >1000 
MeOH 42.8 ± 2.56 33.6 ± 7.0 >250 
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Fig.7.2: Inhibition of LPS and IFN-γ induced production of pro-inflammatory markers with cell 
viability by DCM, 50% DCM / 50% MeOH and MeOH extracts of C. mackinoniana extracts  
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7.3.3 HPLC analysis of DCM extract 
DCM extract exhibited the highest anti-inflammatory activity, which was then subjected to 
analytical HPLC affording 12 fractions (Fig 7.3 A and B).  
 
 [A] 
 
Fig.7.3[A] HPLC chromatogram for DCM extract at 300nm 
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[B] 
 
Fig.7.3 [B] HPLC chromatogram for DCM extract at 210nm 
 
7.3.4 Determination of the anti-inflammatory activity of the fractions 
Anti-inflammatory activity of fraction 1-12 was tested in LPS + IFN-γ activated 264.7 
macrophages using NO and TNF-α production as readouts. Due to insolubility of the 
extracts in the cell culture media, they were diluted in DMSO, leading to final 
concentrations of up to 0.5% DMSO in cell culture medium. This concentration of organic 
solvents did not affect cell viability by more than 10% (data not shown). All these extracts 
showed significant anti-inflammatory activity against the NO inhibition with IC50 less than 
6.5 μg/mL (Table 7.11). Except fraction 3, all the other fractions showed considerable 
TNF-α inhibition with IC50 less than 16.5 μg/mL (Table 7.11).  Fraction 4-8 were the most 
potent extracts, as they inhibited both NO and TNF-α production with IC50 less than 0.65 
μg/mL and 2.55 μg/mL respectively (Table 7.11).  
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Table 7.11:  anti-inflammatory activity of the major fractions 
Fraction Inhibition of 
NO production 
(IC50 in μg/mL 
± SD) 
Inhibition of 
TNFα 
production 
(IC50 in μg/mL 
± SD) 
Cytotoxicity  
(LC50 in μg/mL 
± SD) 
Yield derived 
from 300mg of 
DCM extract 
(mg) 
1 3.85 ±3.7  0.41 ± 0.10 >46    1.6.6 
2 1.98 ± 0.35 13.8 ± 3.7 >46 2.9 
3 6.47 ± 0.90 > 46  > 46 1.9 
4  0.61 ± 0.04 2.54 ± 0.42 8.46 ± 2.68 3.6 
5 0.29 ± 0.02 0.82 ± 0.18 5.05 ± 1.27 2.0 
6 0.52 ± 0.04 2.28 ± 0.55 10.3± 2.9 11.7 
7 0.45 ± 0.03 0.50 ± 0.09 5.63 ± 1.45 13.8 
8 0.22 ± 0.01 0.10 ± 0.02 1.29 ± 0.28 8.4 
9 1.63 ± 0.14 2.17 ± 0.43  8.60 ± 0.99 6.3 
10 1.56 ± 0.08 1.97 ± 0.25  5.82 ± 0.44 6.6 
11 4.90 ± 0.27 6.64 ± 1.07  23.1 ± 1.10 6.6 
12  6.36 ± 0.85  16.2 ± 4.2 > 46 8.0 
 
 
7.3.5 Structure Elucidation of the compounds 
Fraction 12 was identified as a new compound 12 and compound 7C was identified as a 
known compound cryptocaryone from the fraction 7 after  second fractionation using a 
Poroshell 120, 2.7μM, SB-C18 Column (4.6×100mm) ( flow rate of 0.8 mL/min, 10% 
acetonitrile/water to 100% acetonitrile over 40min) (Fig.7.3). Isolation and identification 
of the remaining compounds in other fractions is a work in progress. 
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7.3.6 Structure Elucidation of the compound 12 
 
O OH O
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12 
 
The compound 12 was obtained as colourless sticky solid, UV (MeOH) max (log ) 209 
(4.36). HR-ESI(+)MS analysis of C-12 revealed a pseudo molecular ion ([M + H]+) 
indicative of a molecular formula (C19H27O6) requiring seven double bond equivalents.  
The 13C NMR (DMSO-d6) data (Table. 8.12) revealed that seven degrees of unsaturation 
were accounted for 2 carbonyls (C 170.8) , one ketone carbonyl (C 210.5) and 6 sp2 
resonances from C 126.0 to 141.8) indicating that the compound is monocyclic. 
 The 1H NMR spectrum showed a complex five –proton multiplet at 7.17-7.29, indicating a 
mono-substituted benzene ring, which was confirmed by the presence of 13C NMR 
resonances at δC 141.8, 128.4, 128.5 and 126.0.  
13C NMR (DMSO-d6) data (Table. 7.12) revealed that the compound 12 has two oxy 
carbons at C-11 (δ63.7) and C-13 (δ71.1) and seven-methylene carbons at C-7 (δc 30.1), 
C-8 (δc 45.2), C-10 (δc 51.9), C-12 (δc 41.25), C-14 (δc ), C-15 (δc 21.2) and C-16 (δc 
34.4) and one tertiary methyl at C-19 (δc 22.5).  
COSY Correlations showed the presence of one spin system from methylene H2 – 10 (H 
2.47) to methylene H2 – 16 (H 2.20) (Fig.7.4). A second spin system was observed 
between the methylenes H2-7 and H2-8. The two spin systems were linked by HMBC 
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correlations of H2-10 (H 2.47) to C-9 (C  210.5), C-11 (C  63.7) and the methylene at H2-
8 (H 2.77) to C-7 (C  30.1) and C-9 (C  210.5) (Fig. 7.4). 
 
HMBC correlations showed the methylene at H-16 (H 2.20) to C-14 (C  34.4), C-15 (C  
21.2) and C-17 (C  175.2), ) Furthermore, HMBC correlation of the methyl, H3 – 19 (H 
1.99) to C-18 (C  170.8) and C-13 (C  71.1), confirmed the point of attachment of the 
acetate group to the oxy carbon at C-13 (C  71.1) (Fig. 7.4). Having taken into 
consideration the DBE, the carbonyl at C-17 was identified as a carboxylic acid.  
Finally the HMBC correlation of the methylene H2 – 7 (H 2.77) to the aromatic carbons C-
6, C-1 and C-5 confirmed the point of attachment to the side chain at the C-6 position of 
the benzene ring, leading to the planar structure of 12 (See appendix for NMR spectra of 
12).  
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Fig.7.4 Key 2D NMR correlations for compound 12 
 
The relative stereochemistry of the substituents at the two chiral centres in the bridging 
chain (C-11 and C-13) can be determined by the modified Mosher’s method using the (S) 
and (R)-MTPA [α-methoxy-α-(trifluoromethyl)phenylacetyl] esters of 12 (work in 
progress).  
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The secondary alcohol at C-13 blocked off by an acetate group will allow us to first 
generate a Mosher ester for the carbon at C-11, leading to the absolute stereochemistry of 
C-11 (Fig 7.5). Then we can deacetylate compound 12 (Reaction of 12 with potassium 
carbonate and methanol will afford the deacetlyated 12) (Fig 7.6). The deacetylated 
compound can then be reacted with 2, 2 dimethoxy propane in MeOH in the presence of 
PPTS to generate the acetonide, giving the relative stereochemistry at C-13 (Fig 7.7).   We 
also plan on generating a bis-Mosher ester of the deacetylated compound, leading to the 
absolute stereochemistry of C-13. The derivatives made along the way will also be tested 
for anti-inflammatory activity (work in progress).  
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Fig.7.5 Mosher ester reaction at C-11 position 
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Fig.7.6 Deacetylation at C-13 position 
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Fig.7.7 acetonide of C-12 
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    Table 7.12: NMR (400 MHz, DMSO-d6) data for compounds 12  
pos δC* δH, mult (J in Hz)  COSY 
correlations 
HMBC 
correlations 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
128.5 
128.4 
126.0 
128.4 
128.5 
141.8 
30.1 
45.2 
210.5 
51.9 
63.7 
41.2 
71.1 
34.4 
21.2 
34.4 
175.2 
170.8 
22.5 
            
 
            7.17-7.29, m 
 
 
 
2.74-2.78, ma  
2.77, ma  
 
2.47, dd, (13.2, 4.7) 
3.88, m 
1.55, dd ( 9.1, 3.2 ) 
5.05, m 
1.50, m 
1.41- 1.50, m 
2.20, t (7.1) 
 
 
1.99, s 
         
 
        1-5a 
 
 
 
 
 
 
11 
10, 12 
11, 13 
12, 14 
13, 15 
14, 16 
15 
2, 6, 7 
1, 3 
2, 4 
3, 5 
4, 6, 7 
 
6, 8 
7,9 
 
9, 11 
 
10, 11 
 
15 
14 
14, 15, 17 
 
 
13, 18 
                                               
*13C shifts obtained from 2D HSQC and HMBC experiments. 
     aoverlapping signals. 
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7.3.7 Cryptocaryone 
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      Cryptocaryone  
The known compound, cryptocaryone (7C) was initially isolated in 1972 
from Cryptocarya (C. bourdilloni) (Govindachari 1972), and its structure was first 
formulated as 7C from spectral data and chemical degradation and 
correlation(Govindachari 1973). Later on, its structure was revised as the keto-enol 
tautomeric form 7C (relative confguration) after X-ray crystallographic 
analysis(Maddry 1985). In order to assign the absolute confguration of 
cryptocaryone 7C, 8-bromocryptocaryone derivative was obtained after treatment 
of cryptocaryone by bromine. X-ray analysis of this compound gave the absolute 
configuration 5R,6S of cryptocaryone 7C (Dumontet 2001). ID and 2D NMR data 
of compound 7C was shown in table 7.13 and spectra were shown in appendix. 
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Table 7.13: NMR (400 MHz, DMSO-d6) data for compounds 7C 
pos NMR data for 7C NMR data for reported 
compound(Dumontet 2001) 
δC* δH, mult (J in Hz)  δC  δH, mult (J in Hz) 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
 
12 
1׳ 
2׳ 
3׳ 
4׳ 
5׳ 
6׳ 
OH-4 
141.5 
118.9 
175.0 
33.7 
76.5 
143.2 
129.5 
187.5 
106.0 
35.1 
 
177.5 
132.3 
129.8 
131.2 
131.1 
131.2 
129.8 
 
7.65, d (14)        
7.25, d (14) 
             
4.25, ddd (11,8,8) 
5.62 dd (8,2) 
6.70, dd (9,2) 
6.18, dd (9,2) 
 
 
2.83, dd (16,11) 
2.64, dd (16,8) 
 
 
7.85, m 
 
          7.42-7.48, m 
 
7.85, m 
142.2 
116.9 
174.1 
33.7 
76.2 
140.2 
130.0 
185.8 
103.5 
35.2 
 
174.6 
124.8 
128.3 
129.0 
130.5 
129.0 
128.3 
7.75, d (14)        
6.80, d (14) 
             
3.99, ddd (11,8,8) 
5.46 dd (8,2) 
6.54, dd (9,2) 
6.18, dd (9,2) 
 
 
2.59, dd (16,11) 
2.78, dd (16,8) 
 
 
7.56, m 
7.40, m 
7.40, m 
7.40, m 
7.56, m 
17.00 s 
                                               
  *13C shifts obtained from 2D HSQC and HMBC experiments. 
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7.3.8 Determination of the anti-inflammatory activity of the compound 12 and 
cryptocaryone (7C) 
Anti-inflammatory activity of compound 12 and cryptocaryone were tested in LPS + 
IFN-γ activated 264.7 macrophages using NO and TNF-α production as readouts. 
Compound 12 showed significant anti-inflammatory activity against the NO inhibition 
with IC50 6.36 ± 0.85 μg/mL without any cytotoxicity (Table 7.14) whereas, cryptocaryone 
showed singnificant anti-inflammatory activity for both NO and TNF-α inhibition with 
IC50 1.26 ± 0.18 and 3.58 ± 0.64 respectively (Table 7.14 and Fig.7.8).  
 
Table 7.14 Anti-inflammatory activity of compounds 12 and cryptocaryone 
Compound Inhibition of NO 
production (IC50 in 
μg/mL ± SD) 
Inhibition of TNFα 
production (IC50 in 
μg/mL ± SD) 
Cytotoxicity  
(LC50 in μg/mL ± 
SD) 
12 6.36 ± 0.85  16.2 ± 4.2 >46 
Cryptocaryone 1.26 ± 0.18  3.58 ± 0.64 4.35 ± 0.59 
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Fig.7.8: Inhibition of LPS and IFN-γ induced production of pro-inflammatory markers with 
cell viability by compounds 12 and cryptocaryone (7C) isolated from C. mackinoniana 
extracts  
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7.4 Discussion 
Previous phytochemical investigations on the genus Cryptocarya established the presence 
of numerous different classes of natural products, e.g., flavonoids (Chou 2010, Dumontet 
2001, Kurniadewi and Kinoshita 2010, Feng 2012, Govindachari 1972), pyrones (Davis 
2010, Grkovic 2011, Meragelman 2009), pavines (Lee 1990, Lin 2002, Wu 2001) and 
aporphines (Awang 2008, Lee 1993, Wu 2001), stilbenes (Juliawaty 2000b), lignans 
(Saad) with diverse bioactivities (Table 8.2-8.8). The pioneering work by the group of 
Feng et al has demonstrated anti-inflammatory flavonoids from Cryptocarya chingii (Feng 
2012). However, there are no previous reports about the chemical constituents or anti-
inflammatory activity of the Cryptocarya mackinnoniana and our study was aimed at 
identifying the major anti-inflammatory compounds in this Cryptocarya species. 
The highest level of anti-inflammatory bioactivity was observed in the dichloromethane 
(DCM) extract which were more potent (IC50 for NO and TNF-α were 6.67 ± 0.32 µg/mL 
and 22.4 ± 6.0 µg/mL respectively) than the 50% dichloromethane (DCM) / 50% methanol 
(MeOH) and methanol (MeOH) extracts (Table 7.11), suggesting that the majority of anti-
inflammatory activity is exerted by lipophilic compounds in the DCM. When cytotoxicity 
was investigated, the DCM extract caused some degree of cell death, with an LC50 value of 
98.5 ± 13.0 μg/mL. (Table 7.11). However, none of the other two extracts identified appear 
to be the responsible for cytotoxicity, indicating that minor constituents of the Cryptocarya 
mackinnoniana may be responsible for the cytotoxicity. These data suggested that the 
young leaves extracts of Cryptocarya mackinnoniana are potential sourse of new anti-
inflammatory agents. 
Cryptocarya mackinnoniana young leaf extracts are complex mixtures and therefore 
extensive chromatographic analysis (HPLC, LC-MS and NMR) of the DCM extract 
afforded a new compound (12) and known cryptocaryone (7C). The structures of these 
compounds were determined based on spectral analysis and by comparison with those 
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reported data. The anti-inflammatory activities of both compounds were evaluated against 
RAW264.7 macrophages and both compounds 12 and cryptocaryone showed significant 
anti-inflammatory activity against NO inhibition with IC50 6.36 ± 0.85 µg/mL and 1.26 ± 
0.18 µg/mL respectively. In addition cryptocaryone showed significant TNF-α inhibition 
activity with IC50 3.58 ± 0.64 µg/mL.  
Anti-inflammatory activity of cryptocaryone was previousely reported against the human 
cervical cancer HeLa cells measuring TNF-α-induced NF-κB activity (Feng 2012)  but  to 
our understanding, this is the first time  its anti-inflammatory activity has been reported 
against RAW264.7 cells using NO and TNF-α inhibition activity.  
Cytotoxic activity of cryptocaryone was previously reported against the erythroleukemic 
K562 and doxorubicin-resistant K562 cells using MTT colorimetric assay (after 3days 
incubation with compound) with LC50 2µM (Dumontet 2001) and also Fera et al  reported 
the cytotoxic activity of cryptocaryone against the murine leukemia P-388 cells with LC50 
2.1 µg/mL by MTT assay after one day incubation with compound. These data are 
comparable with our study that cryptocaryone showed significant cytotoxicity with LC50 
4.35 ± 0.59 µg/mL (12 µM) against the RAW264.7 macrophages after one day incubation 
and these data suggested that cryptocaryone can be considered as a potential antitumor 
agent as well. 
Separation, isolation, identification and bioactivity studies of other compounds present in 
DCM, 50% DCM / 50% MeOH and MeOH and the relative stereochemistry of the 
substituents at the two chiral centres in compound 12 are work in progress. 
 
 
 
 
160 
 
7.5 References 
Allard, P. M., Dau, E. T., Eydoux, C., Guillemot, J. C., Dumontet, V., Poullain, C., 
Canard, B., Guéritte, F., Litaudon, M. (2011) Alkylated flavanones from the bark of 
Cryptocarya chartacea as dengue virus NS5 polymerase inhibitors. J Nat Prod. , 74, 
2446-53. 
Awang, K., Hadi, A., Hamid, A., Saidi, N., Mukhtar, M.R., Morita, H., Litaudon, M. 
(2008) New phenantrene alkaloids from Cryptocarya crassinervia. Fitoterapia 79, 
308–310. 
Balandrin, M. F., Klocke, J. A., Wurtele, E. S., Bollinger, W.H. (1985) Natural plant 
chemicals: sources of industrial and medicinal materials. Science., 228, 1154-60. 
Bodeker, G. 2000. Journal of Tropical Medicinal Plants. Total Health Concept. 
Cave, A., Leboeuf, M., Moskowitz, H., Ranaivo, A., Bick, R. C., Sinchai, W., Nieto, M., 
Sevenet, T., Cabalion, P. (1989) Alkaloids of Cryptocarya phyllostemon. Aust. J. 
Chem, 42, 2243-63. 
Chou, T. H., Chen, J.J., Lee, S.J., Chiang, M.Y., Yang, C.W., Chen, I.S. (2010) Cytotoxic 
flavonoids from the leaves of Cryptocarya chinensis. J. Nat. Prod. , 73, 1470–1475. 
Choua, T. H., Chenb, J.J., Pengc, C.F., Chengd, M.J., Chen, I.S. (2011) New Flavanones 
from the Leaves of Cryptocarya chinensis and Their Antituberculosis Activity. 
Chemistry & biodiversity, 8. 
Cragg, G. M. & D. J. Newman (2013) Natural products: a continuing source of novel drug 
leads. Biochim Biophys Acta, 1830, 3670-95. 
Davis, R. A., Demirkiran, O., Sykes, M.L., Avery, V.M., Suraweera, L., Fechner, 
G.A.,Quinn, R.J. (2010) 7',8'-Dihydroobolactone, a typanocidal a-pyrone from the 
rainforest tree Cryptocarya obovata. Bioorg. Med. Chem. Lett. , 20, 4057–4059. 
Dumontet, V., Gaspard, C., Hung, N.V., Fahy, J., Tchertanov, L., Sévenet, T., Guéritte,F., 
Aktan. (2001) New cytotoxic flavonoids from Cryptocarya infectoria. Tetrahedron 
161 
 
57, 6189–6196. 
Dumontet, V., Hung, N.V., Adeline, M.T., Riche, C., Chiaroni, A., Se´venet, T., Gue´ritte, 
F. (2004) Cytotoxic Flavonoids and r-Pyrones from Cryptocarya obovata. J. Nat. 
Prod. , 67, 858-862. 
Feng, R., Guo, Z.K., Yan, C.M., Li, E.G., Tan, R.X., Ge, H.M., (2012) Anti-inflammatory 
flavonoids from Cryptocarya chingii. Phytochemistry 76, 98–105. 
Feng, R., Wang, T., Wei, W., Tan, R.X., Ge, H.M. (2013) Cytotoxic constitutents from 
Cryptocarya maclurei. Phytochemistry 90, 147-153. 
Fu, X., Sevenet, T., Remy, F., Pais, M., Hamid, A., Hadi, A., Zeng, L.M. (1993) Flavanone 
and chalcone derivatives from cryptocarya kurzii. journal of Natural Products, 56, 
1153-1163. 
Geetha, K., Narayanan, K.R., Murugesan, A.G. (2010) Antimicrobial efficiency of 
Achyranthes aspera L. against selected pathogenic organisms. J. Biosci. Res 1, 187-
190. 
Gottlieb, O. R. (1972) Chemosystamatics of the lauraceae. Phytochemistry  11, 1537-1570. 
Govindachari, T. R., Parthasarathy, P.C. (1971) Cryptocaryalactone, a novel 5,6-dihydro-
2H-pyran-2-one from Cryptocarya bourdilioni gamb. Tetrahedron Lett., 37, 3401-
3402. 
--- (1972) Cryptocaryone, a novel 5',6'-dihydrochalcone, from Cryptocarya bourdilloni 
gamb. Tetrahedron Lett., 13, 3419–3420. 
Govindachari, T. R., Parthasarathy, P.C., Desai H.K., Shanbhag, M.N. (1973) Structure of 
cryptocaryone a constituent of cryptocarya bourdilloni gamb. tetrahedron., 29, 309 
I to 3094. 
Grabley, S., Thiericke, R. 1999. Drug Discovery from Nature. Springer. 
Grkovic, T., Blees, J.S., Colburn, N.H., Schmid, T., Thomas, C.L., Henrich, 
162 
 
C.J.,McMahon, J.B., Gustafson, K.R (2011) Cryptocaryols A–H, a-pyrone-
containing 1,3-polyols from Cryptocarya sp. implicated in stabilizing the tumor 
suppressor pdcd4. J. Nat. Prod. , 74, 1015–1020. 
Gunawardena, D., Shanmugam, K., Low, M., Bennett, L., Govindaraghavan, S., Head, 
R.,Ooi, L., Munch, G. (2013) Determination of anti-inflammatory activities of 
standardised preparations of plant- and mushroom-based foods. Eur J Nutr. 
Hawariah, A., Stanslas, J. (1998) In vitro response of human breast cancer cell lines to the 
growth-inhibitory effects of styrylpyrone derivative (SPD) and assessment of its 
antiestrogenicity. Anticancer Res.  , 18, 4383-6. 
Hexum, J. K., Aburto, R.T., Struntz, N.B., Harned, A.M., Harki, D.A. (2012) Bicyclic 
Cyclohexenones as Inhibitors of NF-κB Signaling. ACS Med. Chem. Lett., 3. 
http://en.wikipedia.org/wiki/Cryptocarya. 2014. Cryptocarya. In Cryptocarya. 
http://keys.trin.org.au/key-server/data/0e0f0504-0103-430d-8004-
060d07080d04/media/Html/taxon/Cryptocarya_mackinnoniana.htm.2010. 
Australian tropical rainforest plants. In Cryptocarya mackinoniana. Australia. 
http://www.australia.gov.au/about-australia/our-country/our-natural-environment. 
Huang, H. W., Chung, Y.A., Chang, H.S., Tang,J.T., Chen, I.S., Chang, H.W. (2014a) 
Antiproliferative Effects of Methanolic Extracts of Cryptocarya concinna Hance 
Roots on Oral Cancer Ca9-22 and CAL 27 Cell Lines Involving Apoptosis, ROS 
Induction, and Mitochondrial Depolarization. Hindawi Publishing Corporation, 1-
10. 
Huang, W., Zhang, W.J, Cheng, Y.Q, Jiang, R., Wei, W., Chen, C.J, Wang, G., Jiao, R.H., 
Tan, R.X., Ge, H.M. (2014b) Cytotoxic and antimicrobial flavonoids from 
Cryptocarya concinna. Planta Med. , 80, 925-30. 
Jayaweera, D. M. A. 1981-1982. Medicinal plants (indigenous and exotic) used in Ceylon 
Colombo, Sri Lanka: National Science Council of Sri Lanka. 
163 
 
Juliawaty, L. D., Kitajima, M., Takayama, H., Achmad, S.A., Aimi, N. (2000a) A 6-
substituted-5,6-dihydro-2-pyrone from Cryptocarya strictifolia. Phytochemistry, 54, 
989-993. 
Juliawaty, L. D., Kitajima, M., Takayama, H.,Achmad, S. A., and Aimi, N. (2000b) A New 
Type of Stilbene – Related Secondary Metabolite Idenburgene from Cryptocarya 
idenburgensis. Chem. Pharm. Bull., 48, 1726-8. 
Kurniadewi, F., Juliawaty, L.D., Syah, Y.M., Achmad, S.A., Hakim, E.H., Koyama, K., & 
K. Kinoshita, Takahashi, K. (2010) Phenolic compounds from Cryptocarya 
konishii: their cytotoxic and tyrosine kinase inhibitory properties. J. Nat. Med., 64, 
121–125. 
Kurniadewi, F., Juliawaty, L.D.,Syah, Y.m., Achmad, S.A., Hakim, E.H., Koyama,K., 
Kinoshita, K., Takahashi, K. (2010) Phenolic compounds from Cryptocarya 
konishii: their cytotoxic and tyrosine kinase inhibitory properties. J Nat Med 64, 
121-125. 
Kurniadewi, F., Syah, Y.m., Juliawaty, L.D., Achmad, S.A., Hakim, E.H., Koyama,K. 
(2008) Chalcone derivatives from Cryptocarya konishii Hayata (Lauraceae). 
Proceeding of The International Seminar on Chemistry, 208-210. 
Lee, S. S., Chen, C.H. (1993) Additional alkaloids from Cryptocarya chinensis. J. 
Nat.Prod., 56, 227–232. 
Lee, S. S., Liu, Y.C., Cheng, C.H. (1990) Neocaryachine, a new pavine alkaloid from 
Cryptocarya chinensis, and NMR spectral properties of related alkaloids. J. 
Nat.Prod. , 53, 1267–1271. 
Lin, F. W., Wang, J.J., Wu, T.S. (2002) New pavine N-oxide alkaloids from the stem bark 
of Cryptocarya chinensis HEMSL. Chem. Pharm. Bull. , 50, 157–159. 
Lin, H. R., Chou, T.H., Huang, D.W., Chen, I.S. (2014) Cryptochinones from Cryptocarya 
chinensis act as farnesoid X receptor agonists. Bioorganic & Medicinal Chemistry 
164 
 
Letters, 24, 4181-4186. 
Maddry, J. A., Joshi, B.S., Newton M.G., Pelletier, S.W. (1985) Cryptocaryone: a revised 
structure. Tetrahedron Letters, 26, 5491-5492. 
Meragelman, T. L., Scudiero, D.A., Davis, R.E., Staudt, L.M., McCloud, T.G., Cardellina, 
J.H., Shoemaker, R.H. (2009) Inhibitors of the NF-jB activation pathway from 
Cryptocarya rugulosa. J. Nat. Prod. , 72, 336–339. 
Michael, J. D., Michael, G.B. D., Philip, G. E., Fyaz, M.D. I. (2007) Rational Design 
Strategies for the Development of Synthetic Quinoline and Acridine Based 
Antimalarials. Frontiers in Drug Design & Discovery, 3, 559-609. 
Nasrullah, A. A., Zahari, A., Mohamad, J., Awang, K. (2013) Antiplasmodial alkaloids 
from the bark of Cryptocarya nigra (Lauraceae). Molecules. , 18, 8009-17. 
Ren, Y., Yuan, C., Qian, Y., Chai, H.B., Chen, X., Goetz, M., Kinghorn, A.D. (2014) 
Constituents of an Extract of Cryptocarya rubra Housed in a Repository with 
Cytotoxic and Glucose Transport Inhibitory Effects. J. Nat. Prod. , 77, 550-556. 
Ricardo, M. A. G., Andreo, M.A., Cavalheiro, A.J., Gamboa, I.C., Bolzani, V.S., Silva, 
D.H.S. (2004) Bioactive pyrones and flavonoids from Cryptocarya ashersoniana 
seedlings. Arkivoc 6, 127-136. 
Saad, J. M., Soepadam, E. ( -)-Grandisin from cryptocarya crassinervia. Journal of Natural 
Products, 54, 1681-1683. 
Saidi, N., Hadi, A. H.A., Awang, K., Mukhtar, M.R. (2009) Aphorpine alkaloids from bark 
of cryptocarya ferrea. Indo. J. Chem., 9, 461 - 465. 
Saidi, N., Morita, H., Litaudon, M., Mukhtar, M.R., Awang, K., Hadi, A.H.A. (2011) 
Benzylisoquinoline alkaloids from bark of cryptocarya rugulosa. Indo. J. Chem., , 
11, 59-66. 
Schmeda, H. G., Astudillo, L., Bastida, J., Codina, C., Rojas, D.A., Ferreira, M.E., 
Inchaustti, A., Yaluff, G. (2001) Cryptofolione derivatives from Cryptocarya alba 
165 
 
fruits. J Pharm Pharmacol. , 53, 563-7. 
Sehlapelo, B. M., Drewes, S.E., Scott-Shaw, R. (1994) A 6-Substituted 5,6-dihydro-a-
pyrone from two species of cryptocarya. phytochemistry, 37, 847-849. 
Shanmugam, K., L. Holmquist, M. Steele, G. Stuchbury, K. Berbaum, O. Schulz, O. 
Benavente Garcia, J. Castillo, J. Burnell, V. Garcia Rivas, G. Dobson & G. Münch 
(2008) Plant-derived polyphenols attenuate lipopolysaccharide-induced nitric oxide 
and tumour necrosis factor production in murine microglia and macrophages. 
Molecular nutrition & food research, 52, 427-38. 
Siallagan, J., Hakim, E.H., Syah, Y.M., Juliawaty, L.D., Achmad, S.A., Makmur, L., 
Mujahidin, D. (2008) Secondary metabolites kurzichalcolactone A and B from 
Cryptocarya lucida Blume (Lauraceae). Proceeding of The International Seminar 
on Chemistry, 225-228. 
Siegfried, E. D., Bethuel, M.S., Marion, M.H, Robert, S.S., Peter,S. (1995a) 5,6-Dihydro-
α-pyrones and two bicyclic tetrahydro-α-pyrone derivatives from cryptocarya 
latifolia. Phytochemistry, 38, 1427-1430. 
Siegfried, E. D., Marion, M.H., Robert, S.S. (1995b) -Pyrones and their derivatives from 
two cryptocarya species. Phytochemistry, 40, 321-323. 
Spencer, G. F., England, R.E., Wolf, R.B. (1984) (-)- Cryptocaryalactone and (-)-
deacetylcrytocarya-lactone-Germination inhibitors from Cryptocarya moschata 
seeds Phytochemrrtry, 23, 2499-2500. 
Toribio, A., Bonfils, A.L., Delannay, E., Prost, E., Harakat, D., Henon, E., Richard, B., 
Litaudon, M., Nuzillard, J.M., Renault, J.H. (2006) Novel seco-Dibenzopyrrocoline 
Alkaloid from Cryptocarya oubatchensis. Organic letters, 8, 3825-3828. 
Usman, H., Hakim, E.H., Harlim, T., Jalaluddin, M.N., Syah, Y.M., Achmad, S.A., 
Takayama,H. (2006) Cytotoxic Chalcones and Flavanones from the Tree Bark of 
Cryptocarya costata. Z. Naturforsch., 61c, 184-188. 
166 
 
Wagner, H., Chari, V.M., Sonnenbichler, J. (1976) Carbon-13 NMR spectra of naturally 
occurring flavonoids. Tetrahedron Lett.  , 21, 1799–1802. 
Wells, K. 2013. Australian flora. Australian government. 
Wu, T. S., Lin, F.W. (2001) Alkaloids of the wood of Cryptocarya chinensis. J. Nat. Prod. 
, 64, 1404–1407. 
Wu, T. S., Sun, C.R., Lee, K.H. (2012) Cytotoxic and anti-HIV phenanthroindolizidine 
alkaloids from Cryptocarya chinensis. Nat Prod Commun. , 7, 725-7. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
167 
 
Appendix-1 
 
 F
ig
. A
-1
 1
H
N
M
R
 s
p
ec
tr
u
m
 o
f 
1
2
 (
4
0
0
 M
H
z,
 D
M
S
O
-d
6
) 
168 
 
 
 
 
 
 
 
 
 
Fig.A-2 COSY spectrum of 12 (400 MHz, DMSO-d
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Fig. A-3 HSQC spectrum of 12 (400 MHz, DMSO-d
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Fig.A-5 HMBC spectrum of 12 (400 MHz, DMSO-d
6
) 
172 
 
 
 
F
ig
.A
-6
 1
H
N
M
R
 s
p
ec
tr
u
m
 o
f 
7
C
 (
4
0
0
 M
H
z,
 D
M
S
O
-d
6
) 
173 
 
 
 
 
 
 
 
 
 
Fig.A-7 COSY spectrum of 7C (400 MHz, DMSO-d
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Fig.A-8 HSQC spectrum of 7C (400 MHz, DMSO-d
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8.1 Summary and Future perspectives 
The imbalance between the production of ROS and a biological system’s ability to 
readily detoxify the reactive intermediates or easily repair the resulting damage 
results in oxidative stress. The brain is especially sensitive to oxidative damage due 
to its high content of unsaturated and oxidation-susceptible fatty acids, high use of 
oxygen, and low levels of antioxidants ROS production could activate NF-κB, the 
nuclear transcription factor, by triggering a change in the cell that results in 
phosphorylation of the subunit of an inhibitory protein, I-κB (Siebenlist 1994). 
Downstream products of NF-κB activation include NO and inflammatory cytokines 
such as, IL-1, IL-6 and TNF-α. Antioxidants play an important role in preventing 
these diseases by counteracting these oxidants that modulate NF-κB activation. Due 
to their low cytotoxicity, phytochemicals are potential sources of natural 
antioxidants, which are candidates for the prevention of oxidative damage. A number 
of medicinal and dietary plants extracts containing polyphenols, flavonoids, and 
other compounds exhibited significant antioxidant activities (Phillipson 2001). 
 
8.2 Hydrogen peroxide classifies as a true first messenger? 
The physiological role of nitric oxide (NO) as an extracellular signalling molecule is 
now widely appreciated. NO, synthesized by NO synthase, typically acts in a 
paracrine fashion, where NO synthesized in one cell diffuses through the 
extracellular space and acts on a target in an adjacent cell. However, NO’s mode of 
action appears not to be unique. In chapter 2, we present evidence that hydrogen 
peroxide acts in a very similar fashion – it mediates cell-to-cell communication and 
can thus be classified as a true first messenger.  Having established that activation of 
RAW 264.7 macrophages with different ligands (LPS (10 μg/mL) + IFN-γ (10U/mL, 
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(1 unit = 0.1ng/mL)), IFN-γ (25 U/mL) or AGE-CEA (400 μg/mL)) leads to 
production of NO and TNF-α, we used different concentration of catalase, which 
converts hydrogen peroxide to oxygen and water, to investigate whether it can inhibit 
NO and TNF-α production.  
If hydrogen peroxide travels between cells propagating the signal, then certain 
percentage of the readout should be inhibited by catalase and this should be dose-
dependent. To prove this hypothesis, RAW 264.7 macrophages were activated with 
LPS (10 μg/mL) + IFN-γ (10U/mL, (1 unit = 0.1ng/mL)), IFN-γ (25 U/mL) or AGE-
CEA (400 μg/mL) and nitric oxide (NO) production and TNF-α production were 
measured in the media with increasing concentrations of catalase ranging from 0 to 
4000 U/mL. Our results showed that catalase can inhibit 100% of NO and 40% of 
TNF-α production at the highest catalase concentration. These findings suggest that 
hydrogen peroxide travels through cell membranes and the extracellular space and 
activate adjacent cells. Furthermore, hydrogen peroxide can be considered a first 
messenger, able to transmit cell-to-cell pro-inflammatory signals such as NO and 
TNF-α. In a therapeutic setting, our data suggest that drugs or compounds acting as 
hydrogen peroxide scavengers might not even need to enter the cell to act as anti-
inflammatory drugs. 
To confirm the above result, future research could test with an alternative to catalase 
ex. glutathione peroxidase and check whether the result will be the same as catalase. 
Furthermore according to our result, catalase inhibited 100% of NO and 40% of 
TNF-α.  It may reveal that NO was more redox sensitive to hydrogen peroxide than 
TNF-α. To confirm this, future research needs testing with more cytokines, such as 
IL-1 and IL-6.  
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8.3. Foods having anti-inflammatory properties might be useful in the 
prevention of age-related inflammatory conditions 
Chronic inflammatory processes contribute to the pathogenesis of many age-related 
diseases. In search of anti-inflammatory foods, we have systematically screened a 
variety of common dietary plants and mushrooms for their anti-inflammatory activity 
(Chapter 3). A selection of 115 samples was prepared by a generic food-compatible 
processing method involving heating. These samples were tested for their anti-
inflammatory activity in murine N11 microglia and RAW 264.7 macrophages, using 
nitric oxide (NO) and tumour necrosis factor-a (TNF-α) as pro-inflammatory 
readouts. Ten food samples including lime zest, English breakfast tea, honey-brown 
mushroom, button mushroom, oyster mushroom, cinnamon and cloves inhibited NO 
production in N11 microglia, with IC50 values below 0.5 mg/ml. The most active 
samples were onion, oregano and red sweet potato, exhibiting IC50 values below 0.1 
mg/ml. When these ten food preparations were retested in RAW 264.7 macrophages, 
they all inhibited NO production similar to the results obtained in N11 microglia. In 
addition, English breakfast tea leaves, oyster mushroom, onion, cinnamon and button 
mushroom preparations suppressed TNF-α production, exhibiting IC50 values below 
0.5 mg/ml in RAW 264.7 macrophages. In summary, anti-inflammatory activity in 
these food samples survived ‘cooking’. Provided that individual bioavailability 
allows active compounds to reach therapeutic levels in target tissues, these foods 
may be useful in limiting inflammation in a variety of age-related inflammatory 
diseases. Furthermore, these foods could be a source for the discovery of novel anti-
inflammatory drugs.  
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8.4 E-cinnamaldehyde and o-methoxycinnamaldehyde are responsible for most 
of the inflammatory activity of cinnamon. 
In a previous study, we have shown that Sri Lankan cinnamon (C. zeylanicum) was 
one of the most potent anti-inflammatory foods out of 115 foods tested. Cinnamon 
has been reported to be beneficial for the amelioration of many inflammatory 
diseases including control of blood glucose levels in diabetes arthritic pain (Tsuji-
Naito 2008). In spite of its widespread use, research on its anti-inflammatory 
properties has been limited. The pioneering work by the group of Chang et al. has 
demonstrated anti-inflammatory activity from the essential oil of Cinnamomum 
osmophloeum Kaneh. (Lauraceae) (Tung et al. 2008). However, less is known about 
the compounds responsible for the anti-inflammatory activity of the ‘true’ cinnamon 
of Sri Lanka, Cinnamomum zeylanicum and the ‘Chinese’ cinnamon, C. cassia, and 
our study (Chapter 5) was aimed at identifying the amount and potency of the major 
anti-inflammatory compounds in these foods. 
Cinnamon bark extracts are complex mixtures and therefore we identified and 
quantified all major compounds in the two cinnamon species using GC-MS and 
UPLC-PDA/MS. E-cinnamaldehyde, o-methoxycinnamaldehyde, cinnamyl alcohol, 
benzyl benzoate, eugenol, and cinnamic acid demonstrated considerable anti-
inflammatory activity in terms of inhibition of NO production, whereas only 
cinnamaldehyde, o-methoxycinnamaldehyde and benzyl benzoate were potent 
inhibitors of TNF-α production. In detail, the most potent compounds were E-
cinnamaldehyde and o-methoxycinnamaldehyde which exhibited IC50 values for NO 
(RAW 264.7 cells) at concentrations of 55 μM and 35 μM respectively and IC50 for 
TNF-α of 63 μM and 78 μM, respectively. The data were confirmed in J774A.1 cells, 
where E-cinnamaldehyde and o-methoxycinnamaldehyde emerged as the most potent 
compounds. If therapeutic concentrations (e.g. by using advanced delivery methods 
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such as microencapsulation) can be achieved in target tissues without toxicity, 
cinnamon and its components may be of use as a treatment for the amelioration of 
age-related inflammatory conditions. 
 
8.5 Mushrooms and their anti-inflammatory activity 
In a previous study, honey-brown, button and oyster mushrooms showed strong anti-
inflammatory activity among 115 foods tested. Edible mushrooms are attracting 
more and more attention as functional foods since they are rich in bioactive 
compounds, but their anti-inflammatory properties and the effect of food processing 
steps on this activity has not been systematically investigated. In the present study 
(Chapter 6), White Button and Honey Brown (both Agaricus bisporus), Shiitake 
(Lentinus edodes), Enoki (Flammulina velutipes) and Oyster mushroom (Pleurotus 
ostreatus) preparations were tested for their anti-inflammatory activity in 
lipopolysaccharide (LPS) and interferon-γ (IFN-γ) activated murine RAW 264.7 
macrophages. Potent anti-inflammatory activity (IC50 < 0.1 mg/ml), measured as 
inhibition of NO production, could be detected in all raw mushroom preparations, 
but only raw Oyster (IC50 = 0.035 mg/ml), Shiitake (IC50 = 0.047 mg/ml) and Enoki 
mushrooms (IC50 = 0.099 mg/ml) showed additional potent inhibition of TNF-α 
production. When the anti-inflammatory activity was followed through two food-
processing steps, which involved ultrasonication and heating, a significant portion of 
the anti-inflammatory activity was lost suggesting that the anti-inflammatory 
compounds might be susceptible to heating or prone to evaporation. While our 
results suggest that some mushrooms would more likely deliver higher levels of anti-
inflammatory compounds when eaten raw, consumption of raw mushrooms carries 
some health risks. Therefore, future research could test a range of ‘cooking’ 
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temperatures to see if mushrooms cooked on low heat retain their bioactivity while 
not posing a health risk. 
 
8.6 Novel anti-inflammatory compounds from young leaves of Cryptocarya 
mackioniana 
In our quest for the search of novel potent anti-inflammatory compounds involved 
the screening of 72 Australian tropical rainforest plant extracts from Northern 
Queensland. This chapter highlights the bioassay guided isolation and 
characterization of new anti-inflammatory compounds from one of the most active 
plant, Cryptocarya mackinoniana.  
The aim of this study (Chapter 7) was the identification of novel anti-inflammatory 
compounds present in Cryptocarya mackioniana young leaves. After extraction of 
young leaves using solvents with increasing polarity starting with dichloromethane 
(DCM), 50%dichloromethane/methanol and methanol (MeOH) respectively, the 
extracts were later fractionated using HPLC. The structures were elucidated by the 
interpretation of NMR and mass spectrometry data. Anti-inflammatory activity of 
extracts was assessed in LPS (lipopolysaccharide) + IFN-γ (Interferon-γ) activated 
RAW 264.7 macrophages by measuring the down-regulation of nitric oxide and 
TNF-α production. 
From this study we were able to identify a new compound, 12 and a known 
metabolite cryptocaryone from the DCM extract. Compound 12 suppressed the 
inflammatory markers NO and TNF-α with an IC50 of 6.36 ± 0.85 µg/mL and 1.26 ± 
0.18 µg/mL respectively without cytotoxicity. Compound 12 has two chiral centres and 
the relative stereochemistry of the substituents at the two chiral centres can be 
determined by the modified Mosher’s method using the (S) and (R)-MTPA [α-
methoxy-α-(trifluoromethyl)phenylacetyl] esters of 12 (work in progress). 
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Furthermore we were able to show the anti-inflammatory properties exerted by 
fractions 1-11 of the DCM extract, 50% DCM / MeOH and MeOH extracts. This 
could indicate the presence of potential but yet unidentified compounds in those 
fractions and extracts that needs further investigation (work in progress). 
The anti-inflammatory compounds identified in this study (Chapter 4 and 7) require 
confirmation of their efficacy in vivo. Despite the positive outcomes in murine 
models of AD, the activity could be confirmed by testing in mouse models such as 
mouse with brain overexpressing TNF-α.  
The next ideal step would be intervention trials for the pure compounds in humans 
once they have been confirmed active in animal models. This could be done with a 
single compound or a combination of more than one compound. In addition to the 
drug efficiency, the adverse effects (if any) needs to be documented. 
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